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 ABSTRACT 
Research investigating the regulation of muscle fibre type has traditionally 
been conducted in vivo, analyzing global changes at a whole muscle level. 
Broadly, this thesis aimed to explore more ÒmolecularÓ approaches, utilizing in 
vitro cell biology and molecular biology to understand the expression and 
regulation of myosin heavy chain (MyHC) isoforms as an indicator of muscle 
fibre composition. Improving our understanding of the fundamental biology 
controlling MyHC isoform expression is important since these proteins are key 
determinants of the contractile and metabolic characteristics of the muscle 
fibre; influencing locomotion, metabolism and age related musculoskeletal 
diseases (Schiaffino and Reggiani 2011). Furthermore, establishing whether 
muscle fibre type research can be conducted using molecular and cell biology-
based approaches, may encourage more extensive work to be conducted by 
such methods and advance our molecular understanding of muscle fibre type 
regulation.  
The mRNA expression profile of six MyHC isoform genes during C2C12 
myogenesis was elucidated to reveal that the C2C12 cell line mimics 
developing fast-twitch muscle fibres. Specifically, MyHC mRNA isoforms 
were expressed in a distinct temporal pattern as two distinct cohorts. MyHC 
emb, neo and type I expression was up-regulated during early differentiation 
(day 1/2) and their expression was subsequently down-regulated after 4 to 6 
days in culture (p<0.001). MyHC IIA, IIX and IIB, on the other hand, were 
expressed later in differentiation and their expression continued to increase to 
day 8 (p
 research conducted using this cell line and suggest that the C2C12 cell line 
may be a good model for studying MyHC regulation in vitro.  
The dynamic plasticity of MyHC isoform gene expression was then compared 
between C2C12 muscle cells and fully differentiated adult muscle. Exposure of 
adult muscle to the beta-adrenergic agonist, Ractopamine, induced dynamic 
transitions in MyHC isoform expression, from the IIA/IIX isoforms to 
increased IIB isoform expression (p<0.05 for all genes). Interestingly, an acute 
exposure of C2C12 muscle cells to Ractopamine was capable of inducing an 
exclusive and rapid induction of the MyHC IIB isoform gene expression 
during myogenesis (p<0.001). This work highlights that MyHC isoform 
expression is malleable in the C2C12 muscle cells during myogenesis and 
suggests that the C2C12 cell line is a useful model for studying MyHC gene 
regulation. Furthermore, this work reports a role for beta-adrenergic signaling 
in the transcriptional regulation of MyHC IIB during two developmental 
distinct stages of muscle growth.  
Additional characterization of the C2C12 cell line revealed a dramatic 
restructuring of metabolic gene expression during the switch from proliferating 
to fully differentiated C2C12 muscle cells. Specifically, the changes in 
metabolic gene expression suggest that post-mitotic muscle cells might redirect 
glucose carbons into ATP generating pathways and away from macromolecule 
biosynthesis. In addition, post-mitotic muscle cells exhibited increased 
glycolytic gene expression and reduced oxidative gene expression (p<0.01 for 
all genes). These transitions in metabolic gene expression during myogenesis 
provide important information worthy of consideration when utilizing the 
C2C12 cell for muscle biology research. Furthermore, this work suggests a 
 potential role for very specific metabolic profiles to support, or even regulate, 
distinct stages of myogenic differentiation.   
Finally, the C2C12 cell line was utilized as a host environment for a 
molecular-based approach to understand the role of the promoter sequence in 
regulating the species-differential induction of the MyHC IIB gene during 
myogenesis. Herein, a 3bp miss-match in the CArG-Ebox region (at -74bp,      
-68bp and -48bp) of the proximal MyHC IIB promoter was identified that 
dictates the differential expression of MyHC IIB in pigs and humans. This 
work demonstrates a molecular mechanism regulating a major physiological 
difference in the muscle phenotype between pigs and humans. The successful 
use of the C2C12 cell line as a MyHC IIB expressing environment shows that 
the C2C12 cell line is a useful tool for molecular and cell biology approaches 
to explore the regulation of MyHC isoforms. The genomic mechanism 
identified herein provides important information for understanding the pig as a 
model of human muscle biology research.  
In summary, this thesis reports novel information regarding the regulation of 
MyHC isoform expression, using molecular and cell biology techniques. The 
use of molecular-based approaches may help further elucidate mechanisms 
regulating MyHC genes. An improved understanding of the regulation of 
MyHC isoforms is important given their critical role in dictating the contractile 
and metabolic characteristics of the muscle fibre.   
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1. INTRODUCTION 
 
1.1 Skeletal muscle 
Skeletal muscle is composed of a heterogeneous population of muscle fibres, 
with varying contractile and metabolic characteristics, and is fundamental to 
the locomotive capabilities of all mammals. Furthermore, skeletal muscle 
permits activities such as breathing and eating, making it an essential tissue for 
life. In addition to its mechanical roles, skeletal muscle is a metabolically 
active tissue that both stores and utilizes considerable quantities of energy; it is 
therefore considered to be a key contributor to whole body metabolism. Taken 
together, skeletal muscle is a multifunctional tissue that is critical to the 
survival of all mammals, making it the subject of considerable scientific 
interest for over a century (Schiaffino and Reggiani 2011).  
 
1.2 Myogenesis: the formation of muscle fibres 
Skeletal muscle is a collection of multinucleated muscle fibres formed by a 
process called myogenesis, the regulation of which has been extensively 
reviewed (see Bentzinger et al. (2012) for an up to date review). Briefly, 
precursor cells become committed to the myogenic lineage (denoted as 
myoblasts) before undergoing several rounds of proliferation. Myoblasts then 
terminally exit the cell cycle, align and fuse together to form multinucleated 
myotubes. Ultimately, the myotubes mature to form the muscle fibres. See 
Figure 1.1 for a schematic representation of myogenesis. This process of 
myogenesis is critical to the formation of muscle fibres during development 
but also a fundamental aspect of muscle regeneration in adult muscle, with 
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resident muscle precursors showing the capacity to fuse to existing muscle 
fibres to aid repair of hypertrophic growth (Bentzinger et al. 2012). 
 
Figure 1.1 A schematic, from Jang et al. (2013), detailing the process of myogenesis; 
mesodermal cells undergo determination to the myogenic lineage, forming myoblasts, which 
proliferate to expand cell number. On induction of differentiation, the myoblasts exit the cell 
cycle and fuse to form multinuclear myotubes and ultimately mature into myofibres.  
 
 
The regulation of myogenesis is well characterized (Bentzinger et al. 2012) 
and highly regulated by a family of basic helix-loop-helix transcription factors 
called myogenic regulatory factors (MRFÕs), consisting of MyoD, Myf-5 and 
myogenin (Sabourin and Rudnicki 2000; Bentzinger et al. 2012). Expression 
profiles of the MRF genes are temporally distinct and display a hierarchical 
induction during myogenesis. The central role of MyoD in committing a cell to 
a myogenic fate was originally highlighted by forced expression of MyoD in 
non-muscle cells, which was capable of inducing muscle specific gene 
expression and fusion of non-muscle cells into myotubes (Davis et al. 1987). 
Interestingly, Myf-5 shows reciprocal redundancy to MyoD in vivo, as removal 
of the MyoD or Myf-5 gene from mice results in relatively normal muscle 
development due to compensation by the remaining MyoD or Myf-5 factor 
(Braun et al. 1992; Rudnicki et al. 1992). However, removal of both MyoD 
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and Myf-5 from mice results in neonatal lethality due to the complete lack of 
skeletal muscle formation (Rudnicki et al 1993), emphasizing that either 
MyoD or Myf-5 is required for the commitment of precursor cells to the 
myogenic program. Myogenin, on the other hand, is fundamental to the fusion 
and differentiation of committed myoblasts into myotubes, as demonstrated by 
the lack of differentiated myofibres but the presence of un-fused myoblasts in 
myogenin knockout mice (Nabeshima et al. 1993; Hasty et al. 1993). Thus, 
MyoD and Myf-5 are typically involved in the early stages of myoblast 
commitment, whereas myogenin is involved in the fusion and differentiation of 
myoblasts into myotubes. However, mice lacking both MyoD and Myf-5 
display a lack of myogenin expression (Rudnicki et al 1993), highlighting the 
hierarchical nature of the MRF network, with MyoD or Myf-5 being required 
for the activation of Myogenin expression. The complex network of 
interactions between the MRFÕs to regulate myogenesis is fundamental to the 
formation of multinuclear muscle fibres and the induction in expression of the 
necessary components that constitute the mature, physiologically functional 
muscle fibre (Sabourin et al. 1999; Bentzinger et al. 2012).  
 
1.3 Muscle fibre heterogeneity 
Adult skeletal muscle is comprised of a heterogeneous population of muscle 
fibres displaying a broad range of contractile and metabolic characteristics, 
which remain malleable throughout adult life. It is this heterogeneity in muscle 
fibre characteristics, within a given muscle, that allows skeletal muscle to 
perform a huge variation in contractile functions, from isometric postural 
support to explosive sprinting. The vast heterogeneity and plasticity of muscle 
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fibre phenotype has therefore been of significant interest to the scientific 
community due to its broad application to exercise physiology, ageing and 
sarcopenia, cancer cachexia, skeletal myopathies, metabolic disorders, and 
even livestock production.  
Differences in skeletal muscle phenotype have long been reported since the 
late 19th century (Ranvier 1874), with differences in phenotype originally 
identified by differences in muscle colour (red and white). Further 
characterization in the early 20th century split red and white muscle phenotypes 
into two distinct groups; the fast- and slow- twitch muscles with a glycolytic 
and oxidative metabolism, respectively (Needham 1926). In 1967 it was 
discovered that myosin ATPase activity of the myosin heavy chain molecule 
linked the contractile and metabolic characteristics of muscle fibres (Barany 
1967). A more extensive examination of muscle fibre types began, combining 
physiological, histochemical and biochemical properties of muscle fibres. The 
pivotal work of Brooke and Kaiser (1970) devised a method to stain transverse 
cross sections (~10µM thick) of frozen muscle to visualize differences in 
myofibrillar ATPase (mATPase) activity between muscle fibres, transforming 
muscle biology research. Typically, cross sections are stained for mATPase 
following a pre-incubation in an acidic (pH 4.3-4.6) or alkaline (pH 10.2-10.6) 
environment. An acidic pre-incubation inhibits the activity mATPase in fast 
fibres, thus only staining slow fibres and an alkaline pre-incubation inhibits the 
activity of mATPase in slow fibres, staining only the fast fibres. This method 
categorized muscle fibres into a slow-twitch (type I) fibre type and two fast-
twitch (type IIA and IIB) fibre types. Further biochemical analyses, combining 
mATPase staining with staining for metabolic enzyme activity, such as 
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succinate dehydrogenase (SDH), revealed that the metabolic profile is closely 
correlated with the mATPase within muscle fibres (Burke et al. 1971). Thus, 
fibre types were commonly categorized as slow-twitch oxidative (type I), fast-
twitch oxidative-glycolytic (type IIA) and fast-twitch glycolytic (type IIB). 
However, the introduction of antibodies raised against components that 
constitute the contractile machinery of the muscle fibre, revealed there might 
be more than three muscle fibre types. Specifically, antibodies raised against 
myosin heavy chain (MyHC) isoforms highlighted four distinct fibre types 
expressing type I, IIA, IIX or IIB MyHC isoforms (Schiaffino et al. 1989), 
which now form the labeling system for characterizing muscle fibre types. 
Furthermore, using in situ riboprobe hybridization against MyHC isoform 
transcripts revealed that the classically labeled type IIB fibre type actually 
consisted of two sub-populations expressing either IIX, IIB or both IIX and IIB 
MyHC isoforms (Lefaucheur et al. 1998). Thus, type IIX muscle fibres have 
been erroneously labeled as type IIB muscle fibres in much of the early muscle 
fibre type literature. Furthermore, MyHC analysis in human skeletal muscle 
revealed that classically labeled IIB fibres in fact express a gene homologous 
to the rat type IIX MyHC isoform and actually lack expression of the MyHC 
IIB gene (Smerdu et al. 1994), despite the human genome containing a gene 
encoding the MyHC IIB gene (Weiss, Schiaffino & Leinwand, 1999). 
Molecular analysis of MyHC isoform expression in single fibres has also lead 
to the discovery that muscle fibre phenotypes do not fit exactly into discrete 
fibre types, often expressing multiple MyHC isoforms (Lefaucheur et al. 1998; 
Stephenson 2001), and thus display a continuum of characteristics. However, 
MyHC is the molecular motor of the muscle sarcomere and closely correlates 
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with the contractile and metabolic characteristics of the muscle fibre plus it is 
differentially expressed in physiologically diverse muscle fibre types, thus 
making it an excellent marker of muscle fibre type (Schiaffino and Reggiani 
2011; Gundersen 2011). Furthermore, global expression of MyHC isoforms in 
muscle tissue homogenate gives an average indication of phenotype across the 
sample. The figure below details the characteristics correlating with MyHC 
isoform expression (Gundersen 2011). Briefly, physiological characteristics 
generally follow a sequential order with the corresponding MyHC isoform 
expressed in the order of type I > IIA > IIX > IIB (oxidative to glycolytic, slow 
to fast, small to large, high to low endurance; see Figure 1.2 below for 
example). 
 
Figure 1.2 This Figure, from Gundersen (2011), shows the physiological characteristics of the 
four adult muscle fibre types, classified by their expression of myosin heavy chain isoform (I, 
IIA, IIX, IIB). 
 
 
As it stands, measuring MyHC isoform expression as an indicator of muscle 
fibre type is likely a gross over-simplification, as there are many components 
of the muscle sarcomere that display fibre type specific expression, but it is 
currently considered the best and most convenient marker of muscle fibre 
composition (Schiaffino and Reggiani 2011). However, MyHC is a key 
component of the muscle sarcomere and is actively (not just passively) 
involved in directly influencing the physiology of the muscle fibre. Thus, it is 
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not only a useful ÒbiomarkerÓ of muscle fibre type but of physiological interest 
to the scientific community as an influential component of the muscle fibre 
phenotype.  
 
1.4 The muscle sarcomere and the myosin heavy chain isoforms 
Skeletal muscle fibres consist of a collection of myofibrils which contain the 
major contractile components, the sarcomere, which permits contraction of the 
muscle (see Figure 1.3).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Each skeletal muscle fibre contains a collection of myofibrils, which contain the 
sarcomere structures (diagram from Powers and Howley 2007). 
 
The sarcomere is a highly ordered molecular structure that forms the 
contractile machinery of the muscle fibre (Schiaffino and Reggiani 2011). 
Information regarding the molecular structures and functions of the sarcomere 
described herein, can be obtained from an excellent review by Schiaffino and 
Reggiani (2011) unless otherwise stated. The sarcomeres are aligned in a 
parallel, back-to-back, alignment to form the myofibrils, generating the 
characteristic striated pattern of muscle fibres (see Figure 1.4 below).  
9 
 
Figure 1.4 Schematic diagram of the muscle sarcomere and a respective comparison to an 
electron microscope image of a sarcomere within a myofibril (Schiaffino and Reggiani 2011). 
The sarcomere is annotated with it key components; labels in red or green denote selective 
expression in fast and slow muscle fibres respectively.  
 
 
The cytoskeletal sarcomeric structures, comprising the Z-disc and M-band, 
align perpendicular to the direction of the myofibril, and provide a structural 
scaffold for the contractile machinery. The myosin (thick) and actin (thin) 
filaments form the ÒmajorÓ components of the sarcomeric contractile 
machinery, which run longitudinal to the myofibrils and transverse to the Z-
disc and M-disc sarcomeric structures (see Figure 1.4). The interaction 
between the myosin and actin filaments largely determines the contractile 
function of the sarcomere; hence they are commonly denoted as the ÒmajorÓ 
contractile components. Also of critical importance to the contraction of the 
sarcomere is the troponin-tropomyosin complex attached to the actin filament. 
This complex interacts with calcium (the chemical signal that induces muscle 
contraction) to expose the myosin binding sites on the actin filaments, 
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permitting actin-myosin interactions and thus allowing sarcomeric contraction. 
Many of the components constituting the sarcomere exist as multiple isoforms, 
resulting in functionally diverse sarcomeres, which reside in fast and slow 
contracting muscle fibres (as shown in Figure 1.4 with ÒfastÓ and ÒslowÓ 
specific isoforms indicated by red and green text, respectively). Although 
many components of the sarcomere exist as multiple isoforms that elicit 
phenotype-specific expression, i.e. in fast and slow muscle fibres, it is 
predominantly the myosin heavy chain (MyHC) isoforms that actively dictate 
the diverse magnitude of actin-myosin force generation.  
 
 1.5 Myosin heavy chain 
The MyHC molecule is a large, 200kDa, elongated protein consisting of two 
globular ÒheadÓ domains (~840 amino acid) and a long alpha-helical coiled 
ÒtailÓ domain (~1,100 amino acid). The myosin tails align together to create 
the ÒthickÓ myosin filament, which comprises hundreds of myosin heads, each 
containing the ATP- and actin- binding sites necessary to facilitate the 
mechanical movements of the myosin molecule, which in turn regulate the 
contraction of the sarcomere. The myosin Òmolecular motorsÓ directly interact 
with the actin filaments causing the sarcomeres to shorten, by sliding the 
myosin and actin filaments across one another in opposing directions.  
 
 1.6 Contraction of the sarcomere 
The mechanism of contraction of the muscle sarcomere is essentially a 
repetitive interaction of the myosin heads with the actin filaments, resulting in 
a shortening of the sarcomeric structure, and has been well reviewed elsewhere 
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(Schiaffino and Reggiani 2011). The arrival of an action potential at the 
muscle fibre results in depolarization and a rapid release of calcium. Calcium 
binds the troponin-tropomyosin complex, which subsequently exposes the 
myosin binding sites on the actin filament, permitting actin-myosin 
interactions in the presence of Adenosine Triphosphate (ATP). The myosin 
head rapidly hydrolyzes ATP into Adenosine Diphosphate (ADP) and 
inorganic phosphate (Pi), which induces an elevation in the myosin lever arm, 
followed by binding of the myosin head to the actin filament (see Figure 1.5 
for schematic representation of sarcomere contraction). Subsequent release of 
Pi from the myosin head causes a structural change to the myosin molecule 
inducing the Òpower strokeÓ, transmitting force against the actin filament and 
displacing the thick (myosin) and thin (actin) filaments in opposing directions, 
resulting in contraction of the sarcomere. Following the power stroke, ADP is 
released, firmly associating the myosin head to the actin filament. Binding of 
ATP to myosin subsequently causes disassociation of the myosin head from 
the actin filament and induces a conformational change in the lever arm of the 
myosin molecule, causing a Òreverse strokeÓ of the myosin head whilst 
unattached to the actin filament. In the presence of ATP and calcium, this 
process repeats itself in a cyclic fashion to induce actin-myosin filament 
sliding, causing a mass shortening of the muscle fibre and ultimately a muscle 
contraction.  
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Figure 1.5 A schematic to illustrate the process of sarcomere contractions, facilitated by the 
actin-myosin interactions in the presence of calcium and ATP (Diagram from Powers and 
Howley 2007). 
 
 
 
 1.7 Myosin heavy chain isoforms and contractile kinetics 
The kinetics of the aforementioned actin-myosin interaction to induce 
contraction of the sarcomere is largely determined by the specific MyHC 
isoform expressed, resulting in a diverse range of contractile speeds. Thus, 
MyHC isoforms in adult muscle are commonly referred to as slow and fast 
MyHCÕs as they have a strong physiological effect on the contractile 
phenotype of the muscle. Differences in the kinetics of the MyHC isoforms are 
due to disparity in their rate of ATP hydrolysis and ADP dissociation 
(Schiaffino and Reggiani 2011). The rate of ATP hydrolysis influences the rate 
of actin-myosin binding, thus influencing the speed of the sarcomere 
contraction. For instance, in rabbit skeletal muscle, differences in the rate of 
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ATP hydrolysis between MyHCÕs are very disparate, with fast MyHC isoforms 
eliciting up to 20-30-fold faster ATP hydrolysis compared to slow (type I) 
MyHC (Weiss and Leinwand 1996). These differences in ATPase activity of 
the fast and slow MyHCÕs results in vastly different contractile characteristics 
between ÒfastÓ and ÒslowÓ muscles. The rate of ADP dissociation is also 
critical to the speed of contraction; influencing the speed of detachment of the 
myosin head from the actin filament, thus increasing the time taken to re-start 
the cycle of sarcomere contraction (Schiaffino and Reggiani 2011). The fast 
type II MyHC isoforms are typically more responsive, with ADP dissociation 
occurring quickly, enabling a shorter delay between sarcomere contractions. 
Taken together, the MyHC isoform is a critical determinant of the contractile 
capacity of a muscle fibre (Schiaffino and Reggiani 2011).  
 
 1.8 The Myosin heavy chain gene family 
In total, there are 11 highly conserved mammalian sarcomeric MyHC genes 
(MYH), each encoding an individual isoform (Figure 1.6). It is suggested that 
the mammalian MyHC gene family arose from multiple replications of a single 
ancestral MyHC gene (Stedman et al 1990, Moore et al 1993). As a result, 
sarcomeric MyHC genes are highly conserved, sharing 78-98% amino acid 
identity, between isoforms and across multiple species (Weiss and Leinwand 
1996). This originally lead to speculation that MyHC genes were highly 
redundant, given the level of gene duplication, but it is now clear that multiple 
MyHC isoforms provide functionally diverse contractile characteristics (Weiss 
and Leinwand 1996). The MyHC gene is typically around 30kb in length, 
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containing 40 or 41 exons, with a similar intron-exon organization (Weiss and 
Leinwand 1996).  
 
Figure 1.6 A diagram illustrating the myosin heavy chain gene family, their respective protein 
names and the distribution of expression (Schiaffino and Reggiani 2011). 
 
 
The MyHC genes are mostly distributed between two clusters on two separate 
chromosomes (Weiss and Leinwand 1996; Schiaffino and Reggiani 2011), 
with one cluster containing the isoforms expressed in cardiac muscle (MyHC-
alpha and MyHC-beta) and the other containing three isoforms expressed in 
adult skeletal muscle (MyHC-IIA, MyHC-IIX, and MyHC-IIB), two 
developmental isoforms (MyHC-emb and MyHC-neo) and one isoform 
exclusively expressed in the extraocular muscles (MyHC-EO; see Figure 1.6). 
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In addition, three highly specialized MyHC isoforms have recently been 
identified (MyHC-slow tonic, MyHC-15 and MyHC-M) which are specifically 
expressed in some head and neck muscles.  
 
1.9 Myosin heavy chain isoform expression 
MyHC genes are induced during the differentiation of myogenic cells to form 
physiologically functional multinuclear myofibres. The induction of the MyHC 
genes during in vivo development has been well characterized (Lyons et al. 
1990; Weydert et al. 1987; Agbulut et al. 2003). Prior to birth, it is 
predominantly only the embryonic (emb) and neonatal (neo) MyHC isoforms 
that are expressed in skeletal muscle (Weydert et al. 1987), with some studies 
showing low levels of the adult type I MyHC isoform (Lyons et al. 1990). 
Postnatally, however, the adult MyHC isoforms are selective induced, possibly 
due to the introduction of contractile activity present after birth (Agbulut et al. 
2003; Cerny and Bandman 1986). A comprehensive analysis of MyHC 
isoform protein expression in postnatal development of mouse muscle 
highlights distinct differences in the induction of MyHC isoforms in fast and 
slow muscles (Agbulut et al. 2003). In slow muscles (e.g. the soleus), the 
MyHC emb, neo and type I isoforms are expressed first, and then the type I 
isoform progressively predominates with a concomitant reduction in 
expression of the emb and neo isoforms. In contrast, fast muscles (e.g. the 
extensor digitorum longus) show a gradual replacement of the emb neo and 
type I isoforms with fast type IIA, IIX and IIB isoforms (Agbulut et al. 2003). 
It is generally well accepted that postnatal transitions occur in vivo due to the 
introduction of neural stimulation, mechanical load and circulating hormones 
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(Schiaffino and Reggiani 2011). Attempts to explore the induction of MyHC 
isoforms during development were extended to in vitro experiments, exploring 
MyHC isoform induction during myogenesis (Silberstein et al. 1986; Weydert 
et al. 1987; Miller 1990). However, these attempts were somewhat limited by 
the use of relatively non-specific antibodies against MyHC isoforms and did 
not completely elucidate the developmental induction profiles of MyHC 
isoforms during myogenesis. They did however show that developmental 
MyHC isoforms were induced earlier during myogenic differentiation than the 
the adult isoforms, which were induced later, suggesting there were ÒearlyÓ 
and ÒlateÓ expressed MyHC isoforms during myogenesis (Silberstein et al. 
1986; Miller 1990). This also suggests that early developmental transitions in 
MyHC isoform expression might occur independent of neural innervation, 
mechanical load and circulating hormones, in contrast to what is commonly 
reported. The specific MyHC isoforms within each of these ÒearlyÓ and ÒlateÓ 
cohorts are yet to be identified during myogenesis. Elucidation of the specific 
expression profiles all skeletal muscle MyHC isoforms during myogenesis was 
therefore an objective of this thesis. Such characterization would be conducted 
on the commonly used to C2C12 cell line to provide important information for 
scientists using this cell line for muscle biology research. It is clear from in 
vivo characterization studies that fast and slow muscles show a differential 
induction of the MyHC isoforms during postnatal development in mice 
(Agbulut et al. 2003), and these transitions are considered as an effect of the 
postnatal introduction of specific motor unit firing patterns and introduction of 
circulating hormones, such as thyroid hormone (Schiaffino and Reggiani 
2011). It is unknown whether C2C12 muscle cells mimic the development of 
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fast or slow muscles with regard to the expression of MyHC isoforms. Such 
information is of importance for scientists using the C2C12 cell line for muscle 
biology research, with particular relevance to muscle fibre type, metabolism or 
growth (hypertrophy and atrophy). In addition, the majority of work conducted 
on elucidating the regulation of muscle fibre type is routinely conducted using 
histochemical and immunochemical methods on whole muscle from in vivo 
experiments. Characterization of the expression profiles of the MyHC isoforms 
during C2C12 differentiation could elucidate whether this cell line could be 
utilized for in vitro experiments examining the molecular regulation of the 
contractile components that constitute the muscle fibre.  
 
 1.10 Species-differential expression of myosin heavy chain IIB 
Although the MyHC isoforms are evolutionary conserved genes with very high 
homology and similar functionality between species, the MyHC IIB isoform 
displays a very noticeable species-specific expression in skeletal muscle. 
Despite all mammals carrying the gene (MYH4) encoding MyHC IIB, 
extensive characterization has revealed a striking divide between large and 
small mammals with regard to MyHC IIB expression. Most small mammals 
such as mice (Pellegrino et al. 2003), rats (Pellegrino et al. 2003), rabbits 
(Wada et al. 1995; Pellegrino et al. 2003), and guinea pigs (Gorza 1990; Tonge 
et al., 2010) express MyHC IIB but most larger mammals such as cows 
(Chikuni et al. 2004), sheep (Hemmings et al. 2009) horses (Rivero et al. 
1999), goats (Arguello et al. 2001), cats (Talmadge et al. 1996; Lucas et al. 
2000), dogs (Toniolo et al. 2007), baboons (Lucas et al. 2000) and humans 
(Smerdu et al., 1994, Pellegrino et al. 2003) do not express MyHC IIB. 
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Originally it was proposed that the powerfully fast contractile speeds of the 
MyHC IIB isoform would be incompatible with the mechanics of muscles 
from large mammals (Hill 1950). From an evolutionary perspective, small 
mammals tend to be preyed upon by larger mammals, therefore the muscles 
surrounding the short limbs of small mammals would be required to contract 
quickly and forcefully to provide whole body locomotion rates similar to that 
of large mammals, permitting predator-prey competition and subsequently 
allowing survival of both mammal groups (Hill 1950). Larger muscles/limbs 
confer mechanical advantages over smaller muscles and thus donÕt require 
such extreme contractile characteristics in order to provide equivalent 
locomotion rates compared to small mammals. Interestingly, despite these 
hypotheses, domesticated pigs present an anomaly amongst the large mammals 
as they express very high levels of MyHC IIB (Lefaucheur et a. 1998; 
Gunawan et al. 2007), a phenotype likely exacerbated by the intensive 
selection pressure for enhanced muscle growth in these animals (Ruusunen and 
Puolanne 2004; Lefaucheur et al. 2004). The contractile properties of MyHC 
IIB fibres from pig skeletal muscle also exhibit comparable shortening velocity 
to that of small mammals, such as rats and rabbits, suggesting that the 
mechanical constraints imposed by larger muscles are in fact still compatible 
with the MyHC IIB isoform. The mechanism(s) dictating the differential 
expression of the MyHC IIB isoform between different species are yet to be 
explored. Elucidating the molecular mechanisms controlling the expression of 
the MyHC IIB isoform between species would improve our understanding of 
the fundamental biology controlling species diversity in muscle physiology. Of 
particular interest would be the mechanisms dictating the expression of MyHC 
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IIB in pig skeletal muscle since expression of this isoform is very unusual 
amongst large mammals. Furthermore, pigs are physiologically similar to 
humans and are therefore increasingly being considered as a good animal 
model for studying a range of human diseases (Luo et al. 2012). Differences in 
the expression of MyHC IIB, and the fast-glycolytic muscle phenotype 
associated with expression of this gene, between pigs and humans presents a 
major limitation of the pig as a model for human muscle biology research. 
Thus, an understanding of mechanisms controlling the differential expression 
of MyHC IIB between pigs and humans would improve our understanding of 
the pig as a model for human skeletal muscle biology research. Furthermore, it 
would elucidate the fundamental biology controlling expression of MyHC IIB 
in a large mammal. Work conducted in this thesis set out to explore the 
molecular mechanisms controlling the expression of the MyHC IIB gene in 
porcine skeletal muscle. Two potential mechanisms exist in controlling the 
transcriptional expression of MyHC IIB in pigs; 1) a genomic difference in the 
MYH4 promoter dictates strong transcriptional activity, leading to MyHC IIB 
expression, or 2) specific transcriptional regulators or co-regulators exist in 
abundance to induce high level transcription of MyHC IIB. Since the list of 
regulatory factors likely controlling transcriptional expression of MyHC IIB is 
far from complete, the former suggested mechanism was explored in this 
thesis, examining the role of the MyHC IIB promoter sequence in dictating 
species-specific expression of MyHC IIB in pig skeletal muscle.   
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1.11 Postnatal transitions in myosin heavy chain isoform expression 
Although the initial induction of the MyHC isoforms is determined during 
early muscle fibre formation and that clusters of MyHC isoforms typically 
display muscle-type specific expression (i.e. in fast and slow muscles), 
dynamic plasticity in the expression of MyHC isoforms remains malleable 
throughout adult life. Transitions in MyHC isoform expression in adult skeletal 
muscle can be induced by a variety of stimuli, such as neural/electrical activity 
(Buller et al. 1960; Gambke et al. 1983; Ausoni et al. 1990), hormones 
(Russell et al. 1988; Hughes et al. 1993; Gambke et al. 1983), ageing 
(Klitgaard et al. 1990) and mechanical load (Loughna et al. 1990; Caiozzo et 
al. 1996). The seminal work of Buller et al. (1960) showed that swapping the 
neural input of slow and fast muscles resulted in a change in muscle phenotype 
according the new nerve supply. This work highlighted that the pattern of 
neural stimulation has a fundamental role in regulating muscle phenotype in 
the adult animal. More recent work has utilized different frequencies of 
electrical stimulation to mimic neural activity of fast and slow muscles to show 
that differences in muscle contractile activity can reprogram muscle fibre type 
and specifically alter MyHC isoform expression (Ausoni et al. 1990). Fast 
muscles, such as the EDL, can be electrically stimulated to become ÒslowerÓ 
muscles (based on MyHC isoform expression) and slow muscles, such as the 
soleus, can be electrically stimulated to become ÒfasterÓ muscles (Ausoni et al. 
1990). Importantly, it is suggested that innervation, and thus neural activity, is 
required for the expression of slow type I MyHC isoforms, whereas induction 
of the fast type II MyHC isoforms can occur independent of neural 
innervation, as demonstrated by denervation in rats (Gambke et al. 1983). In 
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support of the somewhat extreme experimental conditions employed by 
authors using electrical stimulation and neural re-innervation, experiments 
conducted using endurance and resistance exercise training have confirmed 
that physiological levels of muscle activity in vivo are capable of inducing 
alterations in MyHC isoform expression (Demirel et al. 1999; Andersen and 
Aagaard 2000) and that the plasticity in expression of MyHC isoforms remain 
malleable through to elderly ages (Konopka et al. 2011).  
Forced disuse or reduced activity of skeletal muscle also demonstrates the role 
of neural input and muscle contractile activity on MyHC isoform expression. 
For instance, just four days of hindlimb suspension in rats can induce de novo 
expression of the MyHC IIB transcription (Loughna et al. 1990), suggesting 
that the lack of neural/contractile stimuli can induce a transition in expression 
of contractile machinery constituting the muscle fibre. In addition, rats exposed 
to a microgravity environment (spaceflight) for 14 days have shown a switch 
from slow to fast MyHC isoforms in the postural load-bearing muscle, the 
soleus (Caiozzo et al. 1996). Thus, muscle activity and inactivity are potent 
regulators of MyHC isoforms in adult skeletal muscle. A huge body of work 
exists to support this notion that neural input and muscle contractile activity 
regulate postnatal expression of MyHC isoforms and has been aptly named 
Òexcitation-transcription couplingÓ (Gundersen et al. 2011).  
In addition to neural and activity dependent regulation of MyHC isoform 
expression, circulating hormones can be influential to MyHC isoform 
expression in postnatal muscle. Perhaps the most commonly reported hormone 
involved in fibre type regulation is thyroid hormone, which is capable of 
specifically inducing the fast MyHC IIB isoform (Russell et al. 1988; Hughes 
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et al. 1993). Circulating thyroid hormone increases rapidly at birth and is likely 
responsible, at least in part, for the postnatal induction of the MyHC IIB 
isoform in developing muscle (Gambke et al. 1983; Russell et al. 1988). 
Furthermore, a hyperthyroid state (increased circulating thyroid hormone 
levels) is capable of inducing alterations in MyHC isoform in neonatal, young 
and old rats (Russell et al. 1988; Larsson et al. 1995), suggesting thyroid 
hormone can influence muscle fibre composition throughout the lifespan of an 
animal.   
 
1.12 Molecular regulation of myosin heavy chain isoform expression 
Expression of the MyHC genes display remarkably dynamic plasticity 
evidenced by coordinated transition in isoform expression, with single 
isoforms demonstrating an ability to replace one another, generally in a 
sequential manner I<>IIA<>IIX<>IIB (Schiaffino and Reggiano 2011; 
Gundersen 2011). This plasticity in expression of the MyHC genes in response 
to a variety of stimuli has lead scientists to explore the molecular regulation of 
such coordinated and dynamic transitions in MyHC isoform expression. Of 
significant interest are the mechanisms capable of ÒsensingÓ 
external/physiological stimuli and subsequently altering MyHC isoform 
expression according to the demands placed upon the muscle. In addition, the 
precise mechanisms by which multiple isoforms are regulated in transitional 
manner are also of particular interest. Gundersen (2011) provides an excellent 
current review on the molecular mechanisms involved in ÒtranslatingÓ the 
external/physiological stimuli to molecular changes in expression of the 
contractile components of the muscle fibre, often termed Òexcitation-
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transcription couplingÓ. The mechanisms regulating the co-ordinated transition 
in MyHC isoforms remain less well understood but research has identified 
three main mechanisms by which co-ordinated regulation of the MyHC 
isoforms probably occur, along with many more mechanisms identified for 
regulating individual isoforms (Schiaffino and Reggiano 2011). Briefly, the 
three mechanisms include 1) transcriptional regulatory factors influencing gene 
expression, by activation or repression, of MyHC genes, 2) miRNA embedded 
within the introns of MyHC genes that subsequently influence expression of 
other MyHC isoforms, and 3) bi-directional promoters co-regulating 
sequentially located MyHC isoform genes using antisense RNA mediated 
inhibition of neighboring isoforms. In addition, a fourth mechanism may exist 
and relates to how sequence variation in promoter response elements of the 
MyHC isoform promoters influence the selective binding of transcriptional 
regulatory factors and subsequently influence MyHC isoform gene expression. 
However, such work requires extending to identify the role of sequence 
variation between MyHC promoters in regulating the coordinated regulation of 
multiple MyHC isoforms.  
 
1.13 Regulation of the slow myosin heavy chain isoforms 
The regulation of the slow-twitch oxidative muscle fibre phenotype has been 
thoroughly examined with several well established mechanisms of regulation 
being reported. A transcriptional co-regulator, peroxisome proliferator-
activated receptor gamma co-activator 1 alpha (PGC1-α), and two nuclear 
receptors, peroxisome proliferator-activated receptor delta (PPARδ) and 
estrogen receptor-related receptor gamma (ERRγ), have been identified as 
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Òmaster regulatorsÓ of a slow muscle phenotype (Lin et al. 2002; Narker et al. 
2011; Wang et al. 2004). Transgenic mice over-expressing PGC1- α, 
exclusively in skeletal muscle, display an increase in expression of type I 
MyHC, with a concomitant increase in mitochondrial biogenesis and increased 
expression of oxidative enzymes. In addition, a repressive counterpart to 
PGC1-α, RIP140 (nuclear receptor interacting protein; NRIP1), causes the 
opposing effects, namely a reduction in type I MyHC expression and reduced 
oxidative enzyme expression (Seth et al. 2007). Thus, the ratio of PGC1-α to 
RIP140 may be critical in determining the ÒactivityÓ of transcription factors 
inducing expression of the type I MyHC isoform and an oxidative muscle fibre 
phenotype. It is suggested that these transcriptional co-regulators (PGC1-α and 
RIP140) interact with nuclear receptors such NFAT, MEF2, and PPAR 
transcription factors to influence transcriptional activity of ÒslowÓ muscle 
target genes (Lin et al. 2002; Seth et al. 2007). 
Expression of the nuclear receptor, ERRγ, is highly abundant in mammalian 
skeletal muscle and exclusively accumulates in the type I muscle fibres. Forced 
over-expression of this factor in mouse skeletal muscle identified it as a 
Òmaster regulatorÓ of a slow muscle phenotype, displaying a striking 
coordinated induction of slow, type I and IIA MyHC isoforms (with a modest 
concomitant reduction in MyHC IIB) and increased the expression of enzymes 
involved in oxidative metabolism (Narker et al. 2011). Similar results have 
been obtained by generating a transgenic mouse over-expressing the nuclear 
receptor, PPARδ (Wang et al. 2004). Expression of PPARδ is highly abundant 
in skeletal muscle (compared to the other PPARα and PPARγ isoforms) and is 
selectively expressed in slow-twitch muscles, indicating a role in fibre type 
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specification. Over-expression of PPARδ in transgenic mice induced a switch 
to a slow muscle fibre type (expressing more type I fibres), increased 
mitochondrial biogenesis and increased expression of enzymes involved in 
oxidative metabolism (Wang et al. 2004).  
 
1.14 Regulation of the fast myosin heavy chain isoforms  
Relative to the mechanisms discovered that regulate the slow MyHC isoforms 
(or a slow muscle phenotype), transcriptional mechanisms regulating the fast 
contractile MyHC isoforms (IIA, IIX and IIB) remain poorly understood. 
Indeed, only a few studies exist in this area and most of which are yet to be 
repeated or confirmed by others.  
Grifone et al. (2004) reported that the transcription factor Sine Oculis 
Homeobox 1 (SIX1) and a transcriptional co-activator Eyes Absent 1 (EYA1) 
are co-expressed in the nuclei of fast twitch (IIX and IIB) muscle fibres in 
mice. They demonstrate that SIX1 and EYA1 act synergistically when over-
expressed in slow muscle fibres to replace type I and IIA MyHC isoforms with 
type IIX and IIB isoforms. In addition to the MyHC transitions induced by the 
co-operative actions of SIX1 and EYA1, they also induce a coupled switch in 
metabolic gene expression towards a more glycolytic expression profile, 
demonstrating that SIX1 and EYA1 can coordinately regulate a fast-glycolytic 
muscle fibre type.  
The myogenic regulatory factors MyoD and Myogenin, have been shown to 
preferentially accumulate in fast and slow muscle respectively (Voytik et al., 
1993; Hughes et al., 1993; Ekmark et al., 2007). However, MyoD remains the 
only factor to be explored in terms of its role in muscle fibre type regulation 
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and has been shown to induce specific activation of the MyHC IIB promoter 
(Wheeler et al.1999; Allen et al. 2001; Ekmark et al. 2007). Interestingly, 
myogenic regulatory factors bind E-box response elements, that are present on 
all MyHC gene promoters, and it remains unknown how these factors, such as 
MyoD, can elicit specificity in terms of transcriptional induction of MyHC 
isoforms. Ekmark et al. (2007) however, did highlight that MyoD induced 
activation of the fast MyHC genes is dependent on de-phosphorylation of 
MyoD, which is regulated by neural input or contractile activity. Other 
mechanisms regulating the actions of the myogenic regulatory factors on 
MyHC gene regulation warrant exploration, as information in this field 
remains sparse.   
Various stimuli that cause muscle hypertrophy, such as IGF-I signaling, 
myostatin signaling, and beta-adrenergic signaling, have been shown to induce 
fast MyHC isoform expression, although the mechanisms regulating these 
effects remain poorly understood. IGF-1 can induce a MyHC IIB promoter-
reporter construct in C2C12 muscle cells (Shanely et al. 2009). However, IGF-
I appeared to accelerate differentiation, which could subsequently induce an 
early expression of all MyHC genes, suggesting a potentially indirect and 
perhaps non-isoform specific induction of the MyHC IIB gene by IGF-I 
signaling.  
Myostatin, a TGF-beta family member, has been shown to be a fundamental 
negative regulator of myogenesis and muscle growth (Thomas et al. 2000; 
Langley et al. 2002). Myostatin knockout mice display profound muscle 
hypertrophy and hyperplasia with increased IIB muscle fibres and specific 
hypertrophy of type IIB fibres (Matsakas et al. 2010). Hence it is plausible that 
27 
molecular signals driving muscle hypertrophy may also regulate MyHC 
isoform expression towards the fast type II isoforms. However, the 
mechanisms regulating the increased abundance of IIB fibres in myostatin 
knockout animals remain elusive.  
Beta-adrenergic signaling also presents a potent anabolic effect in muscle 
(Ryall et al. 2002; 2004; Kline et al. 2007) and is associated with a transition 
from the slow to fast MyHC isoforms in a variety of species (Baker et al. 2006; 
Bricout et al. 2004; Depreux et al. 2002; Oishi et al. 2002; Gunawan et al. 
2007). The mode of action of beta-adrenergic signaling on muscle growth and 
MyHC isoform regulation remains poorly understood and was therefore 
explored in this thesis. Specifically, transitions in MyHC isoform expression in 
response to beta-adrenergic stimulation were examined across a broad time 
course to fully characterize the dynamic plasticity in transitions of these 
isoforms in adult muscle. Interestingly, the role of beta-adrenergic signaling 
during myogenesis remains relatively unexplored in comparison to the volume 
of work conducted in vivo and was therefore a focus of this thesis. Ryall et al. 
(2010) recently highlighted a substantial yet acute up-regulation of beta-
adrenergic receptor mRNA expression specifically during early myogenic 
fusion, suggesting a potential role for beta-adrenergic signaling during 
myogenesis. Moreover, the majority of studies examining alterations in MyHC 
isoform expression in response to beta-adrenergic signaling have been 
conducted in adult muscle and not during myogenesis. Therefore this thesis 
aimed to extend this work in myoblasts undergoing differentiation to assess the 
role of beta-adrenergic signaling on myogenesis and the initial induction of 
MyHC isoform gene expression during myoblast differentiation.  
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1.15 Bi-directional promoters in myosin heavy chain gene clusters 
A cis acting mechanism has been identified that implicates bidirectional 
promoters, located between MyHC genes, which coordinately regulate 
expression of multiple MyHC isoforms under a single promoter (Pandorf et al. 
2006; Haddad et al. 2008; Rinaldi et al. 2008; see Figure 1.7).  
 
 
 
 
 
 
Figure 1.7 Schematic depiction of the MyHC bi-directional promoters from a recent review by 
Schiaffino and Reggiano (2011). 
 
The majority of MyHC genes are located as two clusters on separate 
chromosomes and are organized in a sequential pattern (i.e. slow to fast 
isoforms), separated by non-protein coding DNA. Several reports have 
highlighted a concomitant up-regulation of an upstream MyHC antisense 
transcript following induction of itÕs nearest downstream sense transcript 
(Pandorf et al. 2006; Haddad et al. 2008; Rinaldi et al. 2008). It is postulated 
that the generation of an upstream antisense transcript can regulate expression 
of the corresponding upstream MyHC isoform gene(s), thus coordinating the 
sequential transitions in expression often exhibited by MyHC isoforms. 
Rinaldi et al. (2008) demonstrated that a down-regulation of the MyHC IIB 
sense transcript in response to resistance exercise produces a concomitant 
down-regulation of the IIX antisense, which the authors proposed was 
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responsible for permitting the subsequent up-regulation of the IIX MyHC 
isoform transcript. Identification of a bidirectional promoter in the cardiac 
MyHC gene cluster has also been identified and was shown to be responsive to 
thyroid hormone during neonatal rat development (Haddad et al. 2008). The 
authors implicate this bidirectional promoter in causing an increase in alpha 
MyHC sense transcript and a concomitant increase in beta-MyHC antisense 
transcript, which subsequently causes a down-regulation of beta-MyHC gene 
expression. Taken together, it would appear that intergenic bidirectional 
promoters might provide a putative cis acting mechanism that coordinately 
regulates MyHC isoforms located in the same cluster (Pandorf et al. 2006; 
Haddad et al. 2008; Rinaldi et al. 2008). However, these results have all been 
produced from the same laboratory and are yet to be replicated by others, at 
least in the available literature. Furthermore, mechanisms of MyHC antisense 
regulation of neighboring MyHC genes remain to be elucidated.  
 
1.16 Intronic miRNAÕs in myosin heavy chain gene regulation 
Recent reports have illustrated that MyHC genes do not only encode their 
respective contractile protein, but also contain intronic sequences encoding 
miRNAÕs involved in the complex regulation of MyHC isoform expression 
(Rooij et al. 2008; 2009). Specifically, miR-208b and miR-499, encoded by an 
intronic region of the MyHC-beta (type I) and MyHC-7b (slow-tonic) 
respectively, are exclusively expressed in slow muscles (Rooij et al. 2009). A 
double knockout of both miR-208b and miR-499 in mice resulted in a 
transition from slow to fast MyHC isoform expression, reducing slow and 
increasing fast MyHC isoform expression (Rooij et al. 2009). In contrast, 
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forced over-expression of miR-499 caused a transition from fast to slow 
MyHC isoform expression, confirming the role of miR208b and miR-499 in 
regulating a slow muscle fibre phenotype. The identification of intronic 
miRNA in MyHC genes has exposed another level of complexity in the 
regulation of MyHC expression, a field that will likely continue to expand 
rapidly (Rooij et al. 2008). 
 
1.17 Myosin heavy chain promoter response elements 
Analysis of the promoter region upstream of the MyHC genes has revealed 
insights into regulatory mechanisms controlling the expression of these genes, 
both in vitro and in vivo (Takeda et al. 1992; Wheeler et al. 1999; Allen et al. 
2001; 2005). In particular, comparisons of proximal promoter sequence 
variation amongst the three fast MyHC promoters (IIA, IIX and IIB) from 
mice has shown several highly conserved regions (AT-2, CArG-box and E-
box) that serve a regulatory role in controlling individual MyHC isoform gene 
expression (Allen et al. 2001; see Figure 1.8 below).  
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Figure 1.8 Characterized response elements that play a critical role in MyHC promoter 
activity (from Allen et al. 2001) 
 
Furthermore, it has been reported that the subtle sequence differences in these 
highly conserved regions (AT-2 and CArG-box) between the IIA, IIX and IIB 
MyHC promoters confers a specific regulatory control of the corresponding 
promoter activity (Allen et al. 2005). The AT-2 and CArG-box regions have 
been thoroughly examined in the context of the mouse MyHC IIB promoter, 
with reports showing that the AT-2 region interacts with MEF2 and Oct1 
proteins, and the CArG-box interacts with SRF (Allen et al. 2005; Lackich et 
al. 1998). However, such work needs to be continued to elucidate how 
promoter sequence variation, between MyHC isoform promoters, permits 
coordinated regulation of multiple MyHC isoforms. For instance, Allen et al. 
(2005) show that sequence variation within the CArG-box response element 
between the MyHC IIB and IIX promoters determine whether this site is bound 
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by activating or repressing transcriptional regulatory factors, respectively. 
Thus, sequence variation within conserved response elements may exist as a 
mechanism to allow differential regulation of different MyHC isoforms. With 
this in mind, there is significant variation in sequence amongst the same 
MyHC promoters from different species and this may therefore confer 
differential expression profiles of MyHC genes between species. Therefore, 
studying MyHC promoters from a variety of different species and attempting 
to elucidate signaling pathways altering activity of MyHC promoters at the 
molecular level would continue to advance the field of muscle fibre type 
regulation.  
 
1.18 Summary and objectives of this thesis 
It is clear that our understanding of skeletal muscle biology and muscle fibre 
type has increased tremendously over the last century and continued advances 
in analytical methods will likely see our understanding improve further over 
the coming years. In particular, further advancements in the use of molecular 
and cell biology is beginning to advance our understanding of the mechanistic 
biology that underpins the regulation of specific components of the muscle 
fibre. Research investigating the regulation of muscle fibre type has 
traditionally been conducted in vivo, analyzing global changes at a whole 
muscle level. Broadly, this thesis aimed to explore more ÒmolecularÓ 
approaches, utilizing in vitro cell biology and molecular biology to understand 
the expression and regulation of myosin heavy chain (MyHC) isoforms as an 
indicator of muscle fibre composition. Given the critical role of specific MyHC 
isoforms to dictate the contractile and metabolic characteristics of skeletal 
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muscle fibres, an understanding of the mechanisms regulating these genes is of 
broad importance. 
The in vitro work within this thesis was conducted using the mouse C2C12 
skeletal muscle cell line, probably the most commonly used muscle cell line in 
muscle biology labs across the world. Since muscle fibre type research is 
typically conducted in vivo, very little is known about the use of a cell line for 
studying fibre ÒtypeÓ. A few studies conducted in the late 1980Õs attempted to 
examine the expression of MyHC isoforms during myogenesis in cultured 
muscle cells (Silberstein et al. 1986; Weydert et al. 1987; Miller 1990). 
However, these studies used relatively non-specific antibodies and therefore 
did not fully elucidate MyHC isoform expression profiles during myogenesis. 
To better understand whether the C2C12 cell line is a suitable in vitro model 
for studying MyHC regulation as an indicator of muscle fibre composition, 
endogenous expression of the MyHC isoforms must first be characterized. This 
body of work was the first objective of this thesis and set out to establish if the 
C2C12 cell line can be used to study the regulation of MyHC isoforms in vitro. 
Moreover, this work specifically intended to provide a detailed 
characterization of MyHC expression during C2C12 myogenesis, permit an 
understanding of the C2C12 cell as a representative model for studying MyHC 
expression and ultimately to provide a foundation of knowledge to support 
future experiments to be conducted in this thesis and by others. In addition to 
the MyHC isoform expression profiles, other important characteristics of the 
C2C12 cell line were established, including metabolic gene expression and 
markers of proliferation and differentiation, to fully understand how the 
C2C12 cell line can be utilized in future experiments.  
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In addition to characterizing the endogenous expression of MyHC isoforms in 
the C2C12 cell line, it was important to validate whether regulation of MyHC 
isoform expression in vitro would mimic the regulation in adult muscle in vivo. 
Therefore, this thesis aimed to examine whether the dynamic plasticity of 
MyHC isoform gene expression in vivo could be mimicked in the C2C12 cell 
line. To test this, the beta-adrenergic agonist Ractopamine, a potent stimulator 
of dynamic transitions in MyHC isoform gene expression (Baker et al. 2006; 
Bricout et al. 2004; Depreux et al. 2002; Oishi et al. 2002; Gunawan et al. 
2007), was utilized both in vivo and in vitro. Furthermore, this work would 
elucidate whether a role for beta-adrenergic signaling in regulating MyHC 
isoform expression during early myogenesis exists, something that currently 
remains unknown.  
Finally, this thesis attempted to utilize the C2C12 cell line as a host 
environment for a ÒmolecularÓ based approach to understand a physiological 
difference in muscle fibre phenotype between two large mammals, the pig and 
the human. The molecular mechanisms regulating the species-differential 
expression of the MyHC IIB isoform, which is partly attributable to the vastly 
different muscle physiology displayed between these two mammals, was 
explored in vitro using the C2C12 cell line as a common MyHC IIB expressing 
environment. In particular, this body of work would establish the role of 
sequence variations between the pig and human MyHC IIB promoters in 
controlling the strength of promoter induction during myogenesis. Such work 
therefore aimed to elucidate why pigs have a very unique muscle fibre 
physiology amongst large mammals and this work would follow a molecular 
and cell biology based approach.  
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In summary, this thesis intended to conduct the following body of work: 
1. Characterize the C2C12 cell line toÉ 
a. Establish the endogenous MyHC isoform expression and 
determine whether the C2C12 cell line can be utilized for 
research into the molecular mechanisms regulating MyHC 
isoform expression. 
b. Provide a useful foundation of knowledge, including 
biomarkers of myogenesis, MyHC expression profiles and 
metabolic gene expression, to underpin future experiments to be 
conducted in this thesis, and by others.  
2. Validate whether the C2C12 cell line can mimic the plasticity of 
MyHC isoform expression profiles that occur in vivo when exposed to 
a known regulator of muscle fibre type transitions (Beta-adrenergic 
agonist, Ractopamine). Furthermore, such work should elucidate 
whether beta-adrenergic signaling has a direct role in MyHC isoform 
regulation during myogenesis.  
3. Examine whether the C2C12 cell line can be used as a host 
environment for molecular based approaches to understand the 
regulation of MyHC isoforms. Specifically, this work will aim to 
elucidate the molecular mechanisms controlling the species-differential 
expression of MyHC IIB between pigs and humans. 
 
It was hypothesized that the C2C12 skeletal muscle cell line would provide an 
interesting and valid in vitro tool for studying the molecular regulation of 
myosin heavy chain isoforms as an indicator of muscle fibre composition.  
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2. MATERIALS AND METHODS 
2.1 CELL CULTURE 
2.1.1 Overview 
In vitro experiments were conducted using the C2C12 cell line. C2C12 cells 
are an immortalized muscle cell line from the mouse hind limb, sub-cultured to 
retain differentiation potential following prolonged cultivation (Yaffe 1968). 
Due to these characteristics, this cell line is commonly used for in vitro muscle 
biology research.  
 
2.1.2 Culturing C2C12 cells 
C2C12 myoblasts were cultured in growth medium (DulbeccoÕs modified 
eagle medium (DMEM; Sigma Aldrich, Poole, UK), 10% fetal bovine serum 
(FBS; Invitrogen, Paisley, UK), 1% penicillin and streptomycin (P/S; 
Invitrogen, Paisley, UK)). In order to prevent C2C12 myoblasts exiting the cell 
cycle, myoblasts were maintained at sub confluence (<70% confluent) to allow 
expansion by serial passaging. C2C12 myoblasts were encouraged to 
differentiate at near confluence by replacing the medium with a low serum 
differentiation medium (DMEM, 2% horse serum (Invitrogen, Paisley, UK) 
and 1% P/S) and cultured for up to 8 days. Myoblasts would fuse to form 
multinuclear myotubes within 4-8 days of differentiation. Culture medium was 
changed every 48 hours to remove harmful waste products, maintain a suitable 
pH and replenish nutrients required for growth.  
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  2.1.3 Passaging cells 
If left to grow, proliferating C2C12 myoblasts would proliferate to cover the 
entire surface of a T75 cell culture flask. If C2C12 myoblasts reach this 
confluent state, they exit the cell cycle and terminally differentiate. To 
maintain C2C12 myoblasts in a proliferative state, cells were transferred to a 
new flask at a lower density to continue growth (passaged). Briefly, cell 
culture medium was removed from proliferating myoblasts (less than 70% 
confluent) and cells were washed with warm PBS (10ml). Cells were 
dislodged by incubating with Trypsin-EDTA (2ml; warm) at 37¡C for ~5 
minutes. Trypsin-EDTA was neutralized by the addition of DMEM containing 
10% fetal bovine serum (8ml). The cell suspension was centrifuged at 
1000rpm for 5 minutes and the cell pellet was re-suspended in 10ml of growth 
medium. Approximately 1/10th of the cells were transferred to a new T75 flask, 
providing 2 days of sub-confluent growth.  
 
2.1.4 Counting cells 
Myoblasts in suspension were counted using a haemocytometer. Cell number 
per ml of culture medium was calculated (see formula below) to ascertain the 
volume of cell suspension required to provide the appropriate cell number for 
seeding cells into culture plates.  
(Desired cell number / total cell number) X volume of cell suspension = 
volume required 
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  2.1.5 Freezing cells 
C2C12 myoblasts were frozen in liquid nitrogen to be used in later 
experiments. Briefly, cells were dislodged from the culture flask and pelleted 
(as described above in Òpassaging cellsÓ). Cells were re-suspended in freezing 
medium (fetal bovine serum with 10% DMSO) in cryovials and slowly frozen 
(using polystyrene insulation) at -80¡C overnight before being transferred to 
liquid nitrogen.  
 
2.1.6 Measuring myotube diameters 
Images of myotubes containing a ZsGreen fluorescence reporter (controlled by 
a differentiation specific promoter (MyHC IIB)) were analysed for myotube 
diameters using Q-Capture Pro (version 7). Images of myotubes were blind 
labelled for analysis, removing bias when analysing treated and non-treated 
myotube diameters. For each field of view, 10 myotube diameters were 
measured at 25%, 50% and 75% of the total myotube length (providing an 
average myotube dimater per myotube). Analysis of 5 fields of view per well 
(n=4 wells) of a 24-well plate was conducted to give an average myotube 
diameter for 200 myotubes per treatment. Examples of the image analysis 
software are shown below (Figure 2.1). Note that diameters were measured 
perpendicular to the myotube length (estimated by eye only). Myotube 
diameters were analysed on raw images captured using a fluorescence 
microscope and were initially measured as Ònumber of pixelsÓ. Myotube 
diamets (in number of pixels) were subsequently converted to µm by dividing 
the number of pixels covering 1µm (1.96 pixels) on an image of a 
haemocytometer at the same magnification.  
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Figure 2.1 Representative images of myotube diameter analysis using Q-Capture Pro (version 
7). Blue lines indicate measurements at 25%, 50% and 75% of total myotube length for 10 
myotubes per field of view. Red text is the myotube measurements in number of pixels. 
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2.1.7 Lowry assay - measurement of total protein content 
A Lowry assay was conducted to determine the total protein content of cells 
cultured in multi-well plates. Cells were washed in warm PBS, scraped into 
500µl tri-sodium citrate (0.05 M; pH 6.8; 4¡C) and frozen at -20¡C until use. 
Fifteen microliters of each sample (quantity loaded was optimized to fit on the 
standard curve) was loaded onto a clear 96-well flat-bottomed plate and 
combined with 150µl of 0.1M NaOH and 35µl dH2O. Serial dilutions of a 
known concentration of bovine serum albumin (BSA; 0-60µg) were loaded 
onto the 96-well plate to generate a standard curve for quantifying protein 
concentration. Following the loading of samples and standards, 50µl of 
Reagent 1 (see Table 2.1) was added to each well and incubated at room 
temperature for 5 minutes. Subsequently, 50µl of Reagent 2 (see Table 2.2) 
was added to each well and incubated at room temperature for 20 minutes prior 
to measuring absorbance (optimal wavelength = 620nm; BioRad 680XR 
Microplate reader).  
 
Table 2.1 Composition of Lowry Reagent 1 
 Volume required (ml) 
2% Na2CO3 in 0.1M NaOH 5 
1% CuSO4 0.5 
2% KNa tartrate 0.5 
 
 
Table 2.2 Composition of Lowry Reagent 2 
 Volume required (ml) 
Folin and cioculteaus phenol reagent 0.5 
0.1M NaOH 5 
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2.1.8 Creatine kinase assay: marker of myogenic differentiation 
Creatine kinase activity was assayed as a marker of myogenic differentiation 
using the CK kinetic assay kit (Thermo Electron Corporation, Fisher 
Scientific, Loughborough, UK). Others have shown that CK activity is 
reflective of differentiation status (Sharples et al. 2010). Cells were harvested 
as described above for the Lowry assay. Cells were lysed by sonication on ice 
(10 seconds at 10 amplitude microns). Ten microliters of each sample (lysed 
cells) was loaded onto a 96 well plate. Solution A and B, from the CK assay 
kit, were combined and 200µl of the combined solution were added promptly 
to each well. Absorbance was read at 340 nm at 37¡C every 5 min for 30 min 
and rate was determined, indicating creatine kinase activity.  
 
2.1.9 DNA assay Ð marker of cell number 
DNA content of cultured cells was used as a marker of cell number. DNA in 
50µl of lysed C2C12 cells was stained using Hoechst dye and assayed using a 
fluorescence platereader (excitation at 350 nm and emission at 460 nm; 
Fluostar Optima, BMG Labtech). Lysed cells (by previous sonication) were 
assayed in 1x TNE (100mM Tris, 1M NaCl, 10mM EDTA; pH 7.4) containing 
1mg/ml Hoechst dye. A standard curve was generated using serial dilutions of 
calf thymus DNA (from 40µg/ml to 0.6µg/ml) and used to quantify DNA 
content in the lysed cells. DNA content was assayed following the 
measurement of creatine kinase activity from the same samples, as creatine 
kinase activity was sensitive to freeze thawing. This allowed for creatine 
kinase activity to be analysed relative to DNA content (cell number).  
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2.2 GENE EXPRESSION ANALYSIS 
2.2.1 Overview 
To assess changes in gene expression, total RNA was extracted from the 
samples of interest, RNA was reverse transcribed to form cDNA, and specific 
transcripts of interest were amplified by Q-RT-PCR to quantify relative gene 
expression (using the standard curve method).  
 
2.2.2 RNA extraction from cells 
Total RNA was extracted from cells using an RNA isolation kit (Roche High 
Pure Isolation Kit for RNA isolation). To lyse the cells and precipitate the 
RNA, 400µl of lysis-binding solution was added directly to the frozen cells, 
allowed to thaw, and then vortexed for 15 seconds. The 600µl sample was 
centrifuged through a spin column at 8000xg for 15 seconds (at room 
temperature for all centrifugations). The flow through was discarded after each 
step. RNA caught on the membrane of the spin column was treated with 10µl 
DNase I and 90µl of DNase-incubation buffer for 15 minutes at room 
temperature. 500µl of wash solutions I and II (containing ethanol to ensure the 
RNA was precipitated and thus remained in the spin-column membrane) were 
passed through the spin column via centrifugation at 8000xg for 15 seconds. A 
further 200µl of wash solution II was passed through the column via 
centrifugation at 13000xg for 2 minutes to ensure all contaminants were 
removed from the RNA on the spin-column membrane. Finally, the RNA was 
eluted in 50µl of RNase-free H2O into a fresh 1.5ml tube via centrifugation at 
8000xg for 1 minute and stored at -80¡C.  
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2.2.3 RNA extraction from porcine skeletal muscle 
Due to the fibrous nature of skeletal muscle, a more robust method, compared 
to that used for cells, was required for RNA extractions from skeletal muscle. 
One hundred milligrams of crushed Longissimus Dorsi (LD) muscle tissue was 
homogenized in 1ml Trizol reagent (Invitrogen) and centrifuged at 12,000xg 
for 10 minutes at 4¡C. The supernatant was transferred to a fresh tube, 
incubated at 20¡C for 5 minutes before the addition of 200µl chloroform. The 
sample was shaken by hand, incubated at 20¡C for 3 minutes before being 
centrifuged at 12,000xg for 15 minutes at 4¡C. The colorless aqueous phase 
was transferred to a fresh tube, mixed with 250µl isopropanol and 250µl high 
salt precipitation solution (0.8M Sodium Citrate/ 1.2M NaCl), incubated for 10 
minutes at 20¡C and then centrifuged at 12,000xg for 10 minutes at 4¡C. The 
supernatant was discarded, the RNA pellet was washed with 1ml 75% ethanol 
and then re-centrifuged at 7,500xg for 5 minutes at 4¡C. The supernatant was 
removed, the RNA pellet was air-dried, re-suspended in 40µl water with 5µl 
DNase 10x buffer (Promega) and 5µl DNase (1U/µl; Promega) and incubated 
for 30 minutes at 37¡C. Following incubation, 150µl water and 200ul 
Phenol/Chloroform/Isoamyalcohol were added to the DNase-treated RNA, 
mixed and centrifuged at 12,000xg for 5 minutes. The upper layer was 
transferred to a fresh tube with 15µl NaAc (3M) and 375ul ethanol and was 
precipitated at -80¡C overnight. Following precipitation, the RNA was pelleted 
via centrifugation, washed in 75% ethanol and re-suspended in water as 
previously described above. RNA was stored at -80¡C until used. RNA 
concentration was determined using a Nanodrop ND-1000 (Thermo Scientific, 
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Wilmington, USA) and concentrations were adjusted to 100ng/µl for cDNA 
synthesis. 
 
2.2.4 RNA integrity check 
As an indicator of RNA integrity, ribosomal RNA (18S and 28S) bands were 
visualised by agarose gel electrophoresis to ensure bands were intact and not 
degraded. Furthermore, RNA concentration and purity was checked using a 
Nanodrop¨ ND-1000 (Thermo Scientific, Wilmington, USA). A 260/280 ratio 
of ~2.0 was suggestive of pure RNA (with minimal contaminants).  
 
2.2.5 cDNA synthesis (Using Promega reagents) 
RNA concentration was quantified using a Nanodrop¨ ND-1000 (Thermo 
Scientific, Wilmington, USA) and concentrations were adjusted to 100ng/µl. 
First strand cDNA synthesis was carried out by combining 5µl of RNA 
(500ng) with 1µl of random primers (500µg/ml; Promega, Southampton, UK) 
and 9µl of RNase-free H2O (total volume 15µl) and incubated at 70¡C for 5 
minutes and then placed immediately on ice. On ice, 5µl Moloney Murine 
Leukemia Virus (MMLV) reverse transcriptase buffer (5X), 1µl of MMLV 
reverse transcriptase (200U/µl), 1.25µl of dNTPÕs (10mM each), 0.5µl RNasin 
(RNase inhibitor; 40U/µl; all Promega, Southampton, UK) and 2.25µl RNase-
free H2O were added to each reaction (total volume 25µl), vortexed and 
incubated for 10 minutes at room temperature followed by 1 hour at 42¡C. 
Following incubation, cDNA was diluted 4-fold by the addition of 75µl 
RNase-free H2O and stored at -20¡C. All synthesized cDNA was tested by 
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conducting a single Q-RT-PCR reaction using a validated primer set to ensure 
every sample contained cDNA. 
 
2.2.6 cDNA synthesis (using Roche reagents) 
Suppliers for cDNA synthesis reagents were changed for improved cost 
effectiveness but all experiments were conducted using reagents from only one 
supplier. First strand cDNA synthesis was carried out using a cDNA synthesis 
kit (Transcriptor First Strand cDNA Synthesis Kit, Roche, Burgess Hill, UK). 
In thin walled PCR tubes, 500ng total RNA was incubated in a total volume of 
13µl with a final concentration of 60µM random hexamer primers at 65¡C for 
10 minutes. The reaction was immediately cooled on ice. Whilst on ice, 
Transcriptor Reverse Transcriptase Reaction Buffer (5X concentrated), 
Deoxynucleotide Mix (final concentration 1mM each), 10 U Transcriptor 
Reverse Transcriptase and 20 U Protector RNase Inhibitor were added to the 
initial reaction, to a final volume of 20µl. The reaction mixture was gently 
pipette mixed and incubated at 25¡C for 10 minutes, 55¡C for 30 minutes, 
85¡C for 5 minutes and then immediately placed on ice. The cDNA was 
diluted 5-fold to give 100µl ÒstockÓ cDNA for Q-RT-PCR and stored at -20¡C 
until analysis. All synthesized cDNA was tested by conducting a single Q-RT-
PCR reaction using a validated primer set to ensure every sample contained 
cDNA. 
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2.2.7 Quantitative RT-PCR 
Real time PCR was conducted on a Lightcycler 480¨ (Roche, Burgess Hill, 
UK) to assess the relative abundance of specific mRNAÕs. Reactions were 
carried out in triplicate on 384 well plates. Each well contained 5µl of cDNA 
with the following reagents: 7.5µl SYBR green master mix (Roche, Burgess 
Hill, UK), 0.45µl forward and reverse primers (10µM each; final concentration 
0.3µM each) and 1.6µl RNase-free H2O (total volume of 15µl per well). 
Samples were pre-incubated at 95¡C for 5 minutes followed by 45 PCR 
amplification cycles (de-naturation: 95¡C for 10 seconds; annealing: 60¡C for 
15 seconds; elongation: 72¡C for 15seconds). A standard curve was produced 
using serial dilutions (typically 1:8) of a pool of cDNA made from all samples 
to check the linearity and efficiency of the PCR reactions (see Figure 2.2). 
PCR efficiency was between 1.8 and 2.1 for all primers. Relative transcript 
abundance was determined using the standard curve and was corrected for the 
quantity of cDNA in each reaction.  
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Figure 2.2 Outputs from the Roche LightCycler380. Upper panel shows a standard curve, 
generated by using serial dilutions of the template cDNA in Q-PCR reaction. The standard 
curve generated confirms the reaction was efficient, producing a linear standard curve which 
subsequently permits quantification of relative mRNA abundance. The lower panel shows melt 
curve analysis of the samples used in the upper panel. Only one melt curve peak was produced 
indicating a single amplicon was generated in the PCR reaction.  
 
 
2.2.8 Testing primers used for quantitative RT-PCR 
Melt-curve analysis for all primer sets was conducted on cDNA (derived from 
the appropriate species) to ensure only one amplicon was being produced in 
the PCR reaction and that no primer-dimers were forming (see Figure 2.3). 
Amplicons were separated by horizontal agarose gel (1.5%) electrophoresis 
following Q-RT-PCR for all primers to ensure a) only one amplicon was being 
produced by the PCR reaction (i.e. no miss-amplified products or primer-
dimers), b) that the amplicon produced was of the correct length, and c) that no 
amplicon was produced in the absence of template cDNA.  
-  Standard curve using serial 
dilutions (1:8) of pooled 
cDNA samples (brown lines) 
-  Sample cDNA expression 
curves are expressed within 
the range of the standards 
-  Melt curve analysis of 
samples in the above 
expression curves (one 
peak indicates only one 
amplicon was produced) 
-  PCR linearity check 
(linear slope) 
-  Optimal gradient = 3.3 
-  Optimal efficiency = 2.0 
49 
 
Figure 2.3 Examples of melt curve analysis outputs to assess the number of amplicons 
produced in the Q-PCR reaction. The upper panel shows a single peak indicating only one 
amplicon was produced. The middle panel shows two peaks, which indicates some non-
specific binding and the generation of two amplicons in the Q-PCR reaction. The lower panel 
shows a single peak for samples with cDNA and a different peak for the non-template controls, 
suggesting the formation of primer-dimers in the absences of cDNA template.  
 
 
 
 
 
 
 
 
-  Clean melt curve analysis 
-  Single peak indicates only 
one amplicon was produced 
-  Non-specific amplification 
-  Two melt curve peaks 
(indicates two amplicons 
have been produced) 
-  Primer-dimers in non-template 
control (smaller peak) 
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2.2.9 Oligreen quantification of total cDNA 
Due to the broad time course studied for cell culture work (from myoblasts to 
mature myotubes) quantifying mRNA transcript abundance relative to a 
housekeeper gene was not possible as unpublished data from this laboratory 
suggests that no housekeeper gene remains constant across the entire time 
course investigated. Thus, total cDNA concentration was determined and 
mRNA transcript abundance was corrected for total cDNA.  
Total cDNA quantification was conducted on a Lightcycler 480¨ (Roche, 
Burgess Hill, UK) using Oligreen (Invitrogen, Paisley, UK), shown to 
specifically bind with single stranded DNA molecules (Rhinn et al. 2008). 
Reactions were carried out in triplicate on 384 well plates. 5µl Oligreen was 
added to 995µl 1x TE buffer to make the working Oligreen solution. Each well 
contained 5µl of cDNA plus 5µl Oligreen working solution. Fluorescence was 
quantified with increasing temperature (constant ramp rate of 0.11¡C/s; up to 
95¡C). The fluorescence at 80¡C was plotted against a standard curve, 
produced using serial dilutions of a pool of cDNA made from all samples, to 
determine the relative quantity of cDNA. Normalization using the oligreen 
method was also used for Q-RT-PCR conducted on cDNA derived from 
porcine skeletal muscle. 
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2.3 SDS-PAGE OF MYOSIN HEAVY CHAIN ISOFORMS 
2.3.1 Overview 
The technique described herein was conducted in an attempt to separate 
porcine myosin heavy chain (MyHC) isoforms by SDS-PAGE (to quantify 
relative proportions of MyHC isoform expression). Unfortunately, separation 
of the porcine type II MyHC isoforms was not possible despite getting the 
method working successfully for other species, such as rat and sheep. The gel 
compositions presented herein successfully separated rat and sheep MyHC 
isoforms. A range of variations in these recipes was conducted (not shown). 
Antibody approaches were not conducted as porcine specific antibodies do not 
exist and existing MyHC antibodies for other species have shown poor cross-
reactivity between species.  
 
2.3.2 Myosin heavy chain protein extraction 
One hundred milligrams of crushed muscle tissue was homogenized at 22,000 
rpm in 5ml of extraction buffer (0.5M NaCl, 20mM NaPPi, 50mM Tris Base, 
1mM EDTA and 1mM DTT). Samples were placed on ice for 10 minutes prior 
to centrifugation at 2,500xg (10 minutes at 4¡C). The interphase (500µl) was 
transferred to a separate tube, mixed with 500µl of 87% glycerol and stored at 
-20¡C. Protein concentration was determined by Lowry assay (previously 
described in this chapter).  
 
2.3.3 Sample preparation 
Samples were adjusted to equal concentrations of protein, combined with an 
equal volume of Laemmli loading buffer (20% (v/v; 87%) glycerol, 125mM 
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Tris (pH 6.8), 4% (w/v) SDS, 0.02% (w/v) pyronin-Y and 10% (v/v) β-
mercaptoethanol), incubated for 10 minutes at room temperature, followed by 
10 minutes at 70¡C. Two micrograms of protein was loaded per lane on 
0.75mm thick SDS-PAGE gels (see section below for gel compositions).  
 
2.3.4 SDS-PAGE gel composition 
A range of gel compositions was tested in an attempt to successfully separate 
all 4 porcine MyHC isoforms by SDS-PAGE. The two tables below show the 
optimal gel compositions for the separation of rat (Table 2.3) and sheep (Table 
2.4) MyHC isoforms. Note that these gels were species-specific and would 
therefore exclusively separate rat or sheep MyHC isoforms (not both).  
 
Table 2.3 SDS-PAGE gel for separating rat MyHC isoforms 
 
Separating gel Stacking gel 
87% Glycerol (ul) 2015 750 
49:1 Acrylamide (ul) 1000 250 
2M Tris pH 8.8 (ul) 500   
700mM Tris pH 6.7 (ul)   250 
50mM EDTA (ul)   200 
1M Glycine (ul) 500   
40mg/ml SDS (ul) 500 250 
dH2O (ul) 435 800 
AMPS (100mg/ml) (ul) 50 25 
TEMED (ul) 2.5 1.25 
Total volume (ml): 5 2.5 
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Table 2.4 SDS-PAGE gel composition for separating sheep MyHC isoforms 
 
Separating gel Stacking gel 
40% Acrylamide (ul) 980 245 
2% Bis-Acrylamide (ul) 393 98 
2 M Tris pH 8.8 (ul) 500   
1 M Tris pH 6.8 (ul)   175 
1 M glycine (ul) 500   
100 mM EDTA (ul)   100 
87% glycerol (ul) 1725 863 
10% SDS (ul) 200 100 
TEMED (ul) 2.5 1.25 
AMPS (ul) 50 25 
Total volume (ml): 4.4 1.6 
 
 
2.3.5 SDS-PAGE 
SDS-PAGE was conducted using Bio-Rad mini-gel tanks. The upper running 
buffer consisted of 100mM Tris, 150 mM glycine, 0.1% (w/v) SDS, and 
10mM β-mercaptoethanol. The lower running buffer was half the 
concentration of the upper running buffer and did not contain β-
mercaptoethanol. Gels were run at 70 volts for 30 hours at 4¡C.   
 
2.3.6 Fixing and staining gels 
Following electrophoresis, gels were stained in fixing solution (30% (v/v) 
ethanol and 5% (v/v) acetic acid) for 30 minutes. After fixing, gels were 
stained for 30 minutes in 25% (v/v) isopropanol, 10% (v/v) acetic acid and 
0.2% (w/v) Coomassie Blue R250. Gels were de-stained overnight in fixing 
solution. Images of the gels were obtained to assess MyHC band migration.  
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2.4 MOLECULAR BIOLOGY METHODS 
2.4.1 Overview 
The methods described herein are a detailed description of the molecular 
biology techniques used to study the role of the myosin heavy chain (MyHC) 
IIB promoter sequence in dictating the expression of the MyHC IIB gene in 
porcine skeletal muscle (Chapter 5). 
 
2.4.2 Experimental design summary 
Approximately 1kb of the pig and human myosin heavy chain IIB (MyHC IIB) 
promoters (-961bp to +32bp, relative to the TATA box) was generated by 
polymerase chain reaction (PCR), cloned into the pZsGreenI-I fluorescence-
reporter plasmid (Clontech) and transfected into the C2C12 mouse myoblast 
cell line to assess relative promoter activities. Additional constructs were made 
to elucidate regions of regulatory control within the MyHC IIB promoters and 
are discussed in detail in the following sections.  
 
2.4.3 Extraction of genomic DNA from tissue and blood 
Porcine genomic DNA (gDNA) was extracted from liver tissue using the 
Qiagen DNeasy kit using the manufacturers guidelines for use with animal 
tissue. Briefly, 15mg of frozen, crushed liver tissue was incubated in 180µl of 
ATL (lysis) buffer and 20µl proteinase-K at 56¡C for 3 hours, vortexing every 
30 minutes, to lyse cells and digest protein. DNA was precipitated by the 
addition of 200µl buffer AL and 200µl 100% ethanol and vortexed for 15 
seconds. The mixture was transferred to a spin column, centrifuged at 6000xg 
for 1 minute and the flow through discarded. The DNA caught in the column 
55 
membrane was washed by the addition of wash buffer AW1, centrifuged at 
6000g for 1 minute and flow through discarded. A second wash was performed 
by the addition of wash buffer AW2 to the column and centrifuged at 20,000xg 
for 3 minutes to remove any residual wash buffers. The spin column, 
containing the trapped DNA, was transferred to a 1.5ml tube, and the DNA 
was eluted by the addition of 100µl elution buffer AE and centrifugation at 
6000xg for 1 minute. Extracted DNA was inspected for quantity and purity 
using a NanoDrop (Agilent Biosystems). Porcine DNA concentration from 
liver tissue was 355ng/µl and had a 260/280 reading of 1.86. This DNA was 
considered pure and ready for PCR applications. 
Human DNA was extracted from anti-coagulated fresh whole blood using the 
Qiagen DNeasy kit according to the manufacturerÕs instructions for use with 
whole blood. In a 1.5ml tube, 20µl proteinase-K was combined with 50µl of 
anti-coagulated human blood and adjusted to a final volume of 220µl with 
phosphate buffered saline. Prior to the addition of ethanol, 200µl buffer AL 
was added to the blood, vortexed and incubated at 56¡C for 10 minutes. 
Following this incubation, 200µl of 100% ethanol was added to the mixture, 
vortexed and then transferred to a spin column membrane for centrifugation at 
6000xg for 1 minute. The flow through was discarded. The membrane, 
containing the DNA, was washed twice by the addition of 500µl of wash 
buffers AW1 and AW2 and centrifuged for 1 and 3 minutes respectively (at 
6000xg and 20,000xg respectively). The spin column was transferred to a fresh 
1.5ml tube. The DNA was eluted in 100µl elution buffer AE by centrifugation 
at 6000xg for 1 minute. Human DNA concentration from whole blood was 
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17ng/µl and had a 260/280 reading of 1.82. This DNA was considered pure 
and ready for PCR applications. 
 
2.4.4 Identification of the MyHC IIB promoter 
Using the current genome builds for pig (Sscrofa10) and human (GRCh37), 
accession numbers for the pig and human MyHC IIB gene (NM_001123141.1 
and ENSG00000264424.1, respectively) and subsequent screening of 
expressed sequence tags, enabled the identification of the first exon of the 
MyHC IIB gene for both species. The 3Õ oligonucleotide primer was designed 
to span into the first exon to ensure inclusion of the transcription start site. 
Both predicted start sites were approximately 25 base pairs downstream of a 
TATA-box, providing confidence in the location of the transcription start site. 
All base pair numbering is given relative to the TATA-box, as a discrepancy 
existed as to the precise location of the transcription start site between the two 
promoters. 
 
2.4.5 PCR of the MyHC IIB promoter from genomic DNA 
Oligonucleotides were designed complementary to the sense and anti-sense 
strand covering the genomic region of interest. Five-prime oligonucleotide 
modifications introduced restriction endonuclease sites and poly-A tails to the 
amplicon produced (Figure 2.4 and 2.5).  
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Figure 2.4 Schematic detailing the engineering of restriction sites onto a PCR amplicon. 
Complementary primer sequences anneal to the template DNA whilst the additional sequence 
(restriction site and poly-A tail) 
 
 
 
Complimentary regions of the primer anneal to the gDNA whilst the 5 prime 
additions remained non-annealed (as shown in Figure 2.4). The PCR amplicon 
produced contained the engineered restriction sites and poly-A tails introduced 
by the oligonucleotide 5 prime modifications (shown in Figure 2.5). 
 
 
 
Figure 2.5 Schematic representation of the PCR amplicon including the restriction sites and 
poly-A tail 
 
 
Inclusion of these modifications allowed directional insertion of the MyHC IIB 
promoter to the host plasmid (pZsGreen1-1 plasmid; explained in detail 
below). The addition of a poly-A tail was included to improve the efficacy of 
the restriction endonucleases employed.  
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Amplification of the 1kb MyHC IIB promoter region was conducted using the 
Expand High Fidelity PCR System (Roche). In a final reaction volume of 50µl, 
50ng of template gDNA was combined with 200µM of each dNTP, 300nM 
forward and reverse primers, 1x Expand High Fidelity PCR Buffer (with 
magnesium at 1.5mM) and 2.6U of Expand High Fidelity Enzyme Mix. The 
reaction was gently mixed by pipetting up and down followed by a brief 
centrifugation prior to incubation in a thermal cycler. Thermal cycling 
parameters were dependant on the length of the amplicon being produced and 
the oligonucleotide sequences employed. Thermal cycling parameters for the 
1kb pig and human MyHC IIB promoters is detailed in Table 2.5. All primer 
sequences are displayed in Table 2.6. 
 
Table 2.5 Thermal cycling parameters for amplification of the 1kb pig and human MyHC IIB 
promoters. 
 
 Temperature Time Cycles 
Initial denaturation 94¡C 2 minutes X 1 
Denaturation 
Annealing 
Elongation 
94¡C 
55¡C 
72¡C 
15 seconds 
30 seconds 
2 minutes 
X 10 
Denaturation 
Annealing 
Elongation 
94¡C 
55¡C 
72¡C 
15 seconds 
30 seconds 
2 minutes + 5 seconds 
X 20 
Final elongation 72¡C 7 minutes X 1 
Cooling 4¡C ∞ X 1 
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Table 2.6 Oligonucleotide primer sequences for all cloning 
 
 
 
Oligonucleotide name Sequence (5'-3')
Human_IIB_R AAAAAACCCGGGAGGAAGGATGGGAAAGAGG
Pig_IIB_R AAAAAACCCGGGAGGAAGGACAGGACAGAGGCAT
Human_IIB_67bp_F AAAAAACTCGAGGCCAAGTAGGTTCCCAGCTAG
Pig_IIB_67bp_F AAAAAACTCGAGGCCAAGTAGGTTCCCAGCTGG
Human+pig_IIB_113bp_F AAAAAACTCGAGCCACAGTCAGTGAATATTGTGCA
Human_IIB_231bp_F AAAAAACTCGAGCAGTGTTAGAAGCCCTGAATCC
Pig_IIB_231bp_F AAAAAACTCGAGTAGCCTTAGAAGCCCTGAATCTC
Human_IIB_466bp_F AAAAAACTCGAGTCCAGACTGTGGCTAGGAATG
Pig_IIB_466bp_F AAAAAACTCGAGTCATCAGTATTTCTAAAATCCAGACC
Pig_961bp_(1kb)_F AAAAAACTCGAGTAGGTGACACACTTAGCGTGGACA
Human_961bp_(1kb)_F AAAAAACTCGAGCTTAGAGTAGGTATATTTCCTGCCAT
Human_IIB_HindIII_F CAGTGTTAGAAGCTTTGAATCCCCATC
Human_IIB_HindIII_R TTTCTCCAGTTTGGCTGTTGCATC
Pig_IIB_HindIII_F GCCTTAGAAGCTTTGAATCTCCATC
Pig_IIB_HindIII_R TATTTCTCCAGCTTTGCTGTTCCATC
Human_IIB_AT3_SDM_F CTATCAAATGCCTCAAAAGAACCCTAGA
Human_IIB_AT3_SDM_R GGGATGGGGATTCAGGGC
Human_IIB_midAT2-3_SDM_F GAACCCTAGATGATCCTCTGTTAAAT
Human_IIB_midAT2-3_SDM_R TTTATAGGCATTTGATAGGGGATGG
Human_IIB_distAT2_SDM_F CTAGATCATCCTCTGTCAAATTATTTATGGG
Human_IIB_distAT2_SDM_R GGTTCTTTATAGGCATTTGATAGGGG
Human_IIB_proxAT2_SDM_F CCTCTGTTAAATTATTTATAGGTGTCAAGAAATA
Human_IIB_proxAT2_SDM_R ATGATCTAGGGTTCTTTATAGGCATT
Human_IIB_CArG_SDM_F AGATTGCCAAAAAAGGTTTTGCCAAG
Human_IIB_CArG_SDM_R CTTTGCACAATATTCACTGACTGTGG
Human_IIB_EBOX2_SDM_F TTCCCAGCTGGGACAGCT
Human_IIB_EBOX2_SDM_R CCTACTTGGCAAAACCGTTTTTGGC
Human_IIB_T_removal_F GCCAAGTAGGTTCCCAGCT
Human_IIB_T_removal_R AAACCTTTTTTGGCAATCTCTTTGCAC
No-CArG_R CTCTTTGCACAATATTCACTGACTGTG
No-CArG_Pig_IIB_F AGTAGGTTCCCAGCTGGG
No-CArG_Human_IIB_F AGTAGGTTCCCAGCTAGGAC
CMV-basic_F AAAAAAAAGCTTGCAAATGGGCGGTAGGC
CMV-basic_R AAAAAACCCGGGGATCTGACGGTTCACTAAACCAGC
MyoD_F AAAAAAAGATCTGCCACCATGGAGCTTCTATCGCCG
MyoD_R AAAAAAACCGGTGCTCAAAGCACCTGATAAATCGC
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To confirm the length of the amplicon produced and that no (or minimal) non-
specific binding and subsequent miss-amplification had occurred, an aliquot of 
the PCR reaction was checked on a horizontal agarose gel (see example below; 
Figure 2.6). A 6µl aliquot of the PCR reaction (including 1x loading buffer) 
was loaded into the well of a horizontal 1% agarose gel, separated by 
electrophoresis and visualised following 30 minutes staining with ethidum 
bromide. 
 
 
 
 
 
 
 
 
 
Figure 2.6 The successful amplification of a 1kb PCR product was checked by agarose gel 
electrophoresis. The DNA was stained with ethidum bromide and visualised under UV light.  
 
 
2.4.6 Spin column purification of PCR amplicons 
If the PCR produced an amplicon of the correct length, the DNA was purified 
through a PCR purification column (PCR clean-up kit, Sigma Aldrich). The 
spin columns used herein effectively separated the large (wanted) DNA 
fragments from the small (unwanted) DNA fragments (<100bp), whilst also 
removing buffers and enzymes. The purified DNA could subsequently be used 
in downstream applications. Briefly, a spin column was prepared by applying 
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500µl of column preparation solution to the column membrane and 
centrifuging at 12,000xg for 30 seconds (flow through was discarded). Five 
volumes of binding solution was added to the PCR, mixed, transferred to the 
spin column and centrifuged at 12,000xg for 1 minute (flow through was 
discarded). The DNA trapped in the column membrane was washed by 
applying 500µl of wash buffer (containing ethanol) to the column and 
centrifuging at 12,000xg for 1 minute. The flow through was discarded and the 
spin column was centrifuged at 12,000xg for 2 minutes to remove residual 
wash buffer from the column. The column membrane was subsequently 
incubated with 50µl molecular grade water (Sigma Aldrich) at room 
temperature for 1 minute to re-dissolve the DNA and then centrifuged 
(12,000xg for 1 minute) to elute the DNA in a final volume of 50µl.   
 
2.4.7 Restriction endonuclease digestion 
The 1kb MyHC IIB promoters were engineered via PCR to contain Xho1 and 
Xma1 restriction sites at their 5Õ and 3Õ ends respectively. These restriction 
sites were unique (i.e. they did not appear elsewhere within the MyHC IIB 
promoters) and were appropriately located in the multiple cloning site (MCS) 
of the host plasmid (pZsGreenI-I). Both the MyHC IIB promoter and the host 
vector underwent a double restriction endonuclease digest reaction to create 
overhanging sticky ends to allow the directional insertion of the promoter into 
the host vector, upstream of the fluorescence reporter gene (ZsGreen; see 
Figure 2.7 below). The activity of Xho1 and Xma1 was 100% in NEB buffer 4, 
allowing both enzymes to be used in the same reaction (known as a double 
digest). 
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Figure 2.7 Schematic representation of the cloning strategy employed herein. The generation 
of complementary overhanging sticky ends, by restriction digest, permitted directional 
insertion of the promoter into the host plasmid.  
 
DNA was digested for approximately 3-4 hours at 37¡C in a reaction volume 
of 50µl containing 1x NEB Buffer 4, ~10U of each Xho1 and Xma1 restriction 
endonucleases (New England Biolabs) and 5ug bovine serum albumin (BSA). 
Inclusion of BSA was necessary to stabilise the Xho1 and Xma1 enzymes 
during the reaction. Control digests were conducted to ensure each restriction 
endonuclease was capable of cutting plasmid DNA in separate reactions. The 
63 
successful digestion of plasmid DNA was confirmed by gel electrophoresis. 
Circular plasmid DNA appeared as multiple bands (supercoiled DNA) whereas 
linearized plasmid DNA appeared a single band, confirming the activity of the 
restriction endonuclease (see Figure 2.8 below).  
 
 
 
 
 
 
 
Supercoiled (circular) 
plasmid DNA to 
linearized DNA 
 
 
 
Figure 2.8 Circular plasmid DNA migrates as multiple bands due to supercoiling (left gel). 
Linearized plasmid DNA, by a single restriction digest, migrates as a single band (right gel).   
 
 
Following a 3-4 hour restriction endonuclease reaction, 20U of calf intestinal 
alkaline phosphatase (CIAP; Promega) was added to the plasmid reaction (but 
not to the promoters) and maintained at 37¡C for an additional 30 minutes. 
Although the overhanging sticky ends were essentially non-cohesive, addition 
of CIAP removed the 5Õ phosphate group from the plasmid DNA to further 
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reduce the risk of plasmid re-ligation and thus reduce background, plasmid-
only, colonies during cloning. CIAP was compatible with the NEB buffers 
being used herein. 
 
2.4.8 Gel purification of MyHC IIB promoter and host plasmid 
Following restriction endonuclease digest of plasmid and promoter DNA, 
removal of buffers, enzymes and most importantly, small fragments of 
digested DNA that could interfere with downstream ligation reactions, was 
conducted via agarose gel purification. The DNA mixture, containing 1x 
loading buffer and 1x SYBRgreen, was loaded onto a 1% agarose gel and 
separated by gel electrophoresis. Since SYBRgreen intercalates with double 
stranded DNA, the DNA bands, attaining to the correct length, could be 
visualised and excised on a transluminator box using a sterile scalpel blade. 
Excising the band of the correct length from an agarose gel ensures that only 
the bands of interest are taken forward for downstream cloning applications. 
The DNA was then purified from the agarose gel using a gel extraction kit 
(Qiagen) according to the manufacturers guidelines. Briefly, the excised band 
was combined with 3 volumes Buffer QG and incubated at 50¡C for 10 
minutes (vortexing occasionally) to dissolve the agarose. To increase the yield 
of large DNA fragments (>4kb; the plasmid DNA used herein), 1 volume 
isopropanol was added to the solution and vortexed. The entire solution was 
then transferred to a spin column, centrifuged at 10,000xg for 1 minute and the 
flow through discarded. The spin column was washed by applying 750µl 
Buffer PE (containing ethanol), centrifugation at 10,000xg for 1 minute and 
discarding the flow through. The spin column was centrifuged for an 
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additional 2 minutes to removal any residual wash buffer. The column was 
transferred to a fresh 1.5ml tube, incubated with 50µl Elution Buffer (10mM 
Tris-Cl, pH 8.5) on the column membrane for 1 minute at room temperature 
and centrifuged for 1 minute at 10,000xg to elute the DNA.  
 
2.4.9 Ligation of the MyHC IIB promoter into the host plasmid 
Following the extraction and purification of the plasmid DNA and the MyHC 
IIB promoters, a small aliquot (5µl) was checked on a 1% agarose gel (see 
Figure 2.9) to a) ensure a single product of the correct length was present and 
b) to estimate the relative quantities of DNA present. An estimate of the 
relative quantity of DNA is required for optimal ligation efficiency (explained 
below). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9 Relative quantities of the plasmid and promoter DNA were estimated by gel 
electrophoresis.  
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The relative quantity of insert:plasmid DNA takes into account both the 
density of the DNA band and the length of the given DNA fragments. For 
example, the bands on the above gel image (Figure 2.9) are of a similar density 
but the insert DNA (MyHC IIB promoter) is 4x smaller than the plasmid. 
Thus, an equal volume of both insert and plasmid DNA would equate to a ratio 
of 4:1 (insert:plasmid). The optimal molar ratio of insert:plasmid DNA for 
ligations reactions is typically between 3:1 and 5:1. Therefore, 1µl of both the 
MyHC IIB promoter DNA and plasmid DNA (molar ratio of 4:1) were used in 
the ligation reaction for the products in the above example.  
 
 
The ligation reaction was carried out in a volume of 10µl with 1x T4 DNA 
Ligase Buffer (Promega), 1.5U T4 DNA ligase (Promega) and an 
insert:plasmid DNA ratio of approximately 4:1. Reactions were conducted 
over night at 16¡C and then stored at 4¡C for approximately 6 hours prior to 
use. Negative ligation controls (containing only plasmid DNA with no insert 
DNA) were used to check for the relative occurrence of plasmid re-ligation.  
Ligation of the MyHC IIB promoter into the MCS of the pZsGreenI-I plasmid 
resulted in the MyHC IIB promoter residing upstream of the ZsGreen 
fluorescence reporter gene as depicted below (Figure 2.10). 
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Figure 2.10 The MyHC IIB promoter was ligated upstream of the ZsGreen gene to generate a 
fluorescence promoter-reporter plasmid. The ZsGreen gene is circled in red. 
 
 
2.4.10 Transformation of JM109 competent E-coli  
Following the ligation reaction, some plasmids should now contain the MyHC 
IIB promoter. To amplify clonal copies of the MyHC IIB pZsGreenI-I 
plasmids, they were cloned in JM109 competent E-coli cells (Promega). 
Approximately 8µl of the ligation reaction was incubated with 50µl competent 
E-coli cells on ice for 30 minutes. This mixture of cells and DNA underwent a 
heat shock by submerging the mixture (in 14ml tubes) into water at 42¡C for 
45 seconds followed by 2 minutes on ice. This process essentially damages the 
cell wall, allowing plasmid DNA to randomly move into the cell. Following 
incubation on ice, 950µl of Super Optimal Broth with additional glucose 
(SOC) medium (Invitrogen) was added and the cells were cultured in 
suspension at 37¡C whilst shaking at 200rpm for 1.5 hours. This allowed the 
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cells to recover and start producing the antibiotic resistance gene encoded by 
the plasmid back bone (see Figure 2.11).  
 
 
 
 
 
 
 
 
 
 
Figure 2.11 The red circle indicates the antibiotic selection marker that ensures antibiotic 
resistance of JM109 cells containing intact copies of the plasmid.  
 
 
Using kanamycin containing agar plates (50µg/ml), 50µl of the cultured 
competent cells were seeded and grown over-night under selection at 37¡C. 
Only competent cells containing the kanamycin resistance gene (encoded by 
intact plasmids; shown in the diagram above) would survive and grow to form 
colonies.  
 
2.4.11 Colony selection for plasmid expansion 
Growth of colonies would only occur if they contained circular plasmid DNA. 
The plasmid DNA in the cell will either contain no insert (i.e. it has self-
ligated) or it will have the MyHC IIB promoter inserted. To estimate the 
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percentage of colonies on a plate that had the MyHC IIB inserted, the number 
of so called positive colonies were corrected for the number of colonies that 
had grown on the negative ligation control plate (that contained only plasmid 
DNA in the ligation reaction). For example, if 100 colonies appeared on the 
plasmid-with-insert ligation plate and 10 colonies appeared on the plasmid 
only (negative) ligation plate, it would stand that approximately 1 in 10 
colonies may contain no insert. Using this information, a number of colonies 
could be selected to ensure that some of these colonies stood a reasonable 
chance of containing plasmid DNA with the MyHC IIB promoter inserted. 
Typically 5 to 10 colonies were selected for expansion. Colonies were picked 
for expansion by touching the colony with a sterile pipette tip, dropping the tip 
into 3ml LB medium containing 50µg/ml kanamycin and grown overnight at 
37¡C (whilst shaking at 200rpm). The medium would turn from clear to cloudy 
over-night indicating bacterial growth.  
 
2.4.12 Small-scale plasmid extraction 
The Sigma Plasmid Miniprep Kit (Sigma Aldrich) was used to extract small 
quantities of plasmid DNA from an overnight culture. Briefly, 3-5ml of 
overnight culture was pelleted by centrifugation at 3,000rpm for 5-10 minutes. 
Medium was removed (which should be clear post-centrifugation) and the 
pellet was re-suspended in 200µl cold (4¡C) re-suspension solution containing 
RNase. Cells were lysed by the addition of 200µl lysis solution and mixed by 
inversion 6-8 times. The addition of 350µl of neutralization solution followed 
by gentle inversion (4-6 times) neutralized the lysis reaction to prevent 
permanent damage to plasmid DNA. Cell debris and chromosomal DNA 
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precipitated and were subsequently pelleted by centrifugation at 12,000xg for 
10 minutes. A miniprep binding column was prepared by adding 500µl of 
column preparation solution to the column and centrifuging at 12,000xg for 30 
seconds and discarding the flow through. The supernatant of the lysed cells 
was then transferred to the pre-prepared spin column and centrifuged at 
12,000xg for 30 seconds and the flow through discarded. The column was 
washed by the addition of 750µl of wash solution (containing ethanol), 
centrifuging at 12,000xg for 30 seconds and discarding the flow through. Any 
residual wash buffers were removed from the column by centrifugation at 
12,000xg for 2 minutes. To elute the plasmid DNA, the column membrane was 
incubated with 100µl molecular grade water for 1 minute prior to centrifuging 
at 12,000xg for 1 minute. The elute, containing approximately 200-300ng/µl, 
plasmid DNA was stored at -20¡C. 
 
2.4.13 Confirming successful cloning 
To identify the successful ligation of the MyHC IIB promoter into the host 
plasmid, the relative size of the purified plasmid DNA was checked on a 1% 
agarose gel by electrophoretic separation. From the example below (Figure 
2.12), it is clear that lanes 2 and 4 contain plasmid DNA that is approximately 
1kb larger than that in lanes 1, 3 and 5, suggesting the insertion of a 1kb DNA 
fragment. To confirm the actual length of the plasmids potentially containing 
the 1kb MyHC IIB promoter, plasmid DNA was linearized by a single 
restriction endonuclease digest and re-checked on a 1% agarose gel against a 
DNA ladder. 
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Figure 2.12 Relative sizes of supercoiled plasmids were checked for differences in size, 
indicating the insertion of the MyHC IIB promoter (left gel). Plasmids were linearized to 
confirm the total length of the plasmids with the inserted MyHC IIB promoter (right gel).  
 
 
2.4.14 DNA sequencing 
Plasmids were sequenced to confirm that the inserted 1kb fragment was a) the 
MyHC IIB promoter, b) contained no errors introduced by the PCR and c) was 
inserted in the correct orientation and location. Sequencing PCR was 
conducted using forward and reverse oligonucleotide primers complementary 
to plasmid DNA flanking the 5Õ and 3Õ regions of the multiple cloning site. 
Sequencing of MyoD cDNA was conducted in the same way (explained 
below). 
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  2.4.15 The Sanger DNA sequencing method 
Sequencing of DNA products was performed in house whilst on placement at 
Pfizer Animal Health (Michigan, USA) using the Sanger fluorescent terminal 
nucleotide capillary detection method. Template DNA was amplified by PCR 
(Applied Biosystems BigDyeFast) using a combination of normal unlabelled 
nucleotides (dNTP) and fluorescent-labelled terminating nucleotides to 
produce amplicons of varying lengths with fluorescent indicators of the final 3Õ 
nucleotide (PCR parameters are in Table 2.7 and 2.8). PCR amplicons were 
cleaned (to remove excess buffers and nucleotides) using the Zymo Research 
PCR clean up kit (ZR-96 DNA sequencing clean up kit). Briefly, 240µl 
sequencing binding buffer was added to the 20µl PCR reaction, gently pipette 
mixed, transferred to a spin column and centrifuged at 3000xg for 2 minutes. 
Without removing flow-through, 300µl sequencing wash buffer was added to 
the spin column and centrifuged at 3000xg for 5 minutes. The spin column was 
transferred to a fresh collecting tube. To elute the DNA, 35µl of molecular 
grade water (Sigma) was added directly to the spin column and centrifuged at 
3000xg for 2 minutes. The eluted DNA amplicons (sequentially varying in 
length by a single base pair) were separated through a capillary (Applied 
Biosystems 3730 DNA Analyser) and the terminating fluorescent nucleotides 
were read to provide the DNA sequence. Example fluorescence images of the 
capillary are provided in Figure 2.13. Each fluorescent ÒbarÓ (per lane) 
indicates the nucleotide sequence (A = red, C = green, T = yellow, G = Blue). 
Chromatograms were trimmed to remove nucleotide readouts with low 
confidence (see Figure 2.14). Note that sequencing of only ~700bp was 
possible with this method as the fluorescence signal strength declines with 
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increasing amplicon length (see Figure 2.13). For DNA products longer than 
700bp, forward sequencing primers were designed to amplify DNA every 
500bp and sequenced amplicons were overlapped to generate the full-length 
sequence.  
 
Table 2.7 Components and quantities of the Applied Biosystems BigDyeFast sequencing PCR 
 
Reagents Volume per reaction (µl) 
5x Applied Biosytems buffer 3.5 
Water (molecular grade) 7.5 
Template DNA (50-500ng) 5 
1µM primer 3 
Big Dye 1 
Total 20 
 
 
Table 2.8 Applied Biosystems BigDyeFast thermal cycling parameters for sequencing PCR 
 
Thermal cycle Temperature Duration 
Initial denaturation 96¡C 1 minute 
 96¡C 10 seconds 
Amplification (25 cycles) 55¡C 5 seconds 
 60¡C 1 minute 15 seconds 
Hold 4¡C ∞ 
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Figure 2.13 Examples of the time-lapse view of the sequencing capillary. The image 
generated shows a coloured bar for each of the colour-coded terminating nucleotides on the 
end of the DNA products (with each product being a single base pair longer than the previous).   
 
 
 
 
 
Figure 2.14 Example of the DNA chromotagram (analysed using Sequencher) signal and 
sequence generation. Highlighted in red boxes are examples of poor base readout signals 
(small inconsistent peaks) and good base readout signal (clear defined and evenly separated 
peaks). The generated sequence shows bases with high and low confidence of correct base call 
(light blue shows high confidence and dark blue shows low confidence).  
 
 
 
DNA sequencing capillary 
Individual sequencing lanes 
A T C G 
Colour-coded 
terminating 
nucleotides 
Signal strength with 
increasing base pair read 
Example of low/poor 
signal strength Example of strong/clean 
signal strength 
= High confidence 
= Low confidence 
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Sequencing data for the MyHC IIB promoters was cross-checked with their 
respective database sequence (from Ensembl or NCBI). Final versions of the 
pig and human MyHC IIB promoters are displayed below (Figure 2.15). The 
human DNA donor had a single nucleotide polymorphism (SNP) relative to the 
current human genome database (highlighted in red; C substituted for a T).  
 
Pig_MYHC IIB -pZsGreen1-1 
CTGTGGATAACCGTATTACCGCCATGCATTAGTTATTACTAGCGCTACCGGACTCAGATCTCG
AGTAGGTGACACACTTAGCGTGGACAGATTTGCTGTTACATTCAGCAGCAGCTGTGTCTGTGG
CAAAACCACCAAAACCCAATTTACAAGCATCGTGGGCATATGTGATAGCCCCCTTATGTTCTC
AACCCACAAAGAGTCCTGTGGGTATCACATCTCTCCTCCCACCTTAAATAAAAATACGTATTA
CCCACCTCATTAGAGCTACTGCTAGTCATGAGGATTTGCCTGTGAACTAGGAATGCATATTGA
TGCCTCCTTCCATCATTATGCGGTAGAAACACACATAGAACATCACACGGACTCCTGCAGTCC
CCCCAGTGAAAACATGTGAGCTCAAGACAGCCACGGCAAGCTCTCCAGAAAAGGAAAAGAAGT
GTTTCTATCTATTCTAAATCCCTTATGGCTCCCCCACTGGTCTGTCACCATGGCTTAGCCCGA
GAATCTGCCTAAACTTTCTCCTTCATGCTTAGTCTTTTAGACTTTAAAAAAATCTATCATCAG
TATTTCTAAAATCCAGACCCAGGCTAGGAGTTTTCTGCTTTAATACCAATCATGTTGTCAGAG
CTAAAACTCATCCCAGCTCCTCAATGGCCCTAAGCACTAACAAATCAATTAGTTCTCAACTCC
TCGTGTCTGGCTCATTCTGTCGGACCAATTTTACAGGCAGGAGAGTAAGTGGGAACCTGGCTT
TCAACTCAGTGATGAATGATGGAACAGCAAAGCTGGAGAAATAGCCTTAGAAGCCCTGAATCT
CCATCCCTATCAAATGCCTCAAAAGAACCCTAGATGATCCTCTGTCAAATTATTTATAGGTGT
CAAGAAATATTTCTAATTATATCCATTCACAGCCACAGTCAGTGAATATTGTGCAAAGAGATT
GCCAAAAAAGGTTTGCCAAGTAGGTTCCCAGCTGGGACAGCTGAGGTGGCTGCTGTGTTTGCA
AAATGGTCTCTATAAAAGTGGAGCTGAGATGCCTCTGTCCTGTCCTTCCTCCCGGGATCCACC
GGTCGCCACCATGGCCCAGTCCAAGCACGGCCTGACCAAGGAGATGACCATGAA 
 
Human_MYHC IIB-pZsGreen1-1 
ATGCATTAGTTATTACTAGCGCTACCGGACTCAGATCTCGAGCTTAGAGTAGGTATATTTCCT
GCCATATTCAGTAACAGCTGTGTATGTAGCAAAACCATCAAAAGCCAATTTATGAGTATTATG
GGCATATGTGATGGCCCATCCATCTTTTCAATCCACAGGGAGAATATCGTGGATACCATGACT
TTCCTCCCACCTTAAATAAAAATATGCGGTTCCCACCTCATTAGAGCTATAGCTAGTCATGAG
AGTCTGCCCATGAACTAGGAATGCATGTTTGTGTCTCCTTCCATTATGCAGAGGAAACATGCA
TGGAACATCACACAGCATCCTGTTGTTCCTTCAGTGAAAACATACAAGCTGGAGATATCCATG
GAAAGTCCTCCAGAAAAAGAACAGAAGTGTTTATATCTATTCTAAATCCCTTATGCCTCCCCC
AGTGGTCCATCACCACTGCCTAATCTGAGAATTCACTTTCACCTTCATATTTAGACTTTCAGA
CTTTAAAAGAATCTATCGCCAGTCTTTCTAAAATCCAGACTGTGGCTAGGAATGTTGTCTTAA
AATCCATCGCTCACTGCTTCCAATCATAGTGTCAGGTCTAAAATTCATTCCAGACTCCTTAAT
GGCTCTAAGAACCAACAAATTAATTAATCCTAAATTCCTCACATCAGACTCATTCTGTTGGAC
CAATTTTATAGGCAGAGGAGTAAGTGGGAATCTGGCTTTGAATTCTGTGATGAATGATGCAAC
AGCCAAACTGGAGAAACAGTGTTAGAAGCCCTGAATCCCCATCCCCTATCAAATGCCTATAAA
GAACCCTAGATCATCCTCTGTTAAATTATTTATGGGTGTCAAGAAATATTTCTAATTATATCC
ATTCACAGCCACAGTCAGTGAATATTGTGCAAAGAGATTGCCAAAAACGGTTTTGCCAAGTAG
GTTCCCAGCTAGGACAGCTGAGGTGGCTGCTGTGTTTGCAGAATGGTCTCTATAAAAGTGGAG
CTGAGATGCCTCTTTCCCATCCTTCCTCCCGGGATCCACCGGTCGCCACCATGGCCCAGTCCA
AGCACGGCCTGACCAAGGAGATGACC 
 
Key:    Plasmid    Insert (MyHC IIB promoter)      Transfection Start Site    
PCR Primers     RE-site (Xho1 + Xma1)    Single Nucleotide Polymorphism 
 
Figure 2.15 Pig and Human MyHC IIB promoter sequences located in the correct orientation 
within the multiple cloning site of the pZsGreenI-I. Annotations are described in the key. 
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2.4.16 Large-scale, endotoxin-free plasmid preparations 
To conduct mammalian cell transfections using plasmids cloned in bacterial 
cells, the plasmid DNA was a) produced in a quantity large enough to perform 
the transfection procedure and b) removed of any contaminants that may 
damage mammalian cells and potentially inhibit transfection efficiency. In 
order to achieve this, a single colony containing the plasmid of interest was 
cultured in 3ml of LB medium containing the appropriate antibiotic for 6-8 
hours. From this, 100µl of culture was transferred to 40ml of LB medium (with 
appropriate antibiotic) and cultured overnight at 37¡C (200rpm shaking). A 
Sigma Endotoxin-free Plasmid MidiPrep Kit (Sigma Aldrich) was used to 
extract and purify plasmid DNA from large cultures. The majority of the 
procedure is similar to the plasmid miniprep extraction (see above; but on a 
larger scale) with the addition of an endotoxin removal step. Following lysis 
and neutralization of the cells, the lysate containing plasmid DNA was 
incubated on ice with 300µl of endotoxin removal solution for 5 minutes. The 
solution was then moved to a 37¡C water bath for 5 minutes (the solution 
turned cloudy) and centrifuged at 3,000rpm for 5 minutes and the supernatant 
(free of endotoxins) was transferred to a fresh tube. This step was repeated. 
The remaining steps were as in the plasmid miniprep protocol. Plasmid DNA 
was eluted in 1ml of endotoxin-free water.  
To further purify the plasmid DNA prior to transfection, an ethanol 
precipitation of the DNA was conducted using 0.1 volumes 3M Sodium 
Acetate and 2.5 volumes Ethanol, vortexing the entire solution and stroring at -
20¡C overnight. The DNA was pelleted by centrifugation at 13,000rpm for 30 
minutes (at 2¡C). The supernatant was removed, the pellet was washed in 1 ml 
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70% Ethanol, re-pelleted by centrifugation at 13,000rpm for 10 minutes and 
the supernatant removed again. The pellet was air dried on the bench to allow 
ethanol to evaporate and then re-suspended in an appropriate volume of 
endotoxin-free water (typically 500µl) to give the desired concentration of 
plasmid DNA.  
 
2.4.17 Five prime deletion of the MyHC IIB promoters 
Equivalent 5Õ deletion of the pig and human MyHC IIB promoters was 
conducted to elucidate regions of regulatory control. Pig and human MyHC 
IIB promoters of varying lengths (-961bp, -466bp, -231bp, -113bp, -67bp; 
promoter lengths are relative to the TATA-box) were generated by PCR using 
the 1kb MyHC IIB-pZsGreenI-I plasmids as template DNA (<1ng). PCR 
primers were designed to introduce a 5Õ and 3Õ restriction site (Xho1 and 
Xma1, respectively) to clone the new shorter promoter into the pZsGreen1-1 
vector (as described above). The PCR thermal cycle used during amplification 
of the 5Õ deletion promoters was the same as when creating the 1kb promoters 
(as described above).  
 
2.4.18 Pig-human chimeric promoter constructs 
Chimeric MyHC IIB promoters (containing combinations of both distal and 
proximal regions of the pig and human MyHC IIB promoters) were produced 
according to a similar design previously demonstrated by Harrison et al., 
(2011). A HindIII restriction site (2bp mutation; at -218bp and -217bp) was 
first introduced (by site directed mutagenesis PCR Ð explained below) to both 
the pig and human 1kb promoter. The sequence was mutated from AAGCCC 
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to AAGCTT (bold case indicate changes) and was situated such that it would 
disrupt the sequence of both the pig and human MyHC IIB promoters in the 
same way. The new HindIII restriction site and the 3Õ Xma1 restriction site 
were digested and the two fragments (the proximal promoter and the remaining 
linear plasmid containing the distal promoter) were gel purified. The proximal 
promoters were subsequently ligated (as described above) to the linear plasmid 
containing the distal promoter of the opposing species, generating chimeric 
promoters (see Figure 2.16). For completeness, the proximal promoter regions 
were also swapped with a minimal CMV promoter (84bp) to test for potential 
regulatory regions in the 5Õ distal region (~750bp) of each promoter, 
independent of the proximal promoter (see Figure 2.16).  The minimal CMV 
promoter was produced by PCR, using the pDsRed-Express-NI plasmid as 
template DNA, and cloned as described above (primer sequences in Table 2.6). 
 
 
 
 
 
 
 
 
 
Figure 2.16 Schematic diagram detailing the chimeric promoter constructs containing 
combinations of the pig and human MyHC IIB promoters. CMV is a minimal basal promoter 
(84bp), used herein to test for enhancer activity from the distal MyHC IIB promoters.  
 
 
Human IIB distal 5Õ ZsGreen!CMV 
Pig IIB distal 5Õ ZsGreen!CMV 
ZsGreen!CMV 
Pig IIB promoter (1kb) ZsGreen!
Human IIB promoter (1kb) ZsGreen!
Human-pig IIB 5Õ Ð 3Õ ZsGreen!250bp 
Pig-human IIB 5Õ Ð 3Õ ZsGreen!250bp 
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The location of the HindIII chimeric junction is displayed below (Figure 2.17). 
Swapping the proximal pig and human MyHC IIB promoters, downstream of 
the HindIII chimeric junction, effectively equated to 14bp changes in the 
proximal promoter region (highlighted in black below; Figure 2.17). The 
mutated promoter (2bp to generate HindIII restriction site) was used as a 
control and had no effect on the relative promoter activities of the pig and 
human 1kb MyHC IIB promoters (Figure 2.18). 
 
 
Figure 2.17 Alignment of the proximal pig and human MyHC IIB promoter showing the 
location of the HindIII chimeric junction. Downstream of the chimeric junction, there are 14bp 
mismatches between the pig and human sequence (highlighted in black). Grey highlights 
indicate regions of known regulatory importance. 
 
! ! ! ! ! ! ! !!!!!!HindIII 
       chimeric-junction 
Human   -261   ATGAATGATGCAACAGCCAAACTGGAGAAACAGTGTTAGAAGCCCTGAATCCCCATCCCC   -202 
Pig     -259   ATGAATGATGGAACAGCAAAGCTGGAGAAATAGCCTTAGAAGCCCTGAATCTCCATCCC-   -201 
               ********** ****** ** ********* **  **************** *******  
 
      AT3      AT2 
Human   -201   TATCAAATGCCTATAAAGAACCCTAGATCATCCTCTGTTAAATTATTTATGGGTGTCAAG   -142 
Pig     -200   TATCAAATGCCTCAAAAGAACCCTAGATGATCCTCTGTCAAATTATTTATAGGTGTCAAG   -141 
               ************  ************** ********* *********** ********* 
 
   AT1 
Human   -141   AAATATTTCTAATTATATCCATTCACAGCCACAGTCAGTGAATATTGTGCAAAGAGATTG   -82 
Pig     -140   AAATATTTCTAATTATATCCATTCACAGCCACAGTCAGTGAATATTGTGCAAAGAGATTG   -81 
               ************************************************************ 
 
         CArG-box            E-box2       E-Box1 
Human   -81    CCAAAAACGGTTTTGCCAAGTAGGTTCCCAGCTAGGACAGCTGAGGTGGCTGCTGTGTTT   -22 
Pig     -80    CCAAAAAAGGTTT-GCCAAGTAGGTTCCCAGCTGGGACAGCTGAGGTGGCTGCTGTGTTT   -22 
               ******* ***** ******************* ************************** 
       
              TATA-box (+1) 
Human   -21    GCAGAATGGTCTCTATAAAAGTGGAGCTGAGATGCCTCTTTCCCATCCTTCCT   +32 
Pig     -21    GCAAAATGGTCTCTATAAAAGTGGAGCTGAGATGCCTCTGTCCTGTCCTTCCT   +32 
               *** *********************************** ***  ******** 
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Figure 2.18 The 2bp mutation introduced to the pig and human 1kb MyHC IIB promoters had 
no effect on the relative promoter activity in C2C12 myotubes (measured by fluorescence 
output).  
 
 
2.4.19 Site directed mutagenesis by PCR 
Nucleotide substitutions within the promoter sequence were conducted by 
mutagenesis PCR, amplifying the entire plasmid but strategically forcing non-
specific nucleotide annealing (within the primer) to create a mutated amplicon. 
Similarly, removal of nucleotides was conducted by omitting the relevant base 
pairs from the plasmid sequence being amplified. Nucleotide substitutions 
were typically located in the centre of the primer, with approximately 12 
nucleotides on either side to ensure adequate annealing at the 5Õ and 3Õ ends. 
All primers for mutagenesis PCR were HPLC purified to minimise incorrect 
primer sequences. Primers were 5Õ phosphorylated to allow the linear PCR 
amplicon to be re-ligated into a circular plasmid for transformation in JM109 
competent cells (as described above). A schematic diagram depicting the site 
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directed mutagenesis protocol is shown below (Figure 2.19). The image used is 
from the Phusion Site Directed Mutagenesis protocol (Thermo Scientific). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.19 Schematic diagram (from Phusion SDM protocol, Thermo Scientific) showing the 
principle of the mutagenesis PCR protocol employed herein.  
 
 
 
 
The mutagenesis PCR was conducted using a high fidelity DNA polymerase 
(Q5, New England Biolabs) to amplify the entire plasmid with minimal PCR 
induced errors. The mutagenesis PCR was conducted in a 50µl volume (details 
in Table 2.9). Thermal cycling parameters for the Q5 polymerase is detailed in 
Table 2.10. Elongation times were based on a manufacturers recommendation 
of 30 seconds per 1kb of DNA to be amplified.  
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Table 2.9 Components and quantities for site directed mutagenesis PCR using Q5 polymerase 
 
Reagents 50µl reaction Final concentration 
5X reaction buffer 10µl 1X 
10mM dNTPÕs 1µl 200µM 
10µM Forward Primer 2.5µl 0.5µM 
10µM Reverse Primer 2.5µl 0.5µM 
Template DNA - 50-500ng 
Q5 polymerase 0.5µl 0.02U/µl 
Nuclease-free water Up to 50µl - 
 
 
Table 2.10 Thermal cycling parameters for site directed mutagenesis PCR 
 
Thermal cycle Temperature Duration 
Initial denaturation 98¡C 30 seconds 
 98¡C 10 seconds 
Amplification (30 cycles) 50-72¡C 30 seconds 
 72¡C 30 seconds/kb 
Final extension 72¡C 2 minutes 
Hold 4¡C ∞ 
 
 
2.4.20 Site directed mutagenesis of MyHC IIB promoter  
In order to study the role of sequence variation between the pig and human 
MyHC IIB promoters, site directed mutagenesis was conducted in the proximal 
human MyHC IIB promoter (making base pair alterations to match the 
equivalent pig sequence). Base pair substitutions were conducted at the 
locations specified in Figure 2.20 (highlighted in black), spread over two 
separate experiments. In addition to base pair substitutions, the CArG-box 
region (-63bp to -84bp; including the immediate 5Õ and 3Õ flanking region) was 
deleted from the pig and human 1kb MyHC IIB promoter (via mutagenesis 
PCR Ð simply occluding the amplification of the CArG-box region).  
83 
 
Figure 2.20 Alignment of the proximal pig and human MyHC IIB promoters. Highlighted in 
black are the locations chosen for site directed mutagenesis. Grey highlights indicate regions 
of known regulatory importance.  
 
2.4.21 Electrophoretic mobility shift assay (EMSA)  
Protein-DNA interactions were assessed by incubating C2C12 myotube 
nuclear extracts with a 5Õ biotin labeled double-stranded probe for a 62bp 
region spanning (and inclusive of) the CArG-box and Ebox2 sequence (-93bp 
to -31bp relative to the TATA-box) from the pig MyHC IIB promoter (probe 
sequences are in Table 2.11; a diagram illustrating the sequence of the probe is 
in Figure 2.21). Three shorter un-labelled probes, from the same region for the 
pig and human sequence, were used to compete for bound proteins and identify 
the specific regions within the 62bp probe interacting with nuclear protein(s) 
(see Figure 2.22). The un-labelled pig and human competitor probes were used 
to assess whether the species-specific sequence variation in these regions 
impaired competition for the proteins bound to the pig 62bp biotin labelled 
probe. Un-labelled competitor probes were designed to the following regions, 
CArG-box: -91bp to -60bp, mid-probe: -74bp to -51bp and E-box2 probe: -
63bp to -31bp, all relative to the pig TATA-box.  
! ! ! ! ! ! ! !!!!!!HindIII 
       chimeric-junction 
Human   -261   ATGAATGATGCAACAGCCAAACTGGAGAAACAGTGTTAGAAGCCCTGAATCCCCATCCCC   -202 
Pig     -259   ATGAATGATGGAACAGCAAAGCTGGAGAAATAGCCTTAGAAGCCCTGAATCTCCATCCC-   -201 
               ********** ****** ** ********* **  **************** *******  
 
      AT3      AT2 
Human   -201   TATCAAATGCCTATAAAGAACCCTAGATCATCCTCTGTTAAATTATTTATGGGTGTCAAG   -142 
Pig     -200   TATCAAATGCCTCAAAAGAACCCTAGATGATCCTCTGTCAAATTATTTATAGGTGTCAAG   -141 
               ************  ************** ********* *********** ********* 
 
   AT1 
Human   -141   AAATATTTCTAATTATATCCATTCACAGCCACAGTCAGTGAATATTGTGCAAAGAGATTG   -82 
Pig     -140   AAATATTTCTAATTATATCCATTCACAGCCACAGTCAGTGAATATTGTGCAAAGAGATTG   -81 
               ************************************************************ 
 
         CArG-box            E-box2       E-Box1 
Human   -81    CCAAAAACGGTTTTGCCAAGTAGGTTCCCAGCTAGGACAGCTGAGGTGGCTGCTGTGTTT   -22 
Pig     -80    CCAAAAAAGGTTT-GCCAAGTAGGTTCCCAGCTGGGACAGCTGAGGTGGCTGCTGTGTTT   -22 
               ******* ***** ******************* ************************** 
       
              TATA-box (+1) 
Human   -21    GCAGAATGGTCTCTATAAAAGTGGAGCTGAGATGCCTCTTTCCCATCCTTCCT   +32 
Pig     -21    GCAAAATGGTCTCTATAAAAGTGGAGCTGAGATGCCTCTGTCCTGTCCTTCCT   +32 
               *** *********************************** ***  ******** 
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Figure 2.21 The bold underline indicates the probe sequence used in the EMSA experiment, 
spanning the 3 base pair mismatches in the CArG/E-box region.  
 
 
 
 
 
Figure 2.22 Schematic diagram illustrating the overlapping un-labelled pig and human 
competitor probes relative to the biotin-labelled pig MyHC IIB 62bp probe (stars indicate 
biotin labelled probe). Red text indicates specific regions of interest (CArG-box and E-box). 
Grey boxes indicate base pair differences between the pig and human competitor probes. Only 
the sense probe strand is shown.  
 
 
2.4.22 Producing double stranded EMSA probes 
Oligonucleotides, with 5Õ biotin labels, were synthesized and annealed to 
generate the double stranded probes used for EMSA experiments. Sense and 
antisense oligonucleotides (5µM each) were annealed in Òannealing bufferÓ 
(10mM Tris-base (pH 8), 1mM EDTA, 50mM NaCl Ð in ultrapure water) by 
heating to 95¡C for 5 minutes (in a hot block) and then slowly cooled to room 
! ! ! ! ! ! ! !!!!!!HindIII 
       chimeric-junction 
Human   -261   ATGAATGATGCAACAGCCAAACTGGAGAAACAGTGTTAGAAGCCCTGAATCCCCATCCCC   -202 
Pig     -259   ATGAATGATGGAACAGCAAAGCTGGAGAAATAGCCTTAGAAGCCCTGAATCTCCATCCC-   -201 
               ********** ****** ** ********* **  **************** *******  
 
      AT3      AT2 
Human   -201   TATCAAATGCCTATAAAGAACCCTAGATCATCCTCTGTTAAATTATTTATGGGTGTCAAG   -142 
Pig     -200   TATCAAATGCCTCAAAAGAACCCTAGATGATCCTCTGTCAAATTATTTATAGGTGTCAAG   -141 
               ************  ************** ********* *********** ********* 
 
   AT1 
Human   -141   AAATATTTCTAATTATATCCATTCACAGCCACAGTCAGTGAATATTGTGCAAAGAGATTG   -82 
Pig     -140   AAATATTTCTAATTATATCCATTCACAGCCACAGTCAGTGAATATTGTGCAAAGAGATTG   -81 
               ************************************************************ 
 
         CArG-box            E-box2       E-Box1 
Human   -81    CCAAAAACGGTTTTGCCAAGTAGGTTCCCAGCTAGGACAGCTGAGGTGGCTGCTGTGTTT   -22 
Pig     -80    CCAAAAAAGGTTT-GCCAAGTAGGTTCCCAGCTGGGACAGCTGAGGTGGCTGCTGTGTTT   -22 
               ******* ***** ******************* ************************** 
       
              TATA-box (+1) 
Human   -21    GCAGAATGGTCTCTATAAAAGTGGAGCTGAGATGCCTCTTTCCCATCCTTCCT   +32 
Pig     -21    GCAAAATGGTCTCTATAAAAGTGGAGCTGAGATGCCTCTGTCCTGTCCTTCCT   +32 
               *** *********************************** ***  ******** 
TGCAAAGAGATTGCCAAAAAAGGTTTGCCAAGTAGGTTCCCAGCTGGGACAGCTGAGGTGGC  PIG$IIB$62bp$probe:$
PIG$compe*tor$probes:$
(un3labelled)$
AAGAGATTGCCAAAAAAGGTTTGCCAAGT  
AGTAGGTTCCCAGCTGGGACAGCTGAGGTGGC  
AGGTTTGCCAAGTAGGTTCCCA 
AAGAGATTGCCAAAAACGGTTTTGCCAAGT  
AGTAGGTTCCCAGCTAGGACAGCTGAGGTGGC  
CGGTTTTGCCAAGTAGGTTCCCA 
HUMAN$compe*tor$probes:$
$$$$$$$$$$(un3labelled)$
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temperature over 90 minutes (by removing the metal hot block and leaving to 
cool on the bench), generating 5µM of each double stranded probe. Probes 
were diluted to the required concentrations on the day of use (concentrations 
noted below). 
 
2.4.23 C2C12 nuclear protein extracts 
C2C12 myotubes were removed from a T75 flask using the trypsin method 
(described above). Myotubes in suspension were pelleted at 500rpm for 5 
minutes and re-suspended in cold PBS in a 1.5ml tube. Myotubes were then 
pelleted at 1000rpm for 3 minutes and the supernatant was removed. Myotube 
nuclear proteins were extracted using the NE-PER extraction kit (Thermo 
Scientific). Volumes of reagents used with the NE-PER kit are based on 
packed cell volume (day 4 myotubes from a T75 flask equated to a 100µl 
packed cell volume). The 100µl packed cell volume was combined with 1ml of 
CER I, mixed by vortexing for 15 seconds and then incubated on ice for 10 
minutes to lyse cell membranes. Fifty-five micro litres of CER II was added to 
the lysed cells, vortexed for 5 seconds and incubated on ice for 1 minute. 
Lysed cells were then vortexed for 5 seconds followed by centrifugation at 
16,000xg for 5 minutes. The supernatant, containing cytoplasmic proteins, was 
removed and stored at -80¡C. The remaining pellet (containing myotube 
nuclei) was re-suspended in 500µl NER and incubated on ice for 40 minutes, 
vortexing for 15 seconds for every 10 minutes. Following incubation, lysed 
nuclei debris was pelleted by centrifugation at 16,000xg for 10 minutes. The 
supernatant (containing nuclear proteins) was stored at -80¡C. Nuclear proteins 
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were stored in small aliquots to avoid freeze thawing, helping to maintain the 
integrity of nuclear proteins for use in downstream binding applications.  
 
2.4.24 EMSA binding reactions 
It was predicted that the response elements in the probe (CArG-box and E-box) 
would likely bind serum response factor (SRF) and/or myogenic regulatory 
factors (MRF), respectively. Therefore, the literature was searched for 
commonly used binding conditions for studying SRF or MRF DNA binding 
and the following predicted binding conditions were used herein. Protein-DNA 
binding conditions consisted of 50ng/ul Poly dI-dC, 5% glycerol, 0.05% NP-
40, 50mM KCL, 1mM MgCl2, 1mM EDTA, 20fmol biotin-labeled probe, 
4pmol un-labeled competitor probe and 3µl of C2C12 myotube nuclear extract 
(from NE-PER extraction kit, Thermo Scientific) in 1x binding buffer 
(LightShift Chemiluminescent EMSA kit, Thermo Scientific) in a total volume 
of 20µl. Protein-DNA binding reactions were incubated at room temperature 
for 20 minutes.  
 
2.4.25 Detection of protein-DNA complexes 
Protein-DNA complexes were separated by electrophoresis on a 6% non-
denaturing polyacrylamide gel (Invitrogen, Novex) at 100V for 75 minutes (on 
ice) and transferred by electro-blotting to a Biodyne-B nylon membrane 
(Thermo Scientific) at 100V for 45 minutes. Protein-DNA complexes were 
cross-linked for 60 seconds (auto-crosslink) and biotin-labeled probes were 
detected using the LightShift Chemiluminescent EMSA detection module 
(Thermo Scientific) according to the manufacturerÕs instructions. Briefly, the 
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membrane was blocked in 20ml of blocking buffer for 15 minutes with gentle 
shaking. The blocking solution was then replaced with blocking buffer 
containing stabilized streptavidin-horseradish peroxidase conjugate (1:300 
dilution) for a further 15 minutes with gentle shaking. The membrane was then 
washed for 5 minutes, five times, in 1x wash buffer (made in ultrapure water) 
with shaking. Following the wash steps, the membrane was transferred to 30ml 
of substrate equilibration solution for 5 minutes with gentle shaking. The 
membrane was transferred to a new container containing. A solution 
containing 6ml luminol/enhancer solution and 6ml stable peroxidase solution 
was gentle poured onto the membrane and incubated for 5 minutes without 
shaking. The membrane was then dabbed on a paper towel for 3 seconds, 
transferred to a clear plastic sleeve, placed in a black-out cassette and exposed 
to x-ray film for approximately 5-10 seconds. Film was developed under dark 
conditions to visualise biotin labelled DNA probes.  
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A control EMSA (using manufacturer controls) was conducted to validate the 
method (see Figure 2.23). This experiment confirmed that protein-DNA 
interactions, electrophoretic separation of protein-DNA complexes and 
detection of biotin labelled probes on X-ray film was successfully conducted 
prior to attempting this method on experimental samples.  
 
 
 
Figure 2.23 Control EMSA (using manufacturer controls) shows successful protein-DNA 
interactions (lane 2) and competitive binding of unlabelled probes (lane 3). 
 
 
 
  
[1] Biotin-labeled EBNA DNA probe 
 
[2] Biotin-labeled EBNA DNA probe + EBNA extract 
 
[3] Biotin-labeled EBNA DNA probe + EBNA extract + 200-fold molar excess un-labeled EBNA probe 
[1] [2] [3] 
8
9
 
         
                                                 
  
EMSA probe name EMSA probe sequence (5' to 3')
Pig_MyHC-IIB_probe_sense [biotin]TGCAAAGAGATTGCCAAAAAAGGTTTGCCAAGTAGGTTCCCAGCTGGGACAGCTGAGGTGGC
Pig_MyHC-IIB_probe_anti-sense [biotin]GCCACCTCAGCTGTCCCAGCTGGGAACCTACTTGGCAAACCTTTTTTGGCAATCTCTTTGCA
Human_MyHC-IIB_CArG-competitor_sense AAGAGATTGCCAAAAACGGTTTTGCCAAGT
Human_MyHC-IIB_CArG-competitor_anti-sense ACTTGGCAAAACCGTTTTTGGCAATCTCTT
Human_MyHC-IIB_mid-probe-competitor_sense CGGTTTTGCCAAGTAGGTTCCCA
Human_MyHC-IIB_mid-probe-competitor_anti-sense TGGGAACCTACTTGGCAAAACCG
Human_MyHC-IIB_E-box2-competitor_sense AGTAGGTTCCCAGCTAGGACAGCTGAGGTGGC
Human_MyHC-IIB_E-box2-competitor_anti-sense GCCACCTCAGCTGTCCTAGCTGGGAACCTACT
Pig_MyHC-IIB_CArG-competitor_sense AAGAGATTGCCAAAAAAGGTTTGCCAAGT
Pig_MyHC-IIB_CArG-competitor_anti-sense ACTTGGCAAACCTTTTTTGGCAATCTCTT
Pig_MyHC-IIB_mid-probe-competitor_sense AGGTTTGCCAAGTAGGTTCCCA
Pig_MyHC-IIB_mid-probe-competitor_anti-sense TGGGAACCTACTTGGCAAACCT
Pig_MyHC-IIB_E-box2-competitor_sense AGTAGGTTCCCAGCTGGGACAGCTGAGGTGGC
Pig_MyHC-IIB_E-box2-competitor_anti-sense GCCACCTCAGCTGTCCCAGCTGGGAACCTACT
Table 2.11 Sense and anti-sense sequences of oligonucleotides used to generate double stranded EMSA probes 
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2.4.26 Transfection of C2C12 myoblasts 
C2C12 myoblasts were seeded at approximately 30,000 cells per well of a 24-
well plate and cultured for 30 hours in growth medium (10% FBS and 1% PS; 
0.5ml per well) to reach approximately ~70% confluence. Myoblasts were 
considered to be in the log phase of proliferation at this phase (highlighted by 
the appearance of dividing cells Ð see light refractive cells below (indicated by 
black arrows; Figure 2.24)). Dividing cells elicit the best uptake of foreign 
plasmid DNA by lipid based transfection methods (according to manufacturer 
guidelines).  
 
 
 
 
 
 
 
 
 
 
Figure 2.24 Light microscopy image of the C2C12 myoblasts immediately prior to 
transfection (at ~70% confluence). Arrows indicate proliferating cells.  
 
 
Cells were transfected using the lipid based transfection reagent, FugeneHD 
(Promega), at a ratio of 3:1 (FugeneHD:DNA). To compare the activity of the 
pig and human MyHC IIB promoters in C2C12 cells, 25µl of transfection 
complex containing 200ng of promoter-reporter plasmid and 100ng pDsRed-
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Express-N1 (as a normalization control) was transfected into individual wells. 
A negative (pZsGreenI-I; 200ng per well) and a positive control (pZsGreenI-
NI; 50ng per well) were included in transfection experiments to monitor the 
transfections conditions. The quantity of plasmid DNA used for transfections 
was optimized by a previous PhD student (Dr Mohd Nazmi Bin Abd Manap). 
When cells reached confluence, culture medium was switched to a 
differentiation medium (2% HS, 1% P/S) to encourage differentiation, and this 
medium was refreshed every 48 hours. Fluorescence output (as a marker of 
promoter activity) was measured on day 5 or 6 of differentiation using a 
Typhoon Trio+ (GE Healthcare). The excitation and emission settings for 
measuring ZsGreen and DsRed fluorescence from cell culture plates are 
displayed in the table below (Table 2.12).  
 
Table 2.12 Excitation and emission settings for measuring ZsGreen and DsRed fluorescence 
from cell culture plates using the Typhoon Trio+ (GE healthcare). 
 
 
 
 
 
 
 
 
Filter 
Detected 
fluorescence 
 
(nm) 
Emission 
(nm) 
PMT 
Sensitivity 
setting 
1 ZsGreen 488 520 450 Medium 
2 DsRed 532 580 600 Medium 
Additional notes: Focal plane = 3mm 
Image quality = 100 micron 
Scan time = 20 minutes per plate 
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Figure 2.25 Evidence for co-uptake of pDsRed-express-NI, with pZsGreen1-NI, for use as an 
internal transfection control (fluorescence images taken 48 hours post-transfection in C2C12 
myoblasts).  
 
 
ZsGreen fluorescence values (indicating promoter activity) were normalised 
against DsRed fluorescence values (from the same well) to correct for 
variation in transfection efficiency between wells (ZsGreen Ö DsRed). The 
fluorescence images in Figure 2.25 show co-uptake of the DsRed and ZsGreen 
plasmids validating the efficacy of DsRed as a co-transfection internal control 
for normalizing reporter gene fluorescence.  
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2.4.27 Cloning murine MyoD cDNA 
Full-length open reading frame murine MyoD cDNA (accession number: 
ENSMUST00000072514.1; amino acid sequence in Figure 2.26) was 
generated by RT-PCR for over-expression in C2C12 muscle cells. Firstly, 
RNA was extracted from C2C12 myoblasts as described previously in this 
chapter. First strand cDNA was synthesised (also described previously in this 
chapter) and the full-length MyoD transcript was amplified by RT-PCR using 
the primers in Table 2.13. The PCR was conducted as described previously in 
this Chapter (annealing temperature was 50¡C).  
 
MELLSPPLRDIDLTGPDGSLCSFETADDFYDDPCFDSPDLRFFEDLDPRLVH
MGALLKPEEHAHFPTAVHPGPGAREDEHVRAPSGHHQAGRCLLWACKACKRK
TTNADRRKAATMRERRRLSKVNEAFETLKRCTSSNPNQRLPKVEILRNAIRY
IEGLQALLRDQDAAPPGAAAFYAPGPLPPGRGSEHYSGDSDASSPRSNCSDG
MMDYSGPPSGPRRQNGYDTAYYSEAARESRPGKSAAVSSLDCLSSIVERIST
DSPAAPALLLADAPPESPPGPPEGASLSDTEQGTQTPSPDAAPQCPAGSNPN
AIYQVL 
 
Figure 2.26 Full-length amino acid sequence for murine MyoD. 
 
Following amplification of full-length MyoD cDNA, the 5Õ and 3Õ ends were 
cut by restriction digest and cloned upstream of CMV promoter in the 
pDsRed-Express-NI plasmid (as described previously in this chapter). Below 
is the sequence of the MyoD cDNA located within the multiple cloning site of 
the host plasmid (Figure 2.27). A Kozac sequence was engineered into the 5Õ 
end of the MyoD cDNA (by PCR) to maximise translation efficiency of the 
transcript produced. The downstream DsRed gene remained un-translated due 
to the inclusion of a translation stop codon at the end of the MyoD transcript, 
preventing the production of a MyoD-DsRed fusion protein.  
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Table 2.13 Oligonucleotide primer sequences for amplifying full-length open reading frame 
murine MyoD cDNA and associated sequencing primers. Grey highlights indicate engineered 
nucleotides to introduce a Kozac sequence (forward primer) and in-frame additions (reverse 
primer). Underlined nucleotides indicate restriction sites used for cloning purposes (BglII and 
AgeI).  
 
Primer name Primer sequence 
MyoD forward primer AAAAAAAGATCTGCCACCATGGAGCTTCTATCGCCG 
MyoD reverse primer AAAAAAACCGGTGCTCAAAGCACCTGATAAATCGC 
Mid-sequencing primer GAGGCCTTCGAGACGCTC 
5Õ flank sequencing primer CATTGACGCAAATGGGCGGTAGG 
3Õ flank sequencing primer GGCCACGAGTTCGAGATCGAGG 
 
 
ATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGA
CTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTG
GGAGGTCTATATAAGCAGAGCTGGTTTAGTGAACCGTCAGATCCGCTAGCGCTACCGGACTCA
GATCTGCCACCATGGAGCTTCTATCGCCGCCACTCCGGGACATAGACTTGACAGGCCCCGACG
GCTCTCTCTGCTCCTTTGAGACAGCAGACGACTTCTATGATGACCCGTGTTTCGACTCACCAG
ACCTGCGCTTTTTTGAGGACCTGGACCCGCGCCTGGTGCACATGGGAGCCCTCCTGAAACCGG
AGGAGCACGCACACTTCCCTACTGCGGTGCACCCAGGCCCAGGCGCTCGTGAGGATGAGCATG
TGCGCGCGCCCAGCGGGCACCACCAGGCGGGTCGCTGCTTGCTGTGGGCCTGCAAGGCGTGCA
AGCGCAAGACCACCAACGCTGATCGCCGCAAGGCCGCCACCATGCGCGAGCGCCGCCGCCTGA
GCAAAGTGAATGAGGCCTTCGAGACGCTCAAGCGCTGCACGTCCAGCAACCCGAACCAGCGGC
TACCCAAGGTGGAGATCCTGCGCAACGCCATCCGCTACATCGAAGGTCTGCAGGCTCTGCTGC
GCGACCAGGACGCCGCGCCCCCTGGCGCCGCTGCCTTCTACGCACCTGGACCGCTGCCCCCAG
GCCGTGGCAGCGAGCACTACAGTGGCGACTCAGATGCATCCAGCCCGCGCTCCAACTGCTCTG
ATGGCATGATGGATTACAGCGGCCCCCCAAGCGGCCCCCGGCGGCAGAATGGCTACGACACCG
CCTACTACAGTGAGGCGGCGCGCGAGTCCAGGCCAGGGAAGAGTGCGGCTGTGTCGAGCCTCG
ACTGCCTGTCCAGCATAGTGGAGCGCATCTCCACAGACAGCCCCGCTGCGCCTGCGCTGCTTT
TGGCAGATGCACCACCAGAGTCGCCTCCGGGTCCGCCAGAGGGGGCATCCCTAAGCGACACAG
AACAGGGAACCCAGACCCCGTCTCCCGACGCCGCCCCTCAGTGTCCTGCAGGCTCAAACCCCA
ATGCGATTTATCAGGTGCTTTGAGCACCGGTCGCCACCATGGCCTCCTCCGAGGACGTCATCA
AGGAGTTCATGCGCTTCAAGGTGCGCATGGAGGGCTCCGTGAACGGCCACGAGTTCGAGATCG
AGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAAGG
GCGGCCCCCTG 
 
Key:   MyoD sequence    RE site (BglII + AgeI)    Primers    Plasmid  
engineered Kozak sequence 
 
Figure 2.27 Full-length murine Myod cDNA in the pDsRed-Express-NI plasmid. 
 
 
MyoD over-expression plasmids were transfected into proliferating myoblasts 
(at approximately 70% confluence) at a ratio of 1:1 with MyHC IIB promoter-
reporter plasmids.  
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2.4.28 Generating a pDsRed-Express-NI vehicle transfection 
control Ð Klenow Large Polymerase blunt-ending 
Cells transfected with MyoD over-expression plasmids were compared against 
cells transfected with an equivalent quantity of non-functional, control plasmid 
DNA. The control plasmid DNA was generated by removing the CMV 
promoter from the MyoD host plasmid, pDsRed-Express-NI.  
 
 
Figure 2.28 Schematic illustrating the removal of the CMV promoter from the pDsRed-
Express-NI plasmid for use a vehicle transfection control in MyoD over-expression 
experiments 
 
 
Restriction sites (AseI and XhoI) flanking the CMV promoter were digested 
and the linear plasmid, lacking the CMV promoter, was subsequently gel 
purified as described previously in this chapter. The digested restriction sites 
generated non-cohesive overhanging ends, making re-circularisation of the 
plasmid not possible. Therefore, the overhanging ends were converted to blunt 
ends using Klenow Large Polymerase (Promega) and the linear plasmid was 
blunt-end ligated. Purified linear plasmid (lacking the CMV promoter) was 
incubated as described in Table 2.14 at room temperature for 12 minutes. The 
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reaction was stopped by heating to 75¡C for 10 minutes and the blunt-ended 
fragment was cleaned by conducting a PCR clean up procedure as previously 
described in this chapter. The blunt-ended linear plasmid was then re-ligated as 
described previously using T4 DNA ligase.  
 
Table 2.14 Components and quantities for the Klenow Large Polymerase reaction 
 
 
 
 
 
  
Reagent Volume (µl) Final concentration 
Klenow Buffer (10X) 4µl 1X 
dNTP (500µM) 3.2µl 40µM 
BSA (400µg/ml) 2µl 20µg/ml 
Klenow Large Polymerase (5U/µl) 1µl 5U 
Linearized plasmid 29.8µl 1-4µg 
Total: 40µl - 
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3 
CHARACTERIZIATION OF THE C2C12 CELL LINE 
FOR MYOSIN HEAVY CHAIN STUDIES 
 
 
 
 
It was hypothesized that the C2C12 skeletal muscle cell line would 
exhibit dynamic alterations in expression of the myosin heavy chain 
isoform genes during myogenesis. Furthermore, it was 
hypothesized that the induction in expression of myosin heavy chain 
isoforms genes during myogenic differentiation would coincide 
with a restructuring of metabolic gene expression.  
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3.1  CHARACTERIZING C2C12 MYOGENESIS AND THE 
ENDOGENOUS TRANSITIONS IN MYOSIN HEAVY CHAIN 
ISOFORM EXPRESSION 
 
3.1.1 INTRODUCTION  
Measuring myosin heavy chain (MyHC) isoform expression currently offers 
the most suitable marker of muscle fibre composition as specific MyHC 
isoforms generally coincide with a well-defined set of contractile and 
metabolic properties (Delbono 2010). Adult skeletal muscle is composed of 
four major muscle fibre types (type I, IIa, IIx and IIb; Lefaucheur 2010) with 
two further isoforms, embryonic (emb) and neonatal (neo), which are generally 
only expressed during development or states of muscle regeneration (Harrison 
et al. 2011; DÕAntona et al. 2006). Research investigating muscle fibre type 
transitions are typically studied in vivo with relatively few reports in vitro. 
Furthermore, the few studies which have explored transitions in expression of 
MyHC isoforms in vitro have been conducted using relatively non-specific 
antibodies. These antibodies typically detect several MyHC isoforms and thus 
are ineffective in elucidating the precise pattern of expression as myogenic 
cells differentiate and mature (Silberstein et al., 1986; Miller 1990). Thus this 
study attempted to produce a comprehensive analysis of the endogenous 
mRNA expression of all six specific MyHC isoforms and myogenic regulatory 
factors (MRF) during the proliferation and differentiation of the C2C12 mouse 
myoblast cell line (a commonly used cell line for muscle biology research). 
Understanding the typical characteristics of this cell line will provide important 
information to any scientist working with this cell line and also enables further 
in vitro research into the molecular mechanisms regulating transitions in 
MyHC isoform expression.  
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3.1.2 MATERIALS AND METHODS 
The materials and methods described here are a brief overview only. A more 
comprehensive explanation of the techniques described herein is detailed in 
the Materials and Methods Chapter. 
 
3.1.2.1 Cell culture 
C2C12 muscle cells were seeded at 100,000 cells per well of 6-well plates and 
grown in growth medium (DMEM, 10% FBS, 1% P/S). Cells were encouraged 
to differentiate at near confluence (day 0; 36-48hrs post seeding) by replacing 
the medium with a low serum differentiation medium (DMEM, 2% HS, 1% 
P/S) and cultured for 8 days to allow myoblasts to fuse to form mature 
myotubes. Medium was replenished every 48 hours.  
 
3.1.2.2 Cell harvest 
Cells were harvested on days -1, 0, 1, 2, 4, 6 and 8. Immediately prior to 
harvesting cells, the culture medium was removed. Cells harvested for RNA 
were scraped directly into 200µl of RNase-free phosphate buffered saline 
(PBS), snap frozen on dry ice (solid CO2) and stored at -80¡C until analysis. 
Cells harvested for DNA content and creatine kinase (CK) activity were 
washed with 1ml PBS and then scraped into 500µl tri-sodium citrate (4¡C), 
placed on ice whilst the other samples were harvested and then stored at -20¡C 
until use.  
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3.1.2.3 DNA, Creatine Kinase and protein quantification assay 
Cells harvested for DNA content and CK activity were initially stored at -
20¡C. Cells were thawed slowly on ice followed by immediate lysis by 
sonication (Soniprep150, MSE, UK) on ice with amplitudes of 10 microns for 
10 seconds (until the sample turned clear). Lysed cells were assayed for CK 
activity using a CK kinetic assay kit (Thermo Electron Corporation, Fisher 
Scientific, Loughborough, UK) on a 96-well absorbance platereader. Hoechst 
fluorescent dye was used to quantify DNA content in lysed cell samples using 
a 96-well fluorescence platereader assay (described in detail by Hurley et al. 
2006). Total protein of the cell lysate was measured by the assay of Lowry.  
 
3.1.2.4 Quantitative RT-PCR 
Total RNA was extracted from cells using an RNA isolation kit (ROCHE High 
Pure Isolation Kit for RNA isolation) and stored at -80¡C until use. RNA 
concentrations were adjusted to 100ng/µl and first strand cDNA was 
synthesised (using Promega reagents). Relative abundance of specific 
transcripts was determined by Q-RT-PCR using the standard curve method 
(conducted on a Roche Lightcycler480). Transcript abundance was normalized 
for total cDNA in the Q-RT-PCR reaction (using the oligreen method; Rhinn 
et al. 2008). A list of genes measured by Q-RT-PCR and their respective 
primer sets are displayed in Table 3.1.  
 
Primer sequences for measuring MyHC I, IIA, IIX and neonatal isoforms were 
obtained from Zhou et al. (2010) and primer sequences for MyHC IIB and 
embryonic isoforms were from Da Costa et al. (2007). Primer sequences for 
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MyoD (ENSMUST00000072514), Myf-5 (ENSMUST00000000445) and 
Myogenin (ENSMUST00000027730) were previously designed and tested in-
house (by Dr Zoe Daniel).  
 
 Table 3.1 Forward and reverse primers for the mouse MyHC and MRFÕs genes 
 
 
3.1.2.5 Mouse MyHC primer test 
Melt-curve analysis for each primer set was conducted on C2C12 derived 
cDNA. Due to the very similar sequences of the MyHC isoforms, Q-RT-PCR 
amplicons were separated by horizontal agarose gel (1.5%) electrophoresis to 
ensure the amplicons produced in the reaction were of the correct length (see 
Figure 3.1 for MyHC primer test), providing confidence that the correct 
isoforms were being measured.  
 
 
Gene Forward primer Reverse primer 
Amplicon 
length 
MyHC I CTCAAGCTGCTCAGCAATCTATTT GGAGCGCAAGTTTGTCATAAGT 152bp 
MyHC IIa AGGCGGCTGAGGAGCACGTA GCGGCACAAGCAGCGTTGG 130bp 
MyHC IIx GAGGGACAGTTCATCGATAGCAA  GGGCCAACTTGTCATCTCTCAT  154bp 
MyHC IIb CAATCAGGAACCTTCGGAACAC GTCCTGGCCTCTGAGAGCAT 80bp 
MyHC emb TCCGACAACGCCTACCAGTT CCCGGATTCTCCGGTGAT 72bp 
MyHC neo CAGGAGCAGGAATGATGCTCTGAG  AGTTCCTCAAACTTTCAGCAGCCAA  113bp 
Myogenin CCCATGGTGCCCAGTGAA GCAGATTGTGGGCGTCTGTA 130bp 
Myf5 CAGCCCCACCTCCAACTG GCAGCACATGCATTTGATACATC 117bp 
MyoD CGTGGCAGCGAGCACTAC TGTAATCCATCATGCCATCAGA 79bp 
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Figure 3.1 Horizontal agarose gel (1.5%) electrophoretic separation of MyHC PCR amplicons 
to confirm primers are specific 
 
 
3.1.2.6 Statistical analysis 
All analyses were carried out on a single experiment with four biological 
repeats (separate wells) spread over two 6-well plates. Changes in mRNA 
transcript abundance, DNA content and CK activity across the time course 
were analysed by one-way analysis of variance. Tukey HSD post hoc analysis 
was used to determine differences between specific time points. Significance 
was accepted if p<0.05. All statistical analyses were performed on SPSS 
statistical package version 16 (SPSS Inc., Chicago, IL, USA). Data in figures 
is displayed as mean ± standard deviation (SD).  
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3.1.3 RESULTS 
3.1.3.1 Proliferation 
DNA content was measured as a marker of cell proliferation, with an increase 
in DNA content suggesting an increase in cell number. As expected, DNA 
content changed significantly over the time course (p<0.001). DNA content 
increased rapidly from day -1 to day 0 (3.7-fold increase; p<0.001) as cells 
proliferated (Figure 3.2A). This coincided with a visual increase in cell number 
(Figure 3.2A; day -1 and day 0). DNA content increased slightly between day 
0 and day 1 (p=0.039) when it began to plateau as cells started to differentiate 
(Figure 3.2A; Figure 3.3).  
 
Figure 3.2 (A) DNA content and (B) creatine kinase activity (corrected for DNA content) 
during C2C12 proliferation and differentiation (mean ± SD; p<0.001). * indicates significant 
difference from the previous timepoint (p < 0.05).  
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3.1.3.2 Differentiation 
Creatine kinase (CK) activity (corrected for DNA content) was measured as a 
marker of muscle differentiation and changed significantly across the time 
course (p<0.001). CK activity was low in myoblasts and did not change 
between day -1 and day 0 (p=1.0), when cells were still proliferating (Figure 
3.2B). This was confirmed visually by a lack of myotubes observed at days -1 
and 0 (Figure 3.3). CK activity increased slightly on day 1 (p=0.014; Figure 
3.2B), which coincided with the cells becoming confluent and beginning to 
fuse (Figure 3.3). As cells formed small, early stage myotubes (day 2; Figure 
3.3) CK activity increased substantially (4.7-fold increase over day -1; 
p<0.001) and continued to increase to day 6 (6.3-fold increase over day -1; 
p<0.001; Figure 3.2B). Interestingly, CK activity peaked at day 6 and began to 
decline on day 8 (Figure 3.2B).  
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Figure 3.3 Light microscopy images of C2C12 cells during proliferation and differentiation 
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3.1.3.3 Myoblast fusion to form myotubes 
As highlighted in the pictures below, myoblasts in Figure 3.4A (stained with 
Hoechst dye) contain single nuclei (examples indicated by white arrows). In 
Figure 3.4B, myotubes expressing ZsGreen in the cytoplasmic regions show 
that individual myotubes contain several nuclei per cell (black circles; 
examples indicated by white arrows). Collectively, these images confirm the 
fusion of single nuclear myoblasts to form multinucleated myotubes during 
myogenesis.  
 
Figure 3.4 (A) Hoechst stained C2C12 myoblasts show that myoblasts contain a single nuclei 
per cell (examples indicated by arrows). (B) ZsGreen expressing C2C12 myotubes highlights 
that myotubes contain multiple nuclei (black circles Ð examples indicated by arrows).  
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3.1.3.4 RNA yield from proliferating myoblasts and 
differentiating myotubes 
Average RNA yield (per well) from C2C12Õs cultured in 6-well plates is 
presented below (Figure. 3.5). Crude RNA concentration from cultured cells 
shows total RNA yield increasing with differentiation. Interestingly, when 
RNA yield is corrected for total DNA (as a marker of cell number), relative 
RNA abundance displays a biphasic profile (Figure 3.5). The highest 
RNA:DNA ratio was exhibited by proliferating myoblasts. RNA:DNA ratio 
initially declined with myoblast fusion and then increased throughout 
differentiation.  
 
Figure 3.5 RNA yield from C2C12Õs during proliferation and differentiation represented (A) 
per well of 6-well plates or (B) relative to DNA content. Data presented as mean ± SD.            
* indicates significant difference relative to the previous time point (p < 0.05); ♯ indicates a 
significant difference between day 1 and 6 (p < 0.01). 
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3.1.3.5 Myogenic regulatory factor (MRF) mRNA expression 
MyoD mRNA expression did not change (p=0.189) during the time course 
(Figure 3.6A). In contrast, Myf5 mRNA expression changed over the time 
course (p<0.001), being high in myoblasts, with a similar level of expression 
from day -1 to day 1 (Figure 3.6B). On day 2, myf5 mRNA expression 
dramatically declined (to ~50% of the level of expression at days -1 to day1; 
p<0.001) whereby it remained the same throughout differentiation (Figure 
3.6B). There were also significant changes in expression of myogenin mRNA 
across the time course (p<0.001). Figure 3.6C shows myogenin mRNA 
expression was low in myoblasts (day -1 and 0), increased substantially on 
days 1 (48.3-fold increase over day -1; p<0.001) and 2 (70.8-fold increase over 
day -1; p<0.001), but then declined on days 6 and 8 (approx. 35-fold increase 
over day -1; p<0.001). The initial and substantial increase in myogenin mRNA 
expression at days 1 and 2 coincided with myotube formation being observed 
at day 2 (Figure 3.3).  
Crossing point values during Q-PCR analysis of myogenic regulatory factors 
are displayed in Table 3.2.   
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Figure 3.6 (A) MyoD (p=0.189) (B) myf5 (p<0.001) and (C) myogenin (p<0.001) mRNA 
expression during C2C12 proliferation and differentiation (mean ± SD). * indicates a 
significant difference relative to the previous time point (p < 0.05). 
 
Table 3.2 Crossing point values for Q-PCR analysis of myogenic regulatory factors 
  MyoD Myogenin Myf5 
Day -1 27.9 31.8 27.0 
Day 0 27.4 28.5 26.4 
Day 1 27.8 25.3 26.5 
Day 2 27.6 24.6 27.9 
Day 4 27.8 24.7 28.2 
Day 6 27.8 25.6 28.2 
Day 8 27.8 25.8 28.2 
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3.1.3.6 Myosin Heavy Chain mRNA expression 
Expression of all six myosin heavy chain (MyHC) mRNA isoforms changed 
significantly across the time course of differentiation (all p<0.001), but in two 
distinct cohorts. Expression of MyHC emb, neo and type I isoforms was low 
on day 1, increased dramatically at day 2 (p<0.001), peaked at days 2 or 4 and 
then declined to day 8 (Figure 3.7A, 3.7B and 3.7C). The fast, type II isoforms 
(IIa, IIx and IIb) were expressed in a distinctly different pattern to the emb, neo 
and type I isoforms, in that their expression appeared much later during 
differentiation and continued to increase to day 8 (Figure 3.7D, 3.7E and 3.7F). 
MyHC IIa and IIx expression first appeared at a low level on day 2 (Figure 
3.7D and 3.7E), whereas MyHC IIb mRNA expression appeared later, on day 
4 (Figure 3.7F). 
 
Figure 3.7 (A) MyHC emb (B) neo (C) type I (D) type IIa (E) type IIx and (F) type IIb mRNA 
expression during C2C12 proliferation and differentiation (mean ± SD; p<0.001). * indicates a 
significant difference relative to the previous time point (p < 0.05).  
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Assessment of the crossing point values during Q-PCR of the MyHC isoforms 
confirms that individual isoforms do exhibit differential expression profiles 
during differentiation (Table 3.3). Using crossing point values as an indicator 
absolute transcript abundance, these data show that fully differentiated C2C12 
myotubes express an abundance of transcripts for type IIX and IIB MyHC 
isoform, with lower quantities of the emb, neo, type I and IIA MyHC isoforms. 
 
Table 3.3 Crossing point values for Q-PCR analysis of MyHC isoforms 
  
MyHC 
emb 
MyHC 
neo 
MyHC 
I 
MyHC 
IIA 
MyHC 
IIX 
MyHC 
IIB* 
Day -1 39.2 36.5 37.0 39.1 32.4 35.5 
Day 0 38.2 35.8 36.0 37.2 31.1 33.7 
Day 1 32.0 31.8 33.1 34.7 28.3 32.4 
Day 2 29.9 29.3 30.0 32.4 26.8 31.5 
Day 4 29.6 28.9 29.3 30.9 24.5 27.5 
Day 6 30.6 30.3 30.5 29.9 23.3 24.9 
Day 8 31.1 31.2 31.0 29.4 22.7 24.4 
 
* conducted on a different batch of cDNA 
 
 
3.1.3.7 Myosin Heavy Chain I promoter activity in C2C12 cells 
Transcripts for the type I MyHC isoform were present from day 1 in 
differentiation, which was surprisingly early as this was prior to myoblast 
fusion (Figure 3.3 and 3.7C). Therefore, a 1kb mouse MyHC I fluorescence 
promoter-reporter plasmid was constructed and transfected into C2C12 
myoblasts to visually confirm the timing of MyHC I promoter activation. 
Indeed, MyHC I promoter activity was detected in myoblast cells, prior to 
fusion into myotubes (Figure 3.8). As differentiation proceeded to day 4, 
MyHC I promoter activity was restricted to myotubes.  
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Figure 3.8 Visualization of mouse 1kb MyHC I promoter activity using a ZsGreen reporter 
plasmid in C2C12 muscle cells. Note that the MyHC I promoter is active in myoblasts (day 1), 
prior to myotube formation. By day 4 of differentiation, MyHC I promoter activity was strong 
and restricted to differentiated myotubes.  
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3.1.4 DISCUSSION 
Understanding the typical characteristics of a cell line is a prerequisite for any 
scientific intervention. Thus, this initial study set out to characterize the 
process of C2C12 myogenesis and in particular, the changes in relative mRNA 
expression of the MyHC isoforms and myogenic regulatory factors (MRFs) 
during differentiation.  
Muscle differentiation (myogenesis) is associated with the activation of muscle 
specific genes (Sabourin and Rudnicki 2000) and is characterized by myoblasts 
fusing to form myotubes. The present study highlighted that C2C12 myoblasts 
fuse/differentiate to form multinuclear myotubes, supporting the wealth of 
literature detailing myogenesis. During muscle cell differentiation, genes 
encoding contractile proteins, such as the MyHCÕs, are activated (Sabourin et 
al. 1999). This study revealed, for the first time, that during in vitro C2C12 
myogenesis, the activation of MyHC genes are not all activated at the same 
time nor in the same pattern and that potentially, a transition from emb, neo 
and type I to the fast, type II MyHC isoforms is occurring.  
The results of the present study provide probably the most detailed account of 
the endogenous MyHC isoform expression during C2C12 myogenesis, with 
few previously published in vitro studies examining MyHC isoform transitions 
during myogenesis (Silberstein et al. 1986; Weydert et al. 1987; Miller 1990). 
Miller et al. (1990) conducted immunofluorescent staining of C2C12 cells and 
immunoblotting using monoclonal antibodies, R11D10 (against type I MyHC), 
F47 (against perinatal (also known as neonatal), type IIa and type IIb) and F59 
(against all MyHC isoforms). The authors report that C2C12 myotubes 
differentiated for 7 days expressed predominantly type I and perinatal MyHC 
114 
isoforms. However, the use of antibodies that were not specific to individual 
isoforms does not enable an accurate elucidation of the expression patterns of 
specific MyHC isoforms. Furthermore, previous studies used antibodies raised 
against MyHC isoforms expressed in human muscle at fetal and neonatal 
stages of development (Silberstein et al. 1986). The fetal antibody (F1.652) 
detected MyHC in mouse fetal (gestation day 17), but not adult (4 months) 
muscle, whereas the neonatal antibody (N3.36) detected MyHC in mouse 
perinatal muscle (gestation day 19) and adult (4 months and 6 months) 
muscles, but not fetal muscle. Immunofluorescence studies in cell culture using 
these antibodies allowed the identification that transitions from ÒearlyÓ to 
ÒlateÓ MyHC isoforms occur in vitro, but did not reveal the specific MyHC 
isoforms present in these ÒearlyÓ and ÒlateÓ MyHC groups (Silberstein et al. 
1986). For the first time, data presented herein shows that these two cohorts of 
MyHC isoforms consist of emb, neo and type I as ÒearlyÓ isoforms and fast 
IIa, IIx and IIb as ÒlateÓ isoforms. In support of our findings, Weydert et al. 
(1987) reported that C2/7 mouse myotubes, cultured for 3 days, exhibit a 
sequential accumulation of embryonic, perinatal and adult IIb MyHC 
transcripts. We report a sequential pattern of accumulation of these mRNA 
isoforms during early differentiation (up to day 2 or 4) but in addition, we also 
report a transition from day 2 or 4 onwards in that embryonic and neonatal 
isoforms become down regulated as the adult IIa, IIx and IIb isoforms are up-
regulated. Importantly, the transitions in MyHC isoforms expressed in C2C12 
cells described here are in agreement with the pattern of transitions reported 
previously in mouse skeletal muscle during postnatal development in vivo, at 
both the mRNA (Weydert et al. 1987) and the protein (Agbulut et al. 2003) 
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levels, suggesting that the C2C12 muscle cell line is a good model for studying 
developmental myogenesis. Interestingly, the responses observed in the current 
study in C2C12 cells only matched the expression patterns of MyHC in fast 
muscles (EDL, plantaris and Gastrocnemius), but not slow (soleus) muscles 
(Agbulut et al. 2003). In fast muscle, MyHC protein expression began with 
emb, neo and type I isoforms, which were gradually replaced with the fast 
isoforms; whereas in the soleus (a slow muscle), emb and neo isoforms 
declined with development, but type I expression increased. The authors 
suggest that the postnatal transitions from emb, neo and type I MyHC to the 
fast MyHC isoforms in fast skeletal muscle is a result of the introduction of 
external/environmental stimuli such as innervation, contraction and circulating 
hormones. That the same pattern of transitions occurred in vitro in the current 
study (at the mRNA level), suggests that the driving factors inducing 
transitions from emb, neo and type I MyHC isoforms to the adult, fast MyHC 
isoforms can occur independent of innervation, although effects of 
spontaneous cellular contractions cannot be ruled out. In support of this, 
Weydert et al. (1987) reported that injection of beta-bungarotoxin (which 
destroys peripheral nerves) into mouse fetuses had no effect on the 
accumulation of perinatal and adult IIb MyHC isoform transcripts. However, 
the involvement of contraction mediated transitions in MyHC isoforms cannot 
be excluded, as sodium channel blockers that inhibit spontaneous myotube 
contraction, such as tetrodotoxin, were shown to reduce the appearance of 
neonatal MyHC expression in vitro (Cerny and Bandman 1986).  
It is interesting to speculate, from the data presented herein, that the specific 
timing of MyHC mRNA isoform induction serves a developmental purpose 
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during myogenesis. For example, the embryonic, neonatal and type I MyHC 
isoforms may be induced prior to myoblast fusion to provide the structural 
components to form the immature myotube, but do not permit fast contractions 
that may damage the developing myotubes. The fast contracting, type II 
isoforms, on the other hand, are likely induced later in differentiation only 
once the myotubes are structurally capable of coping with a stronger 
contracting cellular machinery, thus limiting contraction induced cell damage 
during early myotube development.  
The genes encoding the type II isoforms (IIa, IIx and IIb) are found in a gene 
cluster on chromosome 11 for mice in this sequential order from 5Õ to 3Õ, 
which also includes the emb and neo isoforms (on either side of the fast 
isoform cluster). However, the gene encoding the type I isoform is located in a 
separate cluster on a different chromosome (14 for mice). It has been 
suggested that the clustered location of the MyHC genes is involved in their 
regulation (Luther et al. 1998; Pandorf et al. 2006; Giger et al. 2007; Rinaldi et 
al. 2008). Of particular interest, Pandorf et al. (2006) and Rinaldi et al. (2008) 
report that a bi-directional promoter in the intergenic regions of the type II 
MyHC genes produces sense RNA of the target gene whilst simultaneously 
producing antisense RNA of the upstream gene(s) (5Õ direction) and 
subsequently causes a down regulation of the upstream gene(s), although the 
mechanism of action remains elusive. This process would result in a 
coordinated pattern of expression, whereby up-regulating one isoform 
subsequently down-regulates its nearest 5Õ isoform. Although the naturally 
occurring antisense was not measured in the current study, the co-expression of 
the type II MyHC genes suggests that a bi-directional promoter may not be 
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involved in their regulation in this in vitro system. In addition, perhaps this 
mechanism of regulation may require a more physiological system, such as 
innervation, to function. 
The down-regulation of the emb, neo and type I isoforms from day 4 or day 6 
onwards and the continual increase in expression of the type II isoforms from 
day 4 through to day 8 suggests a transition in MyHC isoforms. This transition 
coincided with the visual observation of myotube hypertrophy and presents the 
question as to whether the molecular signals inducing myotube hypertrophy 
also initiate a transition towards the fast MyHC isoforms. It would seem 
logical for enlarging myofibres to express the necessary fast contractile 
machinery as well; particular as the largest myofibres in vivo typically express 
the faster MyHC isoforms (Lefaucheur 2010). Indeed, it has been reported that 
increased proportions of type IIb MyHC transcripts are associated with 
increased muscularity in pigs (Wimmers et al. 2008) and that increased rates of 
hypertrophy during development is likely to be driving a transition to increased 
MyHC IIb content rather than vice versa (Gunawan et al. 2007). Support for 
this notion comes from the observation that small myotubes express ÒearlyÓ 
fetal MyHC isoforms and large myotubes express ÒlateÓ neonatal and adult 
MyHC isoforms (Silberstein et al. 1986), suggesting that MyHC transitions 
coincide with myotube hypertrophy. Interestingly, myostatin knockout mice 
display profound muscle hypertrophy and hyperplasia with subsequent 
alterations in muscle phenotype, namely a transition towards increased IIb 
fibres and hypertrophy of type IIb fibres (Matsakas et al. 2010). Hence it is 
plausible that molecular signals driving hypertrophy may also regulate MyHC 
isoform expression towards the fast type II isoforms. Of course, this may be 
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mediated via changes in contractility, since myotube hypertrophy may lead to 
spontaneous myotube contraction, which could in turn influence MyHC 
expression (Cerny and Bandman 1986).  
Myogenin is a key signalling factor required for muscle cell differentiation 
(Nabeshima et al. 1993; Hasty et al. 1993). The pattern of myogenin mRNA 
expression in the current in vitro study was very similar to that reported in 
cultured L6 rat myoblasts (Wright et al. 1989) and during ovine fetal 
development in vivo (Fahey et al. 2005), all showing increasing myogenin 
mRNA as cells differentiate and declining myogenin mRNA as cells become 
well differentiated. This provides support for the validity of an in vitro muscle 
cell culture system to mimic the in vivo developmental myogenic program. 
Myf5 mRNA expression was high during myoblast proliferation and displayed 
a rapid down-regulation which coincided with myotube formation. This 
supports the notion that myf5 is a proliferative transcription factor during 
myogenesis (Kitzmann et al. 1998; Ustanina et al. 2007; Gayraud-Morel et al. 
2007). MyoD and myogenin have been well documented to accumulate in fast 
and slow muscles, respectively (Voytik et al. 1993; Hughes et al. 1993; Elmark 
et al. 2007). Due to the differential accumulation in phenotypically different 
muscles, the ratio of MyoD to myogenin in skeletal muscle may contribute to 
muscle fibre type regulation. MyoD has been implicated in activating the fast, 
MyHC IIb gene (Wheeler et al. 1999; Allen et al. 2001; Harrison et al. 2011). 
Surprisingly, MyoD mRNA expression remained unchanged throughout 
myogenesis in C2C12 cells in the current study, which agrees with a previous 
study in numerous myogenic cell types (Miller 1990). It is interesting that the 
pattern of expression of MyHC IIb mRNA was not preceded by an up-
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regulation of MyoD mRNA expression, as is the case during muscle fibre type 
transitions towards increasing MyHC IIb observed in vivo (Wheeler et al. 
1999). There is evidence to suggest that MRFÕs may be post-transcriptionally 
regulated as long term changes in MyoD and myogenin at the mRNA level can 
occur without changes at the protein level (Alway et al. 2002). Thus, MRFÕs 
should be measured at the protein level to give a more valid indication of the 
quantity of ÒfunctionalÓ MRFÕs present and to provide more viable data on 
their influence on MyHC isoform regulation. Furthermore, Elmark et al. 
(2007) reported that the phosphorylation status determines the effect of MyoD 
on MyHC IIb activation. Over-expression of MyoD in normally active mouse 
soleus muscle had little effect on fibre type composition, but over-expression 
of MyoD mutated at T115, making it resistant to phosphorylation, had 
profound effects on fibre type composition, increasing type II positive fibres 
from 50% to 85% (Elmark et al. 2007). The slow pattern electrical activity of 
the soleus appears to phosphorylate MyoD, impairing its activity as a MyHC 
IIb inducing transcription factor. The phosphorylation status of other MRFÕs 
and their subsequent role in myogenesis and MyHC expression has not been 
investigated. Due to the lack of nerve innervation in cell culture systems, 
contraction-induced phosphorylation of MRFÕs may be overlooked. Thus, 
studying MRF transcript and protein levels as well as phosphorylation status 
during myogenesis would be informative to elucidate their role, if any, on 
MyHC isoform expression during myogenesis. Furthermore, MRFÕs have been 
shown to physically interact with other transcription factors known to induce 
muscle specific gene expression, such as serum response factor (Groisman et 
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al. 1996), suggesting post-translational regulation of MRFÕs during 
myogenesis is an interesting avenue for further research.  
In summary, this study reports a comprehensive analysis of MyHC and MRF 
mRNA expression during myogenesis of C2C12 mouse myoblasts. MyHC 
mRNA isoforms were expressed in a distinct temporal pattern as two distinct 
cohorts. MyHC emb, neo and type I expression was up-regulated during early 
differentiation and their expression was subsequently down-regulated after 4 to 
6 days in culture. MyHC IIa, IIx and IIb, on the other hand, were expressed 
later in differentiation and their expression continued to increase to day 8. The 
C2C12 cell line therefore mimics the development of a fast muscle fibre type, 
and scientists utilizing this cell line for muscle biology research should take 
this into consideration. The MRF and MyHC mRNA expression observed 
during myogenesis of the C2C12 cell line closely matched the reported 
expression patterns during development in vivo. Thus, in vitro cell culture 
systems may be viable models for studying MyHC isoform transitions during 
development and of myogenic precursor (satellite) cells during adult muscle 
regeneration. However, the lack of stimuli from innervation, circulating 
hormones and stretch does expose a major limitation of in vitro experiments.  
 
 
 
  
121 
3.2  TRANSITIONS IN METABOLIC GENE EXPRESSION DURING 
C2C12 MYOGENESIS Ð ASSOCIATION WITH MYOSIN HEAVY 
CHAIN GENE EXPRESSION 
 
3.2.1 INTRODUCTION 
The C2C12 cell line displayed a transition towards a predominantly fast 
contracting (type II) MyHC isoform profile during myogenic differentiation. 
The ATP consumption of a myofibre is largely determined by the MyHC 
isoform expression (Schiaffino and Reggiani 2011) and increases in the order 
of type I<IIA<IIX<IIB. Consequently, myofibres containing the fast, type II 
MyHC isoforms typically display a glycolytic phenotype (Lefaucheur 2010) in 
order to supply the necessary ATP required to permit forceful contractions of 
these fibres. Given that the rate of the rate of ATP hydrolysis by fast MyHCÕs 
is approximately 20-30-fold greater than that of type I MyHCÕs (Weiss and 
Leinwand 1996), it was hypothesized that mature C2C12 myotubes, 
transitioning to a predominantly type II MyHC expressing phenotype, would 
also display a very glycolytic phenotype in order to rapidly supply the high 
ATP requirements of these MyHCÕs. To assess the metabolic profile of 
cultured C2C12 myotubes, the metabolic gene expression profile of these cells 
was compared to proliferating C2C12 myoblasts. Given that mitotic cells 
typically display a very glycolytic metabolism (Gatenby and Gilles 2004; Lunt 
et al. 2011), they were considered an interesting reference/control to assess the 
relative metabolic gene expression profile displayed by fully differentiated 
muscle cells, expressing type II MyHC isoforms.  
Cellular metabolism is a complex series of interconnecting chemical reactions 
that can be split into ÒcatabolicÓ and ÒanabolicÓ metabolism. The main 
purposes of such chemical reactions are 1) to provide ATP for cellular function 
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(catabolic metabolism) and 2) to provide precursors for the biosynthesis of 
macromolecules to support cell growth and maintenance (anabolic 
metabolism). Catabolic metabolism can occur through glycolytic and/ or 
oxidative metabolic pathways. Glycolytic metabolism is considered relatively 
inefficient, producing just 2 ATP per glucose molecule, but can produce ATP 
very quickly and in the absence of oxygen. Oxidative metabolism, on the other 
hand, is very efficient; producing 36 ATP per glucose molecule but requires 
oxygen. These dynamic metabolic pathways present a very adaptive system, 
adjusting metabolism according to the energy requirements of the cell but also 
the oxidative and nutritional status of the cellular environment. In skeletal 
muscles, the ability to utilize glycolytic and oxidative metabolic pathways for 
ATP production permits the use of skeletal muscle for rapid, powerful force 
production (glycolytic) and slow, prolonged force production (oxidative). In 
addition to metabolism being essential to the provision of ATP for muscle 
contraction and other cellular functions, recent advances in cancer cell biology 
have highlighted a critical dependence on biosynthetic pathways (namely 
serine and nucleotide biosynthesis), stemming from gylcoylsis, to support the 
anabolic requirements of rapidly proliferating cells (Lunt et al. 2011; 
Possemato et al. 2011; Tong et al. 2009). Thus, cancer cells (and most highly 
proliferating cells) switch away from efficient ATP producing metabolic 
pathways (oxidative) and focus on the synthesis of anabolic precursors using 
biosynthetic pathways stemming from glycolysis (Lunt et al. 2011). It was 
therefore hypothesized that gene expression of enzymes in these pathways may 
be highly up-regulated in the proliferating C2C12 myoblasts and down-
regulated in the differentiated myotubes. It was speculated that a dramatic 
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remodelling of metabolic gene expression would occur between the 
proliferating and fully differentiated C2C12 muscle cells, with the emphasis on 
maximising ATP production for the type II MyHCÕs expressed in 
differentiated myotubes.   
Given the relatively un-physiological conditions of most muscle cell culture 
systems (supraphysiological concentrations of glucose, hard plastic culture 
surfaces, high oxygen concentrations and no neural innervation), a combined 
MyHC and metabolic gene expression profile of cultured C2C12 myotubes 
provides important information for understanding the C2C12 cell line as a 
model for skeletal muscle research.  
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3.2.2 MATERIALS AND METHODS 
The materials and methods described here are a brief overview only. A more 
comprehensive explanation of the techniques described herein is detailed in 
the Materials and Methods Chapter. 
 
3.2.2.1 Cell culture 
C2C12 mouse myoblasts were seeded at 50,000 cells per well of a 6-well plate. 
Myoblasts were cultured in growth medium (DMEM, 10% FBS, 1% P/S) until 
near confluent, at which point, cells were encouraged to differentiate by 
switching to a low serum differentiation medium (DMEM, 2% HS, 1% P/S) 
and cultured for 7 days. Culture medium was refreshed every 48 hours.  
 
3.2.2.2 Cell harvest and RNA analysis 
Proliferating myoblasts (approximately 85% confluent; 24 hours post-seeding) 
and mature myotubes (following 7 days in differentiation medium) were 
harvested in 200µl ice-cold PBS for total RNA extraction and subsequent Q-
RT-PCR analysis of metabolic gene expression. Details of RNA extraction, 
cDNA synthesis and Q-RT-PCR analysis were described in the Materials and 
Methods Chapter. Synthesis of cDNA for this experiment was conducted using 
the Roche Transcriptor First Strand cDNA Synthesis Kit.  
 
3.2.2.3 Oligonucleotide primers 
Oligonucleotide primers were designed against the latest mouse genome build 
(GRCm38) using Primer Express. All primers sets were tested by melt-curve 
analysis (Lighcycler480, Roche). The transcripts measured herein were 
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selected to cover major metabolic pathways and muscle specific isoforms were 
selected where possible. Metabolic genes measured are listed in Table 3.4 with 
their accession number and primer sequences. 
 
Table 3.4 Oligonucleotide sequences used for Q-RT-PCR analysis of mouse metabolic genes 
 
 
 
 
Gene Forward primer Reverse primer 
Amplicon 
length 
Hexokinase-2 
(ENSMUST00000000642) 
 
GAGCCTCGGTTTC
TCTATTTGG 
 
ATACTGGTCAAC
CTTCTGCACTTG 
 
117 bp 
 
Phosphofructokinase, muscle type 
(ENSMUST00000051226)  
 
CCGGCTCAGTGAG
ACAAGGA 
 
GGCACCTTCAGC
AACAATGA 
 
64 bp 
 
Enolase-3 
(ENSSSCT00000019484) 
 
GCCTGCTCCTGAA
GGTCAAC 
 
TGCAAGTTTACA
GGCCTGGAT 
 
65 bp 
 
Glucose-6-phosphate dehydrogenase 
(ENSMUST00000004327) 
  
CCCGCTCACGACT
CACAGT 
 
AGTGGCTTTAAA
GAAGGGCTCACT 
 
62 bp 
 
3-Phosphoglycerate dehydrogenase 
(ENSMUST00000065793) 
 
CGTGAACTTGGTG
AACGCTAAG 
 
GTGGGAGGTGGT
GACATTGAG 
 
64 bp 
 
Phosphoserine aminotransferase 1  
(ENSMUST00000025542) 
 
CGTGCTTCAGCAT
CTACGTCAT 
 
GCCCCGCCGTTG
TTCT 
 
61 bp 
 
Phosphoserine phosphatase  
(ENSMUST00000031399) 
 
GGCATAAGGGAGC
TGGTAAGC 
 
GCCACCAGAGAT
GAGGAACAC 
 
66 bp 
 
Pyruvate carboxylase  
(ENSMUST00000113825) 
 
CCAACTTCGCTCA
CGTCTCA 
 
GCGTTCTCATAG
CCTACCTGCTT 
 
66 bp 
 
Citrate synthase  
(ENSMUST00000005826) 
 
GCTGCTGGTAACT
GGACAGATG 
 
GCCCTTTTTGCC
CATTCTC 
 
72 bp 
 
Isocitrate dehydrogenase 2 
(ENSSSCT00000002075) 
 
TTGAGGCTGAGGC
TGCTCAT 
 
CCGGCCCTTCTG
GTGTT 
 
62 bp 
 
Malate dehydrogenase 1  
(ENSMUST00000102874) 
 
GGAAAGGAAGTCG
GTGTGTATGA 
 
GCTGTTGCACAG
TCGTGATGA 
 
79 bp 
 
Malate dehydrogenase 2  
(ENSMUST00000019323) 
 
CAGTCCAAAGAGA
CGGAATGC 
 
GGCCCTTTTTCC
CCAAGA 
 
61 bp 
 
Phosphoenolpyruvate carboxykinase 2 
(ENSMUST00000048781) 
 
GCAGAGCACATGC
TGATTTTG 
 
GGAAAGCAGCT
GCCACGTA 
 
70 bp 
 
Pyruvate kinase, muscle-1 
(ENSMUST00000163694) 
 
GTTTAGCAGCAGC
TTTGATAGTTCTC 
 
GCGGTACCTGGC
CACTTG 
 
68 bp 
 
Pyruvate kinase, muscle-2 
(ENSMUST00000034834) 
 
GGCCAATGCAGTC
CTGGAT 
 
TCGAATAGCTGC
AAGTGGTAGATG 
 
144 bp 
 
Total Pyruvate kinase, muscle 
(combined Pkm 1 and 2 above) 
 
GCGGTGGCTCTGG
ATACAAA 
 
GTGCCGCTGCCC
TTGAT 
 
62 bp 
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3.2.2.4 Statistical analysis 
Gene expression from a single experiment with three biological replicates (for 
myoblasts and myotubes) were analysed by one-way analysis of variance using 
GenStat. Data is displayed as mean ± standard deviation. Significance was 
accepted if p < 0.05. 
 
  
127 
3.2.3 RESULTS 
The two time points at which C2C12 cells were harvested are shown in the 
light microscopy images below (Figure 3.9). Myoblasts were sub-confluent, 
un-fused, and proliferating. Day 7 myotubes were fully differentiated. 
 
 
Figure 3.9 Representative light microscopy images of the two cohorts of C2C12 cells used for 
gene expression analysis of proliferating cells and fully differentiated mature myotubes.  
 
 
3.2.3.1 Glycolytic enzyme gene expression 
In comparison to proliferating myoblasts, differentiated myotubes displayed 
increased mRNA expression of a selection of muscle-specific glycolytic 
enzymes (Hexokinase-2 (HK2), Phosphofructokinase-M (PFKm) and Enolase-
3; Figure 3.10). Of the glycolytic genes measured herein, PFKm transcript 
abundance showed the largest disparity in expression levels between myoblasts 
and myotubes, with myotubes displaying an ~14Ðfold higher (p < 0.001) 
expression level than proliferating myoblasts. Enolase-3 and HK2 mRNA 
expression was approximately 3-fold (p = 0.005) and 2-fold (p = 0.001) greater 
in myotubes compared to myoblasts, respectively.  
Proliferating myoblasts Differentiated myotubes 
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Figure 3.10 Hexokinase-2 (Hk2), Phosphofructokinase (PFKm) and Enolase 3 gene 
expression (muscle specific glycolytic enzymes) in proliferating myoblasts compared to 
differentiated myotubes. Data is presented as mean ± SD. * indicates p <0.01. 
 
 
3.2.3.2 Mitochondrial enzyme gene expression 
Gene expression of mitochondrial enzymes involved in the TCA cycle (Citrate 
Synthase (Cs), Isocitrate Dehydrogenase 2 (IDH2) and Malate Dehydrogenase 
2 (MDH2)) were all approximately 2-fold lower (p = 0.002, p < 0.001, p < 
0.001, respectively) in differentiated myotubes compared with proliferating 
myoblasts (Figure 3.11).  
 
 
Figure 3.11 Citrate synthase (CS), Isocitrate dehydrogenase (IDH2) and Malate 
dehydrogenase-2 (MDH2) gene expression in proliferating myoblasts compared to 
differentiated myotubes. Data is presented as mean ± SD. * indicates p <0.01. 
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3.2.3.3 G6PDH gene expression: The nucleotide biosynthesis 
pathway 
Glucose-6-Phosphate Dehydrogenase (G6PDH) is the committing enzyme of 
the pentose phosphate pathway. G6PDH mRNA expression was ~6-fold 
greater (p < 0.001) in proliferating myoblasts compared to differentiated 
myotubes (Figure 3.12).  
 
 
Figure 3.12 Glucose-6-phosphate dehydrogenase (G6PDH) gene expression in proliferating 
myoblasts compared to differentiated myotubes. Data is presented as mean ± SD. The image 
depicts the location of G6PDH initiating the nucleotide biosynthesis pathway. * indicates p 
<0.001. 
 
 
3.2.3.4 PHGDH, PSAT1 and PSPH: The serine biosynthesis 
pathway 
Gene expression of enzymes involved in the serine biosynthesis pathway all 
displayed a greater level of expression in proliferating myoblasts compared to 
differentiated myotubes (Figure 3.13). The committing enzyme, 3-
phosphoglycerate dehydrogenase (PHGDH), had the greatest difference in 
expression with levels ~3.5-fold greater (p < 0.001) in myoblasts compared to 
myotubes. Phosphoserine aminotransferase-1 (PSAT1) and phosphoserine 
phosphatase (PSPH) mRNA expression levels were approximately 2-fold 
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greater (p = 0.002, p < 0.001, respectively) in myoblasts compared to 
myotubes.  
 
 
Figure 3.13 3-phosphoglycerate dehydrogenase (PHGDH), Phosphoserine aminotransferase-1 
(PSAT1) and phosphoserine phosphatase (PSPH) gene expression in proliferating myoblasts 
compared to differentiated myotubes. Data is presented as mean ± SD. The image depicts the 
location of these enzymes forming the serine biosynthesis pathway. * indicates p <0.01. 
 
 
3.2.3.5 Pyruvate kinase 1/2 splice variant switching 
Total pyruvate kinase (muscle type) mRNA expression was higher in 
proliferating myoblasts compared to fully differentiated myotubes (Figure 
3.14A; p = 0.009). Interestingly, when the Pkm splice variant transcripts, 
Pkm1 and 2, are normalized against total Pkm transcript expression, a switch 
in the relative proportions of Pkm splice variant expression occurs between 
myoblasts and myotubes (Figure 3.14B). In proliferating myoblasts, Pkm2 is 
the predominant mRNA isoform, with only low levels of Pkm1 mRNA 
expression (p < 0.001). Fully differentiated myotubes, on the other hand, 
display an equal abundance of Pkm1 and 2 mRNA expression (p = 0.286). 
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Figure 3.14 (A) Total pyruvate kinase muscle type (Pkm) gene expression in proliferating 
myoblasts compared to differentiated myotubes. (B) Expression of Pkm splice variants, Pkm1 
and Pkm2, relative to total Pkm (Tot.Pkm) in myoblasts compared to myotubes. Data is 
presented as mean ± SD. * indicates p <0.01. NS = not significantly different. 
 
 
3.2.3.6 Gene expression of enzymes involved in 
gluconeogenesis 
Gene expression of enzymes involved in gluconeogenesis showed no common 
alteration in expression levels in proliferating versus differentiated C2C12 
cells (Figure 3.15). Pyruvate carboxylase (Pc) mRNA expression was 
approximately 5-fold greater (p = 0.002) in myotubes compared to myoblasts. 
Phosphoenolpyruvate carboxykinase-2 (PEPCK2; mitochondrial isoform) 
mRNA expression was approximately 2-fold lower (p = 0.008) in myotubes 
compared to myoblasts. Malate dehydrogenase (MDH1; cytoplasmic isoform) 
mRNA expression was not different between myoblasts and myotubes (p = 
0.276). 
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Figure 3.15 Pyruvate carboxylase (Pc), Phosphoenolpyruvate carboxykinase-2 (PEPCK2) and 
Malate dehydrogrenase-1 (MDH-1) gene expression in proliferating myoblasts compared to 
differentiated myotubes. Data is presented as mean ± SD. * indicates p <0.01. 
 
 
 
3.2.3.7 Summary of the metabolic gene expression 
Below is a diagram summarising the metabolic profile of fully differentiated 
myotubes in comparison to proliferating myoblasts (Figure 3.16). Enzymes are 
highlighted in green and red to indicate whether mRNA expression of that 
enzyme was higher or lower (respectively) in myotubes relative to myoblasts. 
Briefly, the metabolic enzyme gene expression profile of differentiated 
myotubes displayed a reduced reliance on pathways associated with nucleotide 
and serine biosynthesis, reduced reliance on the TCA cycle and an increase in 
glycolytic enzyme gene expression, compared to proliferating myoblasts.  
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Figure 3.16 Summary of metabolic gene expression in myotubes relative to myoblasts. 
Enzymes in green and red indicate whether gene expression of that enzyme was increased or 
decreased, respectively, in myotubes relative to myoblasts.  
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3.2.4 DISCUSSION 
The metabolic gene expression profile of C2C12 myoblasts and myotubes 
were compared to assess whether fully differentiated myotubes, expressing 
type II MyHC isoforms, exhibit a concomitant glycolytic gene expression 
profile. Indeed, relative to myoblasts, myotubes displayed an increased mRNA 
abundance of glycolytic genes and a decreased mRNA expression of oxidative 
genes. However, myotubes also showed a decrease in expression of genes 
involved in macromolecule biosynthesis, with a concomitant switch in Pkm 
splice variant expression (from Pkm2 to Pkm1), suggesting myotubes may 
actually re-focus their metabolic profile to support ATP production and shunt 
glucose carbons away from biosynthetic pathways with cellular differentiation.  
Compared to proliferating C2C12 myoblasts, fully differentiated myotubes 
displayed increased expression of glycolytic genes and decreased expression of 
oxidative genes. Chung et al. (2010) also reported increased gene expression of 
a range of glycolytic enzymes (Enolase-3, PFKm and Hexokinase-1) with 
cardiomyocyte differentiation, supporting the data presented herein. It is 
important to note that Chung et al. (2010) also highlighted several examples of 
disparity in mRNA expression and corresponding enzyme activity, suggesting 
that the gene expression data presented herein should be interpreted cautiously 
to avoid misleading conclusions. Gene expression data does however provide 
information as to the transcriptional programming of the cell during different 
stages of myogenesis. It is interesting to speculate that transcriptional changes 
in metabolic gene expression during myogenic differentiation may be closely 
linked to mechanisms regulating transcription of genes encoding contractile 
components of the myotube, to ensure a co-ordinated Òmetabolic-contractileÓ 
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phenotype. For example, fast (type II MyHC) and slow (type I MyHC) 
muscles typically express a glycolytic and oxidative phenotype, respectively 
(Schiaffino and Reggiani 2011), suggesting that both contractile and metabolic 
components of muscles may be co-ordinately regulated. Hence, the mature 
C2C12 myotubes used herein may exhibit a glycolytic gene expression profile 
to support the ATP requirements of their fast (type II MyHC) contractile 
cellular machinery. Indeed, examples of so-called master regulators of skeletal 
muscle phenotype have been identified that show co-ordinated transcriptional 
control of contractile and metabolic components of muscle. For instance, 
transgenic mice over-expressing the transcriptional co-factors, PGC-1alpha or 
PPAR-delta, display a co-ordinated up-regulation of genes encoding slow-
contracting components of muscle and genes encoding oxidative and 
mitochondrial enzymes (Lin et al., 2002; Wang et al., 2004). Such master 
transcriptional regulators of a fast contracting glycolytic muscle phenotype are 
yet to be identified. 
The increased expression of glycolytic genes and decreased expression of 
oxidative genes in differentiated myotubes, compared to myoblasts, was 
somewhat unexpected given that rapidly proliferating cells typically display a 
very glycolytic phenotype (Gatenby and Gilles 2004) and that differentiation 
of C2C12 muscle cells or ES-derived cardiomyoctyes generally exhibit a 
reduced glycolytic capacity, as demonstrated by a progressive reduction in 
lactate production (Leary et al. 1998; Chung et al. 2010). Furthermore, the 
ÒchoiceÓ displayed by fully differentiated myotubes to preferentially increase 
gene expression of glycolytic enzymes and concomitantly decrease gene 
expression of oxidative enzymes is confusing given that oxidative metabolism 
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is typically considered the more efficient mode of ATP production, compared 
to glycolysis (Lunt et al. 2011). It is possible, however, that the 
supraphysiological concentrations of glucose in the culture medium (25mM) 
could allow myotubes to generate greater quantities of ATP (more rapidly) via 
glycolysis, compared to oxidative metabolism (Pfeiffer et al. 2001). Given that 
the glucose concentration in the culture medium was the same for the 
proliferating and differentiated C2C12 cells, the appearance of GLUT4 
transporters with myogenic differentiation likely causes increased transport of 
glucose into myotubes and may subsequently increase reliance on glucose 
metabolism (Shyh-Chang et al. 2013). Increased transport of glucose into 
myotubes and the subsequent increased abundance of intracellular glucose may 
therefore explain the increase in glycolytic gene expression in mature 
myotubes compared to proliferating myoblasts.  
Interestingly, the increased glycolytic gene expression in differentiated 
myotubes (compared to myoblasts) was paralleled by a concomitant reduction 
in gene expression for enzymes involved in serine and nucleotide biosynthesis. 
Such a co-ordinated metabolic switch would suggest that myotubes increase 
glycolytic metabolism but importantly, may shunt glucose carbons away from 
biosynthetic pathways (stemming from glycolysis) and presumably into 
downstream ATP producing pathways (such as the TCA cycle). Chung et al. 
(2010) also demonstrated a major restructuring of glycolytic gene expression 
during cardiomyocyte differentiation and suggested that such changes occurred 
to support downstream ATP production by mitochondrial metabolism. Given 
the recent reports that serine and nucleotide biosynthetic pathways are critical 
for mitotic cell growth (Possemato et al. 2011; Tong et al. 2009), it is perhaps 
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unsurprising that these pathways are down-regulated in differentiated 
myotubes compared to proliferating myoblasts. Indeed, proliferating cancer 
cells are well documented to exhibit a glycolytic phenotype (Gatenby and 
Gilles 2004), but the majority of ATP produced in proliferating cancer cells is 
typically generated by oxidative metabolism, with an average of just 17% 
derived from glycolytic metabolism (Zu and Guppy 2004). This suggests that 
the glycolytic phenotype displayed by proliferating cells is not to rapidly 
generate ATP, but more likely to permit macromolecule biosynthesis to 
support mitotic cell growth (Lunt et al. 2011). Given that the myotubes used 
herein were terminally post-mitotic, it seems logical that they would switch 
their focus to ATP production and away from macromolecule biosynthesis. 
Furthermore, the rate of ATP hydrolysis by fast MyHCÕs is approximately 20-
30-fold greater than that of type I MyHCÕs (Weiss and Leinwand 1996), 
supporting the notion that mature C2C12 myotubes, transitioning to a 
predominantly type II MyHC isoform profile, may switch their metabolic 
focus to maximise ATP production and thus support the energy requirements 
of their contractile machinery.  
Pkm1 and Pkm2 splice variant mRNA expression displayed an interesting 
switch in proliferating versus differentiated C2C12 muscle cells and this 
presents a likely mechanism responsible for re-directing metabolism, away 
from macromolecule biosynthesis and towards ATP production in 
differentiated myotubes. The data presented herein shows that Pkm2 is the 
predominant Pkm splice variant expressed in proliferating myoblasts. 
Expression of the Pkm1 splice variant is increased in differentiated myotubes, 
with a concomitant reduction in the Pkm2 splice variant expression, causing an 
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equalling of the Pkm1:Pkm2 ratio with differentiation. David et al. (2010) also 
reported that C2C12 myoblasts almost exclusively express the Pkm2 splice 
variant and that differentiated C2C12 myotubes express approximately equal 
quantities of both Pkm1 and Pkm2. Further, Clower et al. (2010) reported a 
gradual replacement of the Pkm2 splice variant with the Pkm1 splice variant 
during C2C12 differentiation, strongly suggesting a role for specific Pkm 
splice variants during muscle cell differentiation. Pkm facilitates the final, non-
reversible, step in glycolysis, converting phosphoenolpyruvate (PEP) to 
pyruvate. Recently, the Pkm2 splice variant has been implicated as a 
regulatory component controlling metabolic flux through to mitochondrial 
ATP production or re-directing glucose carbons into biosynthetic pathways 
stemming from glycolysis (Lyssiotis et al. 2012). The splice variant Pkm2 is 
less effective than Pkm1 at facilitating the conversion of PEP to pyruvate and 
its activity can be regulated by various metabolic inputs (Lyssiotis et al. 2012). 
Therefore, the ratio of Pkm2:Pkm1 is likely critical in controlling the 
metabolic fate of glucose carbons. A high ratio of Pkm2:Pkm1 is theorised to 
cause a Òback-logÓ effect, re-directing glucose carbons to biosynthetic 
pathways (Lyssiotis et al. 2012). The induction of Pkm1 and a concomitant 
reduction in Pkm2 splice variant expression with myotube differentiation 
likely better facilitates the conversion of PEP to pyruvate for entry into the 
TCA cycle, thus reducing the Òback-logÓ effect and shunting glucose carbons 
away from macromolecule biosynthesis and into ATP producing pathways 
(Shyh-Chang et al. 2013). The 5-fold increase in pyruvate carboxylase mRNA 
expression in differentiated versus proliferating C2C12 myoblasts (converting 
pyruvate to oxaloacetate for entry into the TCA cycle) supports this notion that 
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myotubes modify glycolytic gene expression to shunt glucose carbons into 
ATP producing pathways. The switching of Pkm splice variant expression 
presented herein may be responsible for re-structuring the Òmetabolic focusÓ of 
C2C12 muscle cells during myogenic differentiation.  
In summary, cultured C2C12 myotubes show an increase in glycolytic gene 
expression and a reduction in oxidative gene expression, compared to 
proliferating myoblasts. Given the previously identified transition in MyHC 
mRNA isoforms during C2C12 myogenesis, from type I to type II MyHC 
isoforms, it is attractive to speculate that contractile and metabolic genes are 
co-ordinately regulated during myogenesis. However, the reduction in gene 
expression of enzymes involved in macromolecule biosynthesis and the switch 
in Pkm splice variant expression (from Pkm2 to Pkm1) strongly suggests that 
the restructuring of metabolic gene expression in C2C12 myotubes (compared 
to proliferating myoblasts) is likely to support ATP generation, instead of 
focusing on macromolecule biosynthesis. The progressive induction of 
contractile machinery during myogenic differentiation and the transition 
towards increased type II MyHC isoforms, is likely to increase the ATP 
requirements of the myotube, compared to proliferating myoblasts, thus 
requiring a dramatic remodelling of metabolism during myogenic 
differentiation. Cross talk between mechanisms regulating contractile and 
metabolic components of muscle cells is an interesting avenue for exploration 
given the importance of these components to display a coupled phenotype.  
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4 
BETA-ADRENERGIC SIGNALLING AND MYOSIN 
HEAVY CHAIN IIB GENE EXPRESSION 
 
!
It was hypothesized that cultured C2C12 skeletal muscle cells 
would exhibit alterations in myosin heavy chain gene expression in 
response to beta-adrenergic receptor stimulation and that these 
changes would mimic those seen in vivo.  
 
 
!
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4.1  BETA-ADRENERGIC AGONIST, RACTOPAMINE, INDUCES 
EXPRESSION OF THE MYOSIN HEAVY CHAIN IIB GENE IN 
GROWING PIGS 
 
 
4.1.1 INTRODUCTION 
 
In the previous chapter, it was shown that MyHC isoforms are a dynamic 
group of genes, displaying a dramatic and coordinated transition in mRNA 
expression during myogenic differentiation. This chapter subsequently 
intended to determine whether the dramatic transitions in MyHC mRNA 
isoform expression during myogenic differentiation were restricted to 
myogenesis or whether chronic transitions in MyHC mRNA isoform 
expression could be induced in adult skeletal muscle in vivo (Chapter 4.1). 
Furthermore, the stimulus used to induce a transition in MyHC mRNA isoform 
expression in vivo was subsequently explored in vitro (Chapter 4.2) to allow 
comparisons between the two developmentally distinct muscle cell types.  
 
Two growth-promoting agents, Ractopamine (a beta-adrenergic agonist) and 
Reporcin (recombinant growth hormone), were administered to growing pigs 
to assess their impact on MyHC mRNA isoform expression. Beta-adrenergic 
receptor stimulation in skeletal muscle has therapeutic potential for inducing 
muscle hypertrophy (Ryall et al. 2002; 2004; Kline et al. 2007), improving 
muscle force producing capacity (Ryall et al. 2002; 2004), enhancing muscle 
regeneration (Beitzel et al. 2004; 2007) and protecting against muscle wasting 
(Ryall et al. 2004; Kline et al. 2007). In addition to their effects on muscle 
growth, beta-adrenergic agonists typically induce a fast, glycolytic muscle 
fibre type in vivo (Baker et al. 2006; Bricout et al. 2004; Depreux et al. 2002; 
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Oishi et al. 2002; Gunawan et al. 2007). To fully characterize the dynamic 
plasticity of MyHC isoform gene expression in response to beta-adrenergic 
agonist (Ractopamine) administration in vivo, a time course of treatment, 
spanning 1 to 27 days, was conducted in adult pigs (aged ~6 months). In 
addition, intramuscular injection of growth hormone (Reporcin) was examined 
over the same 27-day time course to elucidate the effect of this Òrepartitioning 
agentÓ (Sillence 2004) on transitions towards a type II MyHC isoform 
expression. Muscle growth promoter agents were selected for these 
experiments since it has been shown the domestic selection for fast growing 
pigs, with a high lean:fat ratio, has likely inadvertantly selected for a fast 
muscle phenotype, suggesting links between muscle hypertrophy (or lean 
deposition) with muscle fibre type composition (Wimmers et al. 2008). 
Improving the understanding of type II muscle fibre regulation may elucidate 
potential interventions to ameliorate the loss of type II muscle fibres in 
diseases such as sarcopenia (Evans 2010).  
In addition to measuring changes in MyHC mRNA expression in response to 
Ractopamine and Reporcin treatment, several potential mediators of muscle 
fibre type transitions were monitored for associated changes. In particular, we 
measured mRNA expression of factors associated with altered MyHC isoform 
composition. Sine Oculis-related Homeobox 1 (Six1) and Eyes Absent 1 
(Eya1) transcript abundance was measured as these factors have previously 
been implicated in driving a fast, glycolytic muscle fibre type in adult mice 
(Grifone et al. 2004). Transcriptional co-regulators associated with driving a 
slow MyHC isoform expression were also measured (PGC-1α and RIP140; 
Lin et al. 2002; Seth et al. 2007). In addition, markers of cellular 
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differentiation (MyoD and myogenin) were monitored as a potential 
mechanism of altered MyHC isoform expression (Brown et al. 2012). This 
laboratory previously detected altered gene expression of Enolase 3 and IDH2 
(identified by microarray) following 7 days beta-adrenergic agonist treatment 
in ovine skeletal muscle (Dr Krystal Hemmings PhD Thesis) and were thus 
used as markers of metabolic gene expression herein (IDH2 = oxidative 
marker; Enolase 3 = glycolytic marker). 
It was hypothesized that dynamic alterations in MyHC mRNA isoform 
expression would occur in response to Ractopamine and Reporcin 
administration, gradually replacing the slow isoforms with the type IIB MyHC 
isoform. Furthermore, it was predicted that metabolic gene expression would 
remain coupled with changes in MyHC gene expression.  
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4.1.2 MATERIALS AND METHODS 
 
A more detailed account of the techniques employed in this section can be 
found in Chapter 2 (Materials and Methods). 
 
4.1.2.1 Experimental design 
Growing pigs were exposed to a beta-adrenergic agonist (Ractopamine) in 
their feed or were administered recombinant growth hormone (Reporcin) via 
intramuscular injection every 2 days for up to 27 days to elucidate the effects 
of prolonged growth promoter administration on myosin heavy chain isoform 
expression in skeletal muscle.   
 
4.1.2.2 Time course of growth promoter administration 
Approximately 5-month-old growing gilts (C23 X 337 progeny; obtained from 
PIC, UK), with a mean starting weight of 77kg (±7kg), were fed Ractopamine 
HCL (20ppm; Elanco Animal Health, Grenfield, IN) or administered an 
intramuscular injection of Reporcin (Growth hormone; 10mg/pig/48 hours), 
for 1, 3, 7, 13 (n = 10) or 27 days (n = 15).  Pigs were fed twice daily for 45 
minutes (ad libitum) on a non-pelleted, 16.7% protein finisher feed (14MJ/kg). 
The trial was conducted in 3 batches (51, 51 and 63 pigs) over 6 months. All 
pigs were acclimatized in the animal housing facility for 7 days prior to 
treatment. Pigs were individually housed. Feed intake was measured every 2-3 
days. Body weight was determined at the time of slaughter. 
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4.1.2.3 Animal growth and tissue collection 
Following slaughter, a sample of the Longissimus Dorsi (LD) was isolated 
(from the 10th rib in each pig), immediately snap-frozen in liquid nitrogen and 
later stored at -80¡C for subsequent RNA analysis. Following removal of 
organs, the carcass weight was determined. The Vastus Lateralis and 
Semitendinosus muscles were dissected from the left rear leg and weighed as 
an indicator of changes in muscle growth.  
 
4.1.2.4 Total RNA extraction and cDNA synthesis 
Total RNA was extracted from a 100mg sample of LD muscle using the Trizol 
method. RNA concentration was adjusted to 100ng/µl. First strand cDNA 
synthesis was carried out using a cDNA synthesis kit (Transcriptor First Strand 
cDNA Synthesis Kit, Roche, Burgess Hill, UK) as described in the Materials 
and Methods Chapter (Chapter 2). 
 
4.1.2.5 Quantitative-RT-PCR 
Real time PCR was conducted on a Lightcycler 480¨ (Roche, Burgess Hill, 
UK). Reactions were carried out in duplicate on 384 well plates (measuring the 
expression of 1 gene per plate). Details of the Q-RT-PCR are described in 
Chapter 2. Relative transcript abundance was calculated using the standard 
curve method and expression values were normalized to total cDNA in the 
PCR reaction (using the oligreen method).  
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4.1.2.6 Myosin heavy chain primers 
Myosin heavy chain primer sequences were obtained from Wimmers et al. 
(2008; see Table 4.1 below). Melt-curve analysis for all MyHC primer sets was 
conducted using pig muscle derived cDNA. Horizontal Agarose gel (1%) 
electrophoretic separation of the PCR amplicons was performed to ensure a) 
only one amplicon was being produced by the PCR, b) that the amplicon 
produced was of the correct length and c) that no primer-dimers were produced 
in the absence of template cDNA (see Figure 4.1 below). Annealing 
temperature for all porcine MyHC primers was 57¡C (compared to 60¡C for 
other primer sets) to improve the efficiency of detection of the type IIB MyHC 
mRNA isoform.  
 
Table 4.1 Oligonucleotide sequences for measuring porcine myosin heavy chain isoforms 
(from Wimmers et. 2008). 
 
Gene Forward primer Reverse primer 
Amplicon 
size 
MyHC I AAGGGCTTGAACGAGGAGTAGA TTATTCTGCTTCCTCCAAAGGG 115bp 
MyHC IIA GCTGAGCGAGCTGAAATCC ACTGAGACACCAGAGCTTCT 137bp 
MyHC IIX AGAAGATCAACTGAGTGAACT AGAGCTGAGAAACTAACGTG 149bp 
MyHC IIB ATGAAGAGGAACCACATTA TTATTGCCTCAGTAGCTTG 166bp 
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Figure 4.1 Gel electrophoretic separation of the porcine MyHC isoform amplicons produced 
by Q-RT-PCR. The gel indicates single amplicons, of the correct length, were produced by the 
MyHC primer sequences published by Wimmers et al. (2008). In addition, no primer-dimers 
were formed in the absence of template cDNA. 
 
 
4.1.2.7 Other oligonucleotide primers 
Oligonucleotide primers for the following genes were designed (by Dr Zoe 
Daniel or myself; see Table 4.2) using the current available pig genome 
(Sscofa9 Ð note that Sscrofa10.2 is now available and therefore 
sequences/annotations may vary).  Six1 (ENSSSCT00000005607) and Eya1 
(ENSSSCT00000006784) gene expression was measured as these genes were 
previously implicated in regulating a fast muscle phenotype (Grifone et al. 
2004). Further, PGC-1a (ENSSSCT00000029467) and RIP140 
(ENSSSCT00000028007) gene expression was measured as these 
transcriptional co-factors are known regulators of a slow muscle phenotype 
(Lin et al. 2002; Seth et al. 2007). MyoD (ENSSSCT00000014609) and 
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Myogenin (ENSSSCT00000016858) transcript abundance was measured as 
these myogenic regulatory factors are involved in the activation of muscle 
specific genes (Nabeshima et al. 1993; Hasty et al. 1993) and have also been 
shown to preferentially accumulate in fast and slow muscles respectively 
(Voytik et al. 1993; Hughes et al. 1993; Elmark et al. 2007). Enolase-3 
(ENSSSCT00000019484) and IDH2 (ENSSSCT00000002075) transcript 
abundance was measured as a marker of glycolytic and oxidative gene 
expression, respectively. This laboratory previously monitored changes in 
expression of these genes (identified by microarray) following 7 days beta-
adrenergic agonist treatment in ovine skeletal muscle (Dr Krystal Hemmings 
PhD Thesis).  
 
Table 4.2 Oligonucleotide sequences for measuring gene expression in porcine muscle 
 
Gene Forward primer Reverse primer 
Amplicon 
length 
SIX1 AGGAAAGGGAGAACACCGAAA CGAGTTCTGGTCTGGACTTTGG 137bp 
EYA1 CCCTCACCGACTCGTGGTT CAGTTTGTCCGGGAGTGGAT 67bp 
Enolase-3 CATGAGGATTGAGGAGGCTCTT GGCCTTTGGGTTACGGAACT 70bp 
IDH2 TTCATCAAGGAGAAGCTCATCCT TGGTCTGGTCCCGGTTTG 85bp 
PGC-1a GCAGAAGAGCCGTCTCTACTTAAGA TCTGGGTACTGAGACCACTGCAT 91bp 
RIP140 GCTCGGACCTCTGTCATTGAA GCTTTGGCCGATGCAAGTAG 83bp 
MyoD GAGGCGGAGAGCACTACAGC AATCCATCATGCCGTCGG 75bp 
Myogenin TCCTGCAGTCCAGAATGGG AGATGATCCCCTGGGTTGG 59bp 
 
 
4.1.2.8 SDS-PAGE separation of MyHC isoforms 
Separation of the MyHC protein isoforms was attempted by SDS-PAGE. 
Unfortunately, successful separation of the porcine type II MyHC isoforms 
(IIA, IIX and IIB) was not possible with this method. Examples of successful 
separation of MyHC isoforms from other species (rat and sheep) are shown in 
the results section to highlight the difficulties in separating porcine MyHC 
isoforms using this method. Details of this technique are outlined in Chapter 2.  
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4.1.2.9 Statistical analysis 
To determine whether there were significant differences between treatments 
across the 27-day time course, a two-way analysis of variance (ANOVA) was 
performed using GenStat statistical analysis software (Version 14). Statistical 
significance was accepted if p < 0.05.  
Pearson correlation coefficient (r) was conducted to assess the association 
between MyHC mRNA isoform expression with Enolase 3 and IDH2 gene 
expression.   
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4.1.3 RESULTS 
4.1.3.1 Growth performance 
Starting body weight of pigs prior to the administration of treatments was not 
different within treatment or time-point groups (treatment: p = 0.894; time: p = 
0.521; Figure 4.2). Final carcass weight increased with time (p < 0.001) but 
was not influenced by treatment (p = 0.314; Figure 4.2).  The weight of the ST 
and Vlat muscles increased with time (p < 0.001; Figure 4.3) but only the Vlat 
muscle weight was significantly responsive to treatment (p = 0.002), being 
heavier in Ractopamine treated pigs at each time point studied.  
 
 
 
 
Figure 4.2 Starting body weight and final carcass weight of non-treated pigs (grey bars) and 
pigs treated with Ractopamine (black bars) or Reporcin (white bars) for 1, 3, 7, 13 (n=10) or 
27 (n=15) days. Data is displayed as mean ± SEM. * indicates significant difference relative to 
the control at the same time point (p = 0.034). 
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Figure 4.3 Muscle weights (absolute and relative to carcass weight) of non-treated pigs (grey 
bars) and pigs treated with Ractopamine (black bars) or Reporcin (white bars) for 1, 3, 7, 13  
(n=10) or 27 (n=15) days. Data is displayed as mean ± SEM. * indicates significant difference 
relative to the control at the same time point (p < 0.05); $ indicates a trend for a difference 
relative to the control at the same time point (p < 0.06). 
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4.1.3.2 Myosin heavy chain mRNA isoform expression 
Myosin heavy chain (MyHC) isoform mRNA expression was measured in the 
LD muscle (a commercially relevant back muscle of the pig). Crossing point 
values and relative expression of MyHC mRNA isoforms are displayed in 
Table 4.3 and Figure 4.4, respectively. There was a significant treatment effect 
on mRNA expression of the type IIA, IIX and IIB MyHC isoforms (p < 0.001, 
p = 0.021 and p < 0.001 respectively; Figure 4.4). There was no effect of 
treatment on the mRNA expression level of the type I MyHC isoform (p = 
0.554). Ractopamine treatment caused a chronic induction of the IIB MyHC 
isoform mRNA across the full 27-day time course relative to the control and 
growth hormone treated groups. This coincided with a modest reduction in 
mRNA expression of the type IIX MyHC isoform mRNA across the full 27-
days of treatment with Ractopamine. MyHC IIA mRNA expression displayed 
a significant time-treatment interaction (p = 0.035), with Ractopamine 
treatment inhibiting expression levels, reaching its largest reduction by day 7, 
and then returning to normal expression levels by day 27. Growth hormone 
treatment appeared to have no effect on the MyHC isoform mRNA expression 
profile in the LD muscle of treated pigs during the 27-day time course.  
Table 4.3 Crossing point values for porcine MyHC mRNA isoforms following 1-27 days 
treatment with beta-agonist (B), growth hormone (G) or control (C).  
 
  
MyHC I MyHC IIA MyHC IIX MyHC IIB 
Day 1 
B 26.9 23.5 22.4 23.8 
C 27.2 23.5 22.7 25.1 
G 27.2 23.0 22.2 24.4 
Day 3 
B 27.1 24.0 22.3 23.1 
C 26.5 22.9 21.9 23.9 
G 27.4 23.2 22.5 24.0 
Day 7 
B 27.2 25.3 23.0 23.0 
C 26.7 22.9 22.1 25.7 
G 26.6 22.6 21.9 25.1 
Day 13 
B 27.5 23.9 23.0 23.8 
C 26.4 22.8 22.2 24.4 
G 26.6 22.6 22.0 24.8 
Day 27 
B 27.6 23.3 22.5 22.4 
C 27.9 23.4 22.3 23.7 
G 27.4 23.2 22.0 24.5 
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Figure 4.4 Myosin heavy chain (MyHC) mRNA isoform expression in the LD muscle of non-
treated pigs (grey bars) and pigs treated with Ractopamine (black bars) or Reporcin (white 
bars) for 1, 3, 7, 13 (n=10) or 27 (n=15) days. Data is displayed as mean ± SEM. * indicates 
significant difference relative to the control at the same time point (p < 0.05); $ indicates a 
trend for a difference relative to the control at the same time point (p < 0.06). 
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4.1.3.3 Myosin heavy chain protein expression 
Separation of MyHC protein isoforms by SDS-PAGE was attempted but an 
inability to separate the porcine type II MyHC isoforms meant quantification 
of transitions in MyHC protein isoform expression was not possible. Methods 
used for the successful separation of rat and sheep MyHC isoforms by SDS-
PAGE were only capable of separating the porcine type I MyHC isoform from 
the other isoforms (see Figure 4.5). Interestingly, the gel compositions used for 
separating MyHC protein isoforms were specific to the species being studied. 
In particular, the type II MyHC isoforms from different species display 
disparity in migration patterns by SDS-PAGE. It is unknown why these 
differences occur but may be due to very subtle differences in molecular 
weight of the MyHC isoforms or differences in relative charge placed on the 
MyHC isoforms during the electrophoresis.  
!
!
!
!
!
!
!
Figure 4.5 Representative images of SDS-PAGE separation of myosin heavy chain protein 
isoforms. Note: gel compositions that successfully separated sheep or rat myosin heavy chain 
isoforms were unable to separate porcine type II myosin heavy chain isoforms.  
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4.1.3.4 Metabolic gene expression 
Transcript abundance of Enolase 3 and IDH2 were used as markers of 
glycolytic and oxidative gene expression, respectively (Figure 4.6). In response 
to Ractopamine treatment, Enolase-3 displayed a modest but chronic induction 
across the full 27-days of treatment (p < 0.001). IDH2 mRNA expression, 
exhibited an initial reduction in expression levels in response to Ractopamine 
treatment, but returned to control levels by day 27 (p = 0.004).   
 
 
 
 
 
Figure 4.6 Enolase 3 and IDH2 mRNA expression in the LD muscle of non-treated pigs (grey 
bars) and pigs treated with Ractopamine (black bars) or Reporcin (white bars) for 1, 3, 7, 13 
(n=10) or 27 (n=15) days. Data is displayed as mean ± SEM. * indicates significant difference 
relative to the control at the same time point (p < 0.05); $ indicates a trend for a difference 
relative to the control at the same time point (p = 0.067). 
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4.1.3.5 Correlation between metabolic and MyHC expression 
Correlations were conducted between MyHC isoform and metabolic marker 
(Enolase 3 or IDH2) mRNA expression to assess whether contractile and 
metabolic gene expression were closely ÒcoupledÓ (Figure 4.7 and 4.8). 
Enolase-3 and MyHC IIB mRNA expression displayed a very high level of 
correlation (r = 0.73), a pattern that was not observed with the other MyHC 
isoforms (IIX: r = 0.32; IIA: r = 0.17; I: r = 0.24). The correlation between 
IDH2 and type I MyHC mRNA was very strong (r = 0.77). Correlations 
between IDH2 and the MyHC isoforms mRNA expression got progressively 
stronger with the slower contracting MyHC isoforms (IIB: r = 0.14; IIX: r = 
0.56; IIA: r = 0.62; type I: r = 0.77). The large data set analyzed herein (n = 
164) reveals a close correlation between gene expression of metabolic and 
contractile components in porcine skeletal muscle.  
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Figure 4.7 Correlation between MyHC isoform and Enolase 3 mRNA expression. Pearson 
correlation coefficients are displayed in the corresponding boxes. Note that Enolase 3 and 
MyHC IIB display a very high correlation, whereas other isoforms did not correlate well.   
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Figure 4.8 Correlation between MyHC isoform and IDH2 gene expression. Pearson 
correlation coefficients are displayed in the corresponding boxes. Note that correlations 
between IDH2 and MyHC isoforms improved as the MyHC isoforms got slower. 
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4.1.3.6 PGC-1a and RIP-140 mRNA expression 
Transcriptional co-regulatory factors implicated in remodeling towards a 
slower, more oxidative, muscle fibre type were measured at the mRNA level 
(Figure 4.9). No alterations in PGC-1α or RIP140 gene expression were 
displayed in response to treatment (p = 0.068 and p = 0.685, respectively) or 
time (p = 0.620 and p = 0.246, respectively).   
!
!
!
!
Figure 4.9 PGC-1a and RIP140 mRNA expression in the LD muscle of non-treated pigs (grey 
bars) and pigs treated with Ractopamine (black bars) or Reporcin (white bars) for 1, 3, 7, 13 
(n=10) or 27 (n=15) days. Data is displayed as mean ± SEM. * indicates significant difference 
relative to the control at the same time point (p < 0.01). 
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4.1.3.7 Myogenic regulatory factor gene expression 
Myogenic regulatory factor mRNA expression was utilized as a marker of 
myogenesis. Furthermore, these factors have also been associated with specific 
muscle fibre type composition and were thus of interest in the present study. 
Treatments elicited no effect on transcript abundance of myogenic regulatory 
factors, MyoD or myogenin (p = 0.382 and p = 0.694, respectively; Figure 
4.10).  
 
!
!
!
Figure 4.10 MyoD and Myogenin mRNA expression in the LD muscle of non-treated pigs 
(grey bars) and pigs treated with Ractopamine (black bars) or Reporcin (white bars) for 1, 3, 7, 
13 (n=10) or 27 (n=15) days. Data is displayed as mean ± SEM.  
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4.1.3.8 Six1 and Eya1 mRNA expression 
Six1 and Eya1 have been associated with fast, glycolytic muscle fibres 
(Grifone et al. 2004). Transcript abundance of Six1 and Eya1 remained un-
altered in response to treatments across the 27-day time course (p = 0.105 and 
p = 0.406; Figure 4.11).  
 
!
!
 
Figure 4.11 Six1 and Eya1 mRNA expression in the LD muscle of non-treated pigs (grey 
bars) and pigs treated with Ractopamine (black bars) or Reporcin (white bars) for 1, 3, 7, 13 
(n=10) or 27 (n=15) days. Data is displayed as mean ± SEM.  
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4.1.3.9 Summary of in vivo findings 
To briefly summarize, 27 days of Ractopamine or Reporcin administration to 
growing pigs caused little or no change in the growth characteristics of the 
animal. There was, however, a significant transition in MyHC isoform gene 
expression in response to Ractopamine, but not Reporcin, treatment. 
Interestingly, the MyHC IIB isoform displayed a chronic induction across the 
full 27-day time course, whilst the MyHC IIA isoform exhibited an initial 
decline in expression before returning to expression levels comparable to the 
control group. In addition, the type IIx MyHC isoform displayed a modest 
reduction in expression throughout the 27-day treatment window. Taken 
together, this shows that beta-adrenergic agonist administration induces 
dynamic modulation in gene expression of the type II MyHC isoforms, with 
individual isoforms clearly being exclusively regulated, enabling remarkable 
plasticity of these genes in adult skeletal muscle.  
Gene expression of factors previously implicated in muscle fibre type 
regulation displayed unaltered mRNA expression in response to treatments. 
Obviously, post-transcriptional modulation of these factors is possible and 
likely, but this data confirms no transcriptional alteration in expression of these 
regulatory factors in the fibre type switching model used herein.  
These findings are discussed fully in Chapter 4.2 (below) to avoid repetition 
and to permit interesting comparisons of similar work conducted in vivo and in 
vitro.  
!  
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4.2  BETA-ADRENERGIC AGONIST, RACTOPAMINE, ACTS 
DIRECTLY ON MUSCLE CELLS TO ACCELERATE THE 
INDUCTION OF THE MYOSIN HEAVY CHAIN IIB GENE 
DURING C2C12 MYOGENESIS 
 
4.2.1 INTRODUCTION 
Although growth hormone administration caused no effect on MyHC mRNA 
isoform expression in growing pigs (and will therefore no longer be examined 
in this thesis), beta-adrenergic agonist, Ractopamine, induced a chronic 
transition in MyHC mRNA isoform expression in growing pigs (Chapter 4.1). 
This dynamic transcriptional remodeling of the type II MyHC isoforms by 
beta-adrenergic receptor stimulation was further explored in C2C12 muscle 
cells. This approach would examine whether the altered mRNA expression of 
type II myosin heavy chain isoforms was a result of direct interaction of 
Ractopamine on muscle cells. Furthermore, in vitro examination of the effects 
of Ractopamine on cultured muscle cells would help elucidate a role of beta-
adrenergic receptor stimulation on the induction of type II MyHC isoform 
genes during myogenic differentiation (explained below).  
It was previously identified that the MyHC mRNA isoforms are expressed in 
two distinct cohorts during C2C12 myogenesis (Brown et al. 2012; Chapter 
3.1), with the fast type II isoforms (IIA, IIX and IIB) being induced late in 
differentiation. This ÒdelayedÓ induction of the type II MyHC isoforms in 
C2C12 myotubes provides an interesting model for studying the induction of 
type II MyHC isoforms during myogenesis. Since we and others (Baker et al. 
2006; Bricout et al. 2004; Depreux et al. 2002; Oishi et al. 2002; Gunawan et 
al. 2007; Chapter 4.1) have shown beta-adrenergic agonists induce a strong 
induction of MyHC IIB expression in vivo, fusing C2C12 muscle cells, not yet 
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expressing the type II MyHC mRNA isoforms, were utilized to explore 
whether the beta-adrenergic agonist, Ractopamine, could accelerate the initial 
induction of the type II MyHC mRNA isoforms during myogenic 
differentiation. Interestingly, Ryall et al. (2010) previously reported that beta-1 
and beta-2 adrenergic receptor mRNA expression increases during myoblast 
fusion (with expression peaking at day 2 of differentiation) and suggested a 
potential role of beta-adrenergic signaling during early myogenic fusion (see 
Figure 4.12). It was speculated herein that the appearance of beta-adrenergic 
receptor expression during this early stage of myogenic differentiation might 
be involved in the initial induction of the type II MyHC mRNA isoforms.  
 
 
Figure 4.12 Figure (and description) taken from Ryall et al. (2010) showing relative mRNA 
expression of the Beta-1 and Beta-2 adrenergic receptors during early myogenic differentiation 
of C2C12 myoblasts. Ractopamine treatments in the present study were administered before 
and after the peak mRNA expression of the beta-receptors.  
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C2C12 muscle cells used herein were exposed to beta-adrenergic agonist, 
Ractopamine, before and after the peak in mRNA expression of the beta-
receptors (Ryall et al. 2010), which also corresponded to the time of initial 
induction of the type II MyHC isoforms (Brown et al. 2012).  Therefore, acute 
48-hour windows of exposure to Ractopamine (1µM) were conducted during 
the early stages of myogenic differentiation to assess the role of beta-
adrenergic receptor stimulation on the initial mRNA induction of the type II 
MyHC isoforms (see Figure 4.13). It was hypothesized that Ractopamine 
treatment would accelerate the initial induction of the type II MyHC mRNA 
isoforms (see the red arrows in Figure 4.13 below) and would be dependent on 
the timing window of administration.  
 
Figure 4.13 Predicted effects (red arrows) of Ractopamine treatment (48 hour windows 
represented by green lines) on type II MyHC mRNA induction during myogenesis using the 
previously characterized C2C12 cell line (Figure from Chapter 3.1). 
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4.2.2 MATERIALS AND METHODS 
4.2.2.1 Overview 
C2C12 muscle cells were treated with Ractopamine during the early stages of 
myogenic differentiation to assess whether beta-adrenergic receptor 
stimulation causes changes in mRNA induction of the type II MyHC isoforms 
during myogenesis. A brief account of the experimental procedures is detailed 
below. A more detailed explanation of procedures used herein can be found in 
the Materials and Methods Chapter (Chapter 2). 
 
4.2.2.2 Cell culture 
C2C12 cells were grown in proliferation medium (DMEM, 10% FBS, 1% P/S) 
until ~90% confluent (day 0) at which point cells were encouraged to 
differentiate by changing to a low serum differentiation medium (DMEM, 2% 
HS, 1% P/S) and cultured for up to 4 days. All cultures were carried out on 6 
well plates using 2 ml of culture medium per well. Representative images of 
the cells at days 0, 2 and 4 are provided in Figure 4.14. 
 
4.2.2.3 Treatments 
A 1mM solution of Ractopamine Hydrochloride (RAC; Sigma Aldrich, Poole, 
UK) was made in phosphate buffered saline (PBS; Sigma Aldrich, Poole, UK) 
containing 0.5% Dimethyl Sulfoxide (DMSO; Sigma Aldrich, Poole, UK), 
sterile filtered (0.2µm) and added to the differentiation medium (1:1000) to 
give a working concentration of 1µM. Previous literature suggested 1µM to be 
the most ÒresponsiveÓ dose in vitro (Anderson et al. 1990; Grant et al. 1990) 
and was thus used in the present study. The same dilution procedure of DMSO 
167 
only (i.e. without RAC) was carried out for use as a vehicle control (CON). 
Final DMSO concentration in the medium for RAC and CON treated cells was 
0.0005%. Cells were treated with RAC or CON for 48 hours starting at day 0 
(~90% confluence) or day 2 of differentiation. Nine separate wells were used 
per treatment, per time point (spread across 3 six-well plates) for mRNA 
analysis. In addition, six separate wells per treatment, per time point were used 
for creatine kinase, DNA and protein assays (spread across 2 six-well plates).  
 
4.2.2.4 Cell harvest for growth assays 
Following 48 hour treatments (finishing on day 2 or 4), culture medium was 
removed, cells were washed once with 1ml warm PBS, scraped into 500µl tri-
sodium citrate buffer and stored in 1.5ml tubes at -20¡C until use. Creatine 
kinase activity, DNA content and protein content were assayed as described in 
Chapter 2.  
 
4.2.2.5 Cell harvest for RNA extraction  
Following 48 hour treatments, culture medium was removed, cells were 
immediately scraped into 200µl RNase-free phosphate buffered saline (PBS), 
transferred to 1.5ml tubes, snap frozen on dry ice (solid CO2) and stored at -
80¡C until analysis. Total RNA was extracted using an RNA isolation kit 
(High Pure Isolation Kit for RNA isolation, Roche, Burgess Hill, UK). RNA 
concentrations were adjusted to 100ng/µl for cDNA synthesis.  
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4.2.2.6 cDNA synthesis and Quantitative-RT-PCR 
First strand cDNA synthesis was carried out using a Roche cDNA synthesis kit 
(Transcriptor First Strand cDNA Synthesis Kit, Roche, Burgess Hill, UK). 
Quantitative PCR was performed on a Lightcycler480 (Roche, Burgess Hill, 
UK). All reactions were carried out in triplicate on white 384 well plates, as 
described previously. Transcript abundance was determined using the standard 
curve method and subsequently corrected for total cDNA in the PCR reaction 
using the oligreen method (Rhinn et al. 2008; Brown et al. 2012). 
 
4.2.2.7 Quantitative-RT-PCR oligonucleotides primers 
Oligonucleotide primers for detecting transcript abundance of the MyHC 
isoforms (I, IIa, IIx, IIb, embryonic and perinatal), MyoD and Myogenin were 
all tested previously and have been published (Brown et al. 2012). Myogenin 
mRNA expression was used as a marker of muscle cell differentiation (Brown 
et al. 2012). The primers in Table 4.3 were designed in house (by myself or Dr 
Zoe Daniel) to measure the same genes measured in porcine skeletal muscle 
(Chapter 4.1) to allow comparisons of responses in vivo and in vitro. The 
accession numbers for these genes area as follows: Six1 
(ENSMUST00000050029), Eya1 (ENSMUST00000080664), Enolase-3 
(ENSMUST00000108548), IDH2 (ENSMUST00000107384), PGC1-a 
(ENSMUST00000132734) and RIP140 (ENSMUST00000054178).  
 
 
 
 
 
 
 
 
169 
Table 4.4 Oligonucleotide primer sets for Q-PCR analysis of gene expression 
Gene Forward primer Reverse primer 
Amplicon 
length 
SIX1 AGGAAAGGGAGAACACCGAAA CTTCCAGAGGAGAGAGTTGATTCTG 69bp 
EYA1 ACAGCAGAGTACAGTACAATCCACAGT AGCCGCTCGGAGTCAGTCT 65bp 
Enolase-3 GCCTGCTCCTGAAGGTCAAC TGCAAGTTTACAGGCCTGGAT 65bp 
IDH2 TTGAGGCTGAGGCTGCTCAT CCGGCCCTTCTGGTGTT 62bp 
PGC-1a TGCAGCGGTCTTAGCACTCA CATGAATTCTCGGTCTTAACAATGG 89bp 
RIP140 CGACTTCCAGACCCACAACA GGCGCTCTTGGCATCGT 55bp 
 
Melt-curve analysis was conducted for all primer sets to ensure a single 
amplicon of the correct length was produced in the PCR reaction, and that no 
primer dimers were produced in the presence or absence of template DNA. 
Serial dilutions of a pool of all cDNA samples were produced and tested to 
ensure the PCR was linear. 
 
4.2.2.8 Porcine 1kb MyHC IIB promoter-reporter  
The in vivo experiments in Chapter 4.1 were conducted in porcine skeletal 
muscle and the present experiments (Chapter 4.2) are conducted in a mouse 
derived muscle cell line (C2C12 cells). Thus, to examine the effects of 
Ractopamine on MyHC IIB regulation during myogenic cell fusion, a pig 
MyHC IIB promoter-reporter construct was transfected into C2C12 cells to 
assess if the porcine specific MyHC IIB promoter sequence would elicit 
accelerated activity during C2C12 myogenesis following Ractopamine 
treatment in vitro. In addition, cells were treated with dbcAMP to increase 
intracellular cAMP levels in an attempt to mimic a beta-adrenergic response 
via an alternative method. A detailed explanation of how the porcine 1kb 
MyHC IIB promoter-reporter was generated and used is provided in Chapter 2 
(Molecular Biology Methods section).  
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4.2.2.9 Statistical analysis  
Statistical analysis was carried out on a single experiment with 9 biological 
replicates (per treatment, per time point) for quantitative-RT-PCR analysis and 
6 biological replicates for creatine kinase activity and DNA content. To 
determine whether there were significant differences between treatments at 
either day 2 or 4, a one-way ANOVA was performed using GenStat statistical 
analysis software (Version 14). Comparisons across time were not conducted 
since treatments were administered as two discrete experiments. Data is 
displayed as mean ± standard error of the mean (SEM). Significance was 
accepted if p < 0.05. 
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4.2.3 RESULTS 
4.2.3.1 Light microscopy 
Representative images of the C2C12 cells at different stages of 
differentiation/treatment are shown in Figure 4.14. Cells treated from day 0 
were proliferating myoblasts (~90% confluent) and received treatment until 
small, immature myotubes had formed (day 2). Cells beginning treatment on 
day 2 were treated until day 4 whereby significant myotube formation had 
occurred, differentiation was ceasing and myotubes were undergoing 
maturation. No visual differences in cell morphology were apparent in 
response to Ractopamine treatment. 
 
 
Figure 4.14 Representative light microscopy (phase contrast) images of C2C12 cells at days 0, 
2 and 4 during differentiation. Treatments were applied at either day 0 or 2 and harvested 
following 48 hours of Ractopamine treatment (at days 2 or 4). No visual differences between 
treated and non-treated cells was observed. 
 
 
 
Day 0 Day 2
Day 4
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4.2.3.2 Proliferation, differentiation and protein accretion 
DNA content and creatine kinase activity were used as markers of proliferation 
and differentiation, respectively. Cells treated with Ractopamine at day 0-2 
displayed a slight reduction in DNA content (p = 0.026) whereas cells treated 
from day 2-4 displayed no change in DNA content (p = 0.677; Figure 4.15). 
Creatine kinase activity remained unchanged in response to Ractopamine 
treatment from day 0-2 (p = 0.635) and 2-4 (p = 0.983; Figure 4.15). 
Protein:DNA ratio was determined as a marker of protein accretion (or cellular 
hypertrophy) and remained statistically unchanged following treatment from 
day 0-2 and 2-4 (p = 0.052 and p = 0.407, respectively). The trend for 
increased protein:DNA ratio following treatment from day 0-2 (p = 0.052) was 
likely due to a slight reduction in DNA content of Ractopamine treated cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 DNA content, creatine kinase activity and protein:DNA ratio following 48 hours 
Ractopamine treatment finishing at either day 2 or 4. Solid bars = control; Open bars = 
Ractopamine treated (1µM). Significant differences between treated and non-treated groups 
are indicated by * (p = 0.026). 
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4.2.3.3 Myogenic regulatory factor gene expression 
MyoD and myogenin gene expression were measured as these genes are 
considered good markers of cellular differentiation (Brown et al. 2012). 
Expression of MyoD and myogenin mRNA exhibited no response to 
Ractopamine treatment at either day 0-2 (p = 0.564 and p = 0.748, 
respectively) or 2-4 (p = 0.482 and p = 0.509, respectively; Figure 4.16) and 
therefore support the lack of change in creatine kinase activity in response to 
Ractopamine treatment.  
 
 
Figure 4.16 mRNA expression of Myogenin and MyoD following 48 hours Ractopamine 
treatment finishing at either day 2 or 4. Solid bars = control; Open bars = Ractopamine treated 
(1µM). 
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4.2.3.4 Myosin heavy chain mRNA isoform expression 
Following 48 hours of Ractopamine treatment, MyHC IIB mRNA expression 
exhibited a 2.4-fold and 1.6-fold increase at days 0-2 and 2-4, respectively (p < 
0.001; Figure 4.17). Interestingly, mRNA expression of MyHC IIB was the 
only type II isoform that responded to Ractopamine treatment, with the IIA 
and IIX isoforms showing no change in mRNA expression following 
treatments at day 0-2 (p = 0.874 and p = 0.140, respectively) or 2-4 (p = 0.337 
and p = 0.731, respectively). 
Similarly, the mRNA expression of the adult type I and embryonic MyHC 
isoforms showed no response to Ractopamine treatment at day 0-2 (p = 0.818 
and p = 0.391, respectively) or 2-4 (p = 0.518 and p = 0.174, respectively), 
whereas neonatal MyHC mRNA expression showed a small induction with 
Ractopamine treatment at the later treatment time point (day 2-4; p = 0.039), 
but there was no change following 48 hours treatment from day 0 (p = 0.656; 
Figure 4.17).   
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Figure 4.17 mRNA expression of MyHC isoforms (embryonic, neonatal, I, IIA, IIX and IIB) 
following 48 hours Ractopamine treatment finishing at either day 2 or 4. Solid bars = control; 
Open bars = Ractopamine treated (1µM). Significant differences between treated and non-
treated groups are indicated by * (p<0.001) and   (p = 0.039). 
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4.2.3.5 Metabolic gene expression 
Metabolic genes, Enolase-3 and IDH-2, were used as markers of glycolytic and 
oxidative gene expression respectively (as they closely correlated with the type 
I and type II MyHC isoforms respectively in Chapter 4.1)). No changes in 
mRNA expression of Enolase-3 or IDH-2 were observed in response to 48 
hours Ractopamine treatment at either of the time points studied (Table 4.4). 
The transcriptional co-activators, PGC-1α and RIP140, previously reported as 
master ÒregulatorsÓ of a slow oxidative muscle phenotype (Lin et al. 2002; 
Seth et al. 2007), displayed no change in mRNA expression in response to 48 
hours Ractopamine treatment at either day 0-2 or 2-4 (Table 4.4).  
 
Table 4.5 Relative gene expression following 48 hours Ractopamine (1µM) treatment 
finishing at either day 2 or 4.   
 
 
 
 
 
 
 
 
 
 
mRNA 
abundance 
(AU) 
Day 0-2  Day 2-4 
Control Ractopamine 
P-
value 
 
Control Ractopamine 
P-
value 
PGC1-α  2.02 ± 0.14 2.36 ± 0.15 0.112  1.51 ± 0.08 1.50 ± 0.05 0.878 
RIP140  2.50 ± 0.17 2.10 ± 0.12 0.068  1.38 ± 0.11 1.59 ± 0.09 0.142 
Enolase 3 1.31 ± 0.07 1.22 ± 0.05 0.311  1.47 ± 0.09 1.62 ± 0.10 0.312 
IDH2  2.29 ± 0.11 2.14 ± 0.09 0.339  1.23 ± 0.07 1.27 ± 0.08 0.693 
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4.2.3.6 Beta-adrenergic receptor 2 (Adrβ2) mRNA expression 
Ryall et al. (2010) previously demonstrated a significant induction in beta-
adrenergic receptor 2 (Adrβ2) mRNA expression during the early stages of 
C2C12 differentiation. Adrβ2 mRNA expression was therefore measured 
herein to confirm the C2C12 cells utilized in this laboratory also express the 
transcripts encoding the Adrβ2 receptors. Indeed, Adrβ2 mRNA was expressed 
in C2C12 cells and showed a modest reduction (p = 0.011) in expression with 
differentiation (from day 2 to 4; Figure 4.18). Adrβ2 mRNA expression in 
C2C12 cells remained statistically unaltered with Ractopamine treatments at 
both day 0-2 (p = 0.071) and 2-4 (p = 0.288; Figure 4.18).  
 
 
Figure 4.18 Beta-adrenergic receptor 2 (Adrβ2) mRNA expression following 48 hours 
Ractopamine treatment finishing at either day 2 or 4. Solid bars = control; Open bars = 
Ractopamine treated (1µM). 
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4.2.3.7 Six1 and Eya1 mRNA expression 
C2C12 cells treated with Ractopamine for 48 hours from the start of 
differentiation (day 0-2), exhibited a significant up-regulation of Six1 and 
Eya1 mRNA expression (p = 0.002 and p < 0.001, respectively; Figure 4.19). 
However, this response in Six1 and Eya1 mRNA expression was not observed 
if Ractopamine treatment was administered later in differentiation (day 2-4; p 
= 0.925 and p = 0.286, respectively).  
 
 
Figure 4.19 mRNA expression of Six1 and Eya1 following 48 hours Ractopamine treatment 
finishing at either day 2 or 4. Solid bars = control; Open bars = Ractopamine treated (1µM). 
Significant differences between treated and non-treated are indicated by * (p<0.01) and ** 
(p<0.001). 
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4.2.3.8 Porcine MyHC IIB promoter activation 
In Chapter 4.1 it was shown that the beta-adrenergic agonist, Ractopamine, 
elicited a dynamic transition in type II MyHC mRNA isoforms in growing 
pigs, with a chronic induction of the type IIB MyHC mRNA isoform. Here 
(Chapter 4.2), Ractopamine was shown to specifically induce an early 
induction of the MyHC IIB gene in vitro during mouse C2C12 myogenesis. 
Therefore, the next step was to examine if the pig MyHC IIB promoter would 
also exhibit accelerated induction during C2C12 myogenesis following 
Ractopamine treatment in vitro. Indeed, there was a modest induction of the 
porcine 1kb MyHC IIB promoter following 4 days of Ractopamine treatment 
during C2C12 differentiation (p = 0.002; Figure 4.20). This suggests this effect 
probably occurs in multiple species and that the increased MyHC IIB mRNA 
expression in C2C12 cells in response to beta-adrenergic agonist treatment is 
likely due to increased MyHC IIB promoter activity. 
In addition, it was tested if increasing intracellular cAMP levels (as a 
downstream mediator of a beta-adrenergic response) using dbcAMP (1mM) 
would elicit a similar induction of the porcine MyHC IIB promoter during 
C2C12 myogenesis. dbcAMP treatment during the first 4 days of C2C12 
differentiation caused an induction of the porcine MyHC IIB promoter (p = 
0.002) comparable to the Ractopamine induced promoter induction (Figure 
4.20).  
C2C12 cells were analyzed for porcine MyHC IIB promoter activity following 
4 days of treatment because promoter activity was too low prior to this and was 
considered not quantifiable.  
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Figure 4.20 Porcine 1kb myosin heavy chain IIB promoter activity in C2C12 myotubes 
following 4 days of treatment with Ractopamine or dbcAMP during differentiation. Promoter 
activity is displayed as mean ± SEM. * indicates a significant difference compared to the 
control group (p <0.01). Representative light microscopy images show visual differences in 
myotube morphology between treated and non-treated cells.  
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4.2.3.9 Porcine 1kb MyHC IIB promoter lacks cAMP response 
elements (CRE) 
 
The porcine 1kb MyHC IIB promoter-reporter construct was responsive to 
Ractopamine and dbcAMP treatment in C2C12 cells. cAMP typically mediates 
itÕs transcriptional effects by activating cAMP-response element binding 
proteins (also known as CREBÕs or ATFÕs). Interestingly, the 1kb mouse 
MyHC IIB promoter contained a consensus CREB/ATF binding site 
(identified by an online transcription factor search engine; TFSEARCH 
(http://www.cbrc.jp/research/db/TFSEARCH.html)) but the equivalent porcine 
promoter lacked any consensus response elements for CREB/ATF 
transcription factors (Figure 4.21). This suggests that the porcine MyHC IIB 
promoter can be induced during myogenic differentiation by beta-adrenergic or 
cAMP mediated signaling and moreover, this effect may occur independently 
of interactions at CREB/ATF consensus response elements.  
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Pig MyHC IIB promoter (1kb): 
TAGGTGACACACTTAGCGTGGACAGATTTGCTGTTACATTCAGCAGCAGCTGTGTCTGTGGCAAAACCACCAAAACCCA
ATTTACAAGCATCGTGGGCATATGTGATAGCCCCCTTATGTTCTCAACCCACAAAGAGTCCTGTGGGTATCACATCTCT
CCTCCCACCTTAAATAAAAATACGTATTACCCACCTCATTAGAGCTACTGCTAGTCATGAGGATTTGCCTGTGAACTAG
GAATGCATATTGATGCCTCCTTCCATCATTATGCGGTAGAAACACACATAGAACATCACACGGACTCCTGCAGTCCCCC
CAGTGAAAACATGTGAGCTCAAGACAGCCACGGCAAGCTCTCCAGAAAAGGAAAAGAAGTGTTTCTATCTATTCTAAAT
CCCTTATGGCTCCCCCACTGGTCTGTCACCATGGCTTAGCCCGAGAATCTGCCTAAACTTTCTCCTTCATGCTTAGTCT
TTTAGACTTTAAAAAAATCTATCATCAGTATTTCTAAAATCCAGACCCAGGCTAGGAGTTTTCTGCTTTAATACCAATC
ATGTTGTCAGAGCTAAAACTCATCCCAGCTCCTCAATGGCCCTAAGCACTAACAAATCAATTAGTTCTCAACTCCTCGT
GTCTGGCTCATTCTGTCGGACCAATTTTACAGGCAGGAGAGTAAGTGGGAACCTGGCTTTCAACTCAGTGATGAATGAT
GGAACAGCAAAGCTGGAGAAATAGCCTTAGAAGCCCTGAATCTCCATCCCTATCAAATGCCTCAAAAGAACCCTAGATG
ATCCTCTGTCAAATTATTTATAGGTGTCAAGAAATATTTCTAATTATATCCATTCACAGCCACAGTCAGTGAATATTGT
GCAAAGAGATTGCCAAAAAAGGTTTGCCAAGTAGGTTCCCAGCTGGGACAGCTGAGGTGGCTGCTGTGTTTGCAAAATG
GTCTCTATAAAAGTGGAGCTGAGATGCCTCTGTCCTGTCCTTCCT 
 
 
            CREB / ATF response element (score 91.8) 
Mouse MyHC IIB promoter (1kb): 
CAGGCCAGATCACAGGGACAGTTAGAGTAGATTTCCTGTCATATTCAGCAACAGCTGTGCCTGTATCAAGTTAGTCAAA
TCCAACTCGGCCTTTCAAGGGCACCGTGGAGGCCGATCCACCCACCTTCTCTGTCCATGGGGAGAGTTTTGTGGACAGC
ATGCCTTTCCTCCCACCTTAAGTAAAAGTGTGTAGCACCCACCTCATTGGCGTCACCGCTAGCCTTGAGCCTTTGCCTG
TACCCTAGGAAATCTTGTCTGTATCTCCTTCCGTGATGCAGCAGAAACACTCATGGGTATCACACAGCAGTCTGTTGCC
CCTGCAGTGCACGAGGGAGACGTCTATGACAAACCCTCCAGAAACGGGCCAGACAAGTTCATCTCTGTCCTGACTCCCT
CTCCTCTTACTACCAACCCCTTCCACTGCCTAATCTGAGAATTCACTTTCTTCCTCATGGTTAGACCTTCAGACTTTAG
AAGAATCTATCACCAGTCTTTCTAAAACTCCAGCCCTTGCCTAAGAATTTTTATCTTAATATCTGTCACTCGGTGCTTC
CAGTCACAGTGTCAGATCTAAAGTTCACTCCAGACTCCGTAATGGCTCTAAGCACTAGCAGATTAATTAGTCCCACTCG
CCCCACACCGGGCTCGTTCCTGTGGAAACAGCTTTATAGGCACGAGAGTGAGTAGGGACCTGGCTTTGAATTCTGTGAT
GAATGATACAACACCCAAGCCGGGAGAAACAGCCTCCAAAAACCCTGGATCTCCATTCCCTATCAGATGCTTATAAAGA
ACCCTAGATCATCCCCTGTCAAATTATTTATAGATGACAAGAAATATTTCTAATTATATCCATTCACAGCCACAGTCAG
TGAATATTGTGTAAAGAGATTGCCAAAAATGGTTTTGCCAAGTAGGTCCGCAGCTAGGACAGCTGAGGTGGCTGCTGTG
TTTGCAGAACAGCCTCTATAAAAGTGAAGCTGGGGTGCCTCTGTCCTGTCCTTCCTCA 
 
Figure 4.21 Transcription factor search for CREB/ATF consensus binding sites in the pig and 
mouse (1kb) MyHC IIB promoters. Yellow highlighted sequences indicate the start of the first 
exon. Blue sequence shows the TATA box. Red sequence indicates a consensus CREB/ATF 
binding site. Note the pig MyHC IIB promoter lacks CREB/ATF response elements.  
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4.2.4 DISCUSSION 
Muscle fibre type transitions towards increasing the fast, glycolytic, type II 
muscle fibres is a phenomenon well documented to occur in animals exposed 
to beta-adrenergic stimulation (Baker et al. 2006; Bricout et al. 2004; Depreux 
et al. 2002; Oishi et al. 2002; Gunawan et al. 2007). This response was 
confirmed in growing gilts treated with Ractopamine and additionally explored 
in vitro to assess the effect of beta-adrenergic agonist administration directly to 
muscle cells and to specifically examine effects on MyHC regulation during 
early myogenic differentiation. Although cultured muscle cells do not form 
mature muscle fibres, they do express specific patterns of the contractile 
components that constitute the muscle fibre during myogenesis (Brown et al. 
2012; Chapter 3.1). We utilized the C2C12 cell line, which exhibits a late 
induction of the type II MyHC isoforms, as a model to examine whether direct 
exposure of muscle cells to the beta-adrenergic agonist, Ractopamine, might 
accelerate the initial induction of the type II MyHC isoforms in vitro. 
 
4.2.4.1 Ractopamine induces differential regulation of MyHC 
isoforms in vivo compared to in vitro 
Dynamic alterations in transcript abundance of the MyHC isoforms occurred in 
pig skeletal muscle during 27 days of Ractopamine administration. More 
specifically, the MyHC IIB isoform mRNA displayed a chronic induction 
across the full 27-day treatment window, whilst the MyHC IIA isoform mRNA 
exhibited an initial decline in expression before returning to expression levels 
comparable to that of the control group. In addition, the type IIX MyHC 
isoform displayed a modest reduction in expression throughout the 27-day 
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treatment window. This drive towards increasing MyHC IIB expression, at the 
expense of the slower IIA and IIX isoforms, is a phenomenon previously 
documented to occur in response to beta-adrenergic treatment in vivo, using 
rats and pigs (Baker et al. 2006; Bricout et al. 2004; Depreux et al. 2002; Oishi 
et al. 2002; Gunawan et al. 2007). However, the data presented herein shows 
dynamic modulation in expression of the type II MyHC isoforms, with 
individual isoforms clearly being exclusively regulated (displaying differential 
expression profiles with duration of treatment), suggesting remarkable 
plasticity of these genes in adult skeletal muscle. 
In contrast, 48-hour treatment of cultured C2C12 muscle cells with 
Ractopamine resulted in an exclusive up-regulation in mRNA expression of 
MyHC IIB, without altering the expression levels of the other adult type I or 
type II MyHC isoforms. Although there was a small induction in neonatal 
MyHC mRNA expression, the relative fold-induction was small compared 
with the dramatic increase in mRNA expression of the MyHC IIB isoform. 
The up-regulation of MyHC IIB mRNA in response to beta-adrenergic agonist 
treatment presented herein is consistent with a previous report in vitro (Shi et 
al. 2007), but this study used a mouse 1kb MyHC IIB promoter reporter 
construct and did not examine all MyHC isoforms. Importantly, this data 
indicates that beta-adrenergic signaling is capable of exclusively accelerating 
the initial induction of the MyHC IIB gene during C2C12 myotube formation. 
This response was not restricted to murine species as demonstrated by 
increased porcine 1kb MyHC IIB promoter-reporter activity in C2C12 muscle 
cells treated with Ractopamine. Furthermore, this suggests that the increased 
MyHC IIB transcript abundance is likely due to increased MyHC IIB promoter 
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activity. Although this drive towards increasing MyHC IIB expression is well 
documented to occur in response to beta-adrenergic receptor stimulation in 
vivo (Depreux et al. 2002; Gunawan et al. 2007), as shown in Chapter 4.1, this 
response is also normally characterized by an increase in MyHC IIB 
expression at the expense of the slower, more oxidative type II isoforms (IIA 
and IIX), albeit generally in response to a more chronic exposure (up to 28 
days; Depreux et al. 2002; Baker et al. 2006; Gunawan 2007; Chapter 4.1). 
This ÒtransitionÓ in MyHC isoform expression did not occur during the 48-
hour treatments employed herein using C2C12 muscles cells. Interestingly, 
Gunawan et al (2007) report that MyHC IIB is the earliest MyHC isoform to 
change in pigs treated with Ractopamine, increasing mRNA expression in just 
12 hours, compared with 96 hours for the IIA and IIX isoforms. In the present 
in vitro experiments, the treatment time of 48 hours may not have been chronic 
enough to induce a Òfull transitionÓ (i.e. an increase in IIB at the expense of 
another isoform). Thus, it seems likely that MyHC IIB may be the most 
responsive and/ or the earliest MyHC isoform to undergo altered levels of 
expression in response to beta-adrenergic stimulation.  
It is interesting to speculate whether inter- and intra-genic mechanisms 
regulate the subsequent down-regulation in mRNA expression of the type IIA 
and IIX MyHC isoforms following an induction of the MyHC IIB mRNA 
isoform. For instance, after an increase in MyHC IIB gene expression by beta-
adrenergic stimulation, it is plausible that miRNA transcripts within the MyHC 
IIB introns could co-regulate other MyHC isoforms (Van Rooij et al. 2009) or 
bi-directional promoters within the MyHC gene cluster could co-regulate 
subsequent MyHC isoform gene expression (Pandorf et al. 2006; Rinaldi et al. 
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2008). Such genomic mechanisms of gene regulation may also differ between 
species and developmental status (i.e. during myogenesis versus differentiated 
muscle). The data presented herein implicates MyHC IIB as the initial isoform 
targeted for up-regulation by beta-adrenergic signaling. Mechanisms 
controlling the coordinated regulation of the type IIA, IIX and IIB MyHC 
isoforms warrant exploration. 
 
4.2.4.2 Ractopamine altered in vivo but not in vitro metabolic 
gene expression 
Interestingly, chronic exposure (27 days) of pigs to Ractopamine (but not acute 
(48-hour) exposure in C2C12 muscle cells) altered mRNA expression of 
metabolic marker genes, Enolase 3 and IDH2. It is well documented that 
transitions towards increasing MyHC IIB isoform expression in response to 
beta-adrenergic agonist treatment is coupled with a concomitant shift from an 
oxidative to a more glycolytic muscle metabolism in vivo. This is evidenced by 
a reduced oxidative and increased glycolytic gene expression and enzyme 
activity in muscle (Gunawan et al. 2007; Vestergaard et al. 1994) and also a 
reduced muscle glycogen content (Vestergaard et al. 1994; Baker et al. 2006), 
all indicating a shift towards a more glycolytic metabolism in beta-agonist 
treated muscle in vivo. The disparity in response of metabolic gene expression 
presented herein may be due to differences in duration of treatment but also 
differences in the developmental status of the cells being studied 
(differentiated muscle versus differentiating cells). It is possible that 
transcriptional regulation of metabolic enzyme expression may occur 
secondary to alterations in contractile component gene expression and that a 
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more chronic treatment is required to see transcriptional alterations in 
metabolic gene expression in C2C12 muscle cells. Furthermore, as shown in 
Chapter 3.2, it is evident that C2C12 cells undergo significant metabolic 
remodeling during differentiation, which may over-ride the subtle 
Ractopamine induced alterations in metabolic gene expression.  
Interestingly, the metabolic gene expression markers employed herein, Enolase 
3 and IDH2, displayed remarkable correlation with the type IIB and type I 
MyHC mRNA isoforms in vivo, respectively, suggesting these genes may be 
excellent candidates for monitoring associated contractile-metabolic changes 
in skeletal muscle.  
 
4.2.4.3 Ractopamine increased Six1 and Eya1 mRNA 
expression in fusing muscle cells only 
The SIX and EYA gene family were orignally identified as genes essential for 
eye development but certain family members (SIX 1, 4 and 5; Spitz et al. 1998 
and EYA 1, 2 and 4; Grifone et al. 2004) have been shown to accumulate in 
skeletal muscle and have subsequently been implicated in regulating 
myogenesis (Heanue et al. 1999; Kawakami et al. 2000). SIX and SYA 
transcription factors co-operatively bind MEF3 response elements to drive 
expression of myogenic genes such as MyoD, myogenin and myosin heavy 
chain (Spitz et al. 1998; Heanue et al. 1999; Kawakami et al. 2000). The SIX1 
and EYA1 family members were measured herein as they have previously 
been implicated to act in synergy to drive a fast, glycolytic muscle phenotype 
in mice (Grifone et al. 2004), similar to that induced by beta-adrenergic agonist 
treatment (Baker et al. 2006; Bricout et al. 2004).  
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For the first time, the data herein shows that 48 hours beta-adrenergic agonist 
administration can up-regulate mRNA expression of SIX1 and EYA1 in the 
mouse C2C12 muscle cells. However, induction of SIX1 and EYA1 mRNA 
expression was dependent on the timing of administration of the agonist. 
Firstly, Ractopamine administration in vivo did not influence SIX1 or EYA1 
mRNA expression in fully differentiated adult skeletal muscle within a 27-day 
treatment window. However, Ractopamine administered for 48 hours in vitro, 
at the initiation of myoblast fusion (i.e. day 0-2 of differentiation), increased 
SIX1 and EYA1 mRNA expression, but there was no alteration in SIX1 and 
EYA1 mRNA expression when Ractopamine was administered later in 
differentiation (day 2-4 of differentiation). This suggests that the induction of 
SIX1 and EYA1 mRNA expression by beta-adrenergic receptor stimulation 
may occur in a myogenesis dependent manner, occurring only in the early 
stages of myoblast fusion. It is therefore interesting to speculate that beta-
adrenergic signaling may be developmentally relevant during early myogenic 
differentiation. 
The time dependent effect of Ractopamine administration on SIX1 and EYA1 
gene expression and the accelerated induction of MyHC IIB mRNA expression 
in C2C12 cells suggest that beta-adrenergic signaling may play a role in 
regulating a fast type IIB muscle fibre phenotype specifically during the early 
stages of myotube development. The data presented herein also highlights the 
complexity of beta-adrenergic signaling during myogenesis, with downstream 
effects on gene expression differing depending on the stage of myogenesis.  
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4.2.4.4 Increased MyHC IIB mRNA expression was independent 
of changes in cellular differentiation, growth and myogenic 
gene expression 
Ractopamine administration in growing pigs induced dramatic and chronic 
alterations in MyHC isoform expression, largely independent of changes in 
carcass and muscle growth characteristics (contradicting the typical porcine 
growth response to Ractopamine reported by others; Apple et al. 2007). 
Therefore, alterations in MyHC isoforms in response to Ractopamine treatment 
in vivo can occur independent of enhancements in muscle growth.  
In vitro, an increased differentiation stimulus is a potential mechanism for 
inducing expression of the fast MyHC mRNA isoforms in C2C12 cells since 
this may effectively shift the induction of the type II MyHC isoforms to an 
earlier stage in differentiation (Brown et al. 2012). Differentiation status of 
C2C12 cells in the present study, indicated by creatine kinase activity, 
exhibited no change with Ractopamine treatment. Furthermore, no alterations 
in the mRNA expression of myogenin, a key regulatory factor known to drive 
myogenic differentiation (Nabeshima et al. 1993; Hasty et al. 1993), support 
the finding that differentiation status remained unchanged by Ractopamine 
treatment. Therefore, cellular differentiation was ruled out as a potential 
mechanism driving the induction of MyHC IIB mRNA expression in the 
present in vitro study.  
Other in vitro models exploring the effects of beta-adrenergic agonist 
administration on muscle cell differentiation have proven inconclusive. Some 
studies report increased cell fusion in response to beta-adrenergic agonist 
treatments (Grant et al. 1990; McMillan et al. 1992), whilst others have seen 
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no effect (McMillan et al. 1992; McFarland et al. 1995). These studies used a 
variety of myogenic cell types from different species and also administered 
different classes of beta-adrenergic agonists. Clearly, variability in 
responsiveness of different cell types to different classes of beta-adrenergic 
receptor agonists exists and complicates comparisons between studies 
exploring beta-adrenergic agonists. To strengthen this notion, Wannenes et al 
(2012) recently reported that of four different beta-adrenergic agonists tested 
(Clenbuterol, Formoterol, Salbutamol and Salmeterol) on C2C12 cells, 
Clenbuterol was the only one that elicited a gene expression response. Thus it 
would appear that beta-adrenergic agonist pharmacology is likely complicating 
the understanding of beta-adrenergic signaling and its associated effects in 
muscle cells.  
Myogenic regulatory factor MyoD, is a known regulator of myogenesis and an 
influential regulator of MyHC IIB expression (Allen et al. 2001; Harrison et al. 
2011). In the present study, the Ractopamine induced increases in MyHC IIB 
mRNA in C2C12 cells and pig skeletal muscle occured independent of 
changes in MyoD gene expression. This contradicts other in vivo studies 
reporting significant elevation in MyoD transcript abundance and/ or protein 
expression in response to beta-adrenergic agonist administration (Bricout et al. 
2004; Jones et al. 2004; Koopman et al. 2010). However, Brown et al. (2012) 
have previously shown that mRNA expression of MyoD is similar throughout 
C2C12 myogenesis, suggesting that this myogenic regulatory factor can 
remain relatively unchanged at the mRNA level despite dramatic cellular 
changes. Although alterations in MyoD gene expression did not occur in the 
present study, it would be interesting to monitor MyoD phosphorylation status 
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by beta-adrenergic agonist treatment since de-phosphorylation of MyoD has 
been shown to increase MyHC IIB gene expression in soleus muscles of mice 
and rats (Ekmark et al. 2007).  
 
4.2.4.5 Conclusion 
To summarise, Ractopamine administration to growing pigs caused a chronic 
induction of MyHC IIB with concomittent alterations in the slower IIA and 
IIX MyHC isoforms. In contrast, 48-hour Ractopamine treatment during the 
early stages of C2C12 myogenesis selectively accelerated MyHC IIB mRNA 
induction independent of alterations in expression of the other adult MyHC 
mRNA isoforms. Taken together, gene expression of the MyHC IIB isoform is 
dynamic and responsive, both in vivo and in vitro. The data presented herein 
(in Chapter 4) suggests expression of the MyHC IIB isoform mRNA elicits 
plasticity in developing myotubes and in fully differentiated adult muscle 
fibres. Despite the impressive and dynamic plasticity in expression of this very 
fast contracting myosin heavy chain isoform (MyHC IIB), mechanisms 
regulating its expression remain relatively elusive and will be explored further 
in Chapter 5. 
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5 
REGULATION OF THE MYOSIN HEAVY CHAIN IIB 
GENE IN PORCINE SKELETAL MUSCLE  
!
!
!
 
It was hypothesized that sequence variation in the myosin heavy 
chain IIB gene promoter dictates species differential expression of 
this gene in pigs and humans. Furthermore, it was hypothesized 
that the C2C12 skeletal muscle cell line would provide the dynamic 
myosin heavy chain IIB inducing environment required to examine 
this hypothesis in a cultured muscle cell model.  
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5.1  TRANSCRIPTIONAL REGULATION OF THE MYOSIN HEAVY 
CHAIN IIB GENE IN PORCINE SKELETAL MUSCLE: A 
COMPARISON OF PIG AND HUMAN GENE PROMOTER 
ACTIVITIES 
 
5.1.1 INTRODUCTION 
Skeletal muscle is composed of a heterogeneous population of muscle fibres 
that display a broad spectrum of contractile and metabolic characteristics. The 
contractile capacity and ATP consumption of a muscle fibre is largely 
determined by the isotype of the components that constitute the sarcomere 
(Schiaffino and Reggiani 2011). In particular, maximal shortening velocity of a 
muscle fibre is dictated by the predominant Myosin Heavy Chain (MyHC) 
isoform expressed (Pellegrino et al. 2003) and increases in the order of MyHC 
I<IIA<IIX<IIB. This crucial role of the MyHC isoform to influence the 
contractile performance of the muscle fibre has resulted in significant interest 
in understanding the regulation of different MyHC isoforms (Spangenburg and 
Booth 2003; Schiaffino 2010). In the previous chapters it was highlighted that 
the MyHC genes are a highly dynamic set of genes; displaying incredible 
plasticity in expression levels in response to a variety of stimuli. Although 
regulation of the slower (type I and IIA) MyHC isoforms is relatively well 
understood (Lin et al. 2002; Lunde et al. 2007; Narkar et al. 2008; Narkar et al. 
2011), knowledge of the mechanisms regulating the gene expression of the 
faster contracting, type IIB MyHC isoform remains sparse and incomplete 
(Grifone et al. 2004; Ekmark et al. 2007).  
Despite all mammals carrying the gene (MYH4) encoding MyHC IIB, 
extensive characterization has revealed a striking divide between large and 
small mammals with regard to MyHC IIB expression. Most small mammals 
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such as mice (Pellegrino et al. 2003), rats (Pellegrino et al. 2003), rabbits 
(Wada et al. 1995; Pellegrino et al. 2003), and guinea pigs (Gorza 1990; Tonge 
et al., 2010) express MyHC IIB but most larger mammals such as cows 
(Chikuni et al. 2004), sheep (Hemmings et al. 2009) horses (Rivero et al. 
1999), goats (Arguello et al. 2001), cats (Talmadge et al. 1996; Lucas et al. 
2000), dogs (Toniolo et al. 2007), baboons (Lucas et al. 2000) and humans 
(Smerdu et al., 1994, Pellegrino et al. 2003) do not express MyHC IIB. 
Interestingly, domesticated pigs remain an anomaly amongst the large 
mammals as they express high levels of MyHC IIB (Lefaucheur et a. 1998; 
Gunawan et al. 2007; Chapter 4.1), a phenotype likely exacerbated by the 
intensive selection pressure for enhanced muscle growth in these animals 
(Ruusunen and Puolanne 2004; Lefaucheur et al. 2004). This expression of 
MyHC IIB in pig skeletal muscle is associated with a dramatically faster and 
more glycolytic muscle phenotype compared to that of human skeletal muscle. 
Given the impact of MyHC isoform expression on the contractile and 
metabolic characteristics of the muscle fibre, it is interesting to explore the 
mechanisms dictating this unusually high expression of MyHC IIB in porcine 
skeletal muscle, which currently remains unknown. 
Previous studies on the MyHC IIB promoter have elucidated several key 
regions of regulatory control (mAT 1/2/3, CArG-box and Ebox) but have 
predominantly been conducted on the mouse promoter sequence (a MyHC IIB 
expressing species; Takeda et al. 1992, 1995; Lakich et al. 1998; Swoap 1998; 
Wheeler et al. 1999; Allen et al. 2001, 2005). A recent study Harrison et al. 
(2011) extended this work to compare the activity of the human and mouse 
MyHC IIB promoter and revealed that a single base pair mismatch in the 
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human CArG-box sequence (-74bp relative to the TATA-box) inhibits binding 
of serum response factor (SRF) and results in reduced MyHC IIB promoter 
activity, relative to the equivalent mouse promoter.  
Differences in the regulation of MyHC IIB expression between rodent species 
and humans might be expected as their muscle metabolism, and therefore their 
contractility characteristics, are different, probably reflecting the metabolic 
constraints caused by body size (Rennie et al. 2010).  Pigs, on the other hand, 
are physiologically similar to humans and are increasingly being considered as 
a good animal model for studying a range of human diseases (Luo et al. 2012). 
Therefore it is important to determine what differences exist between these 
species in order to have confidence in the use of pig as a model. Given that 
pigs also have high expression of MyHC IIB, unlike humans and most large 
animals, we wished to determine whether the mechanisms by which this is 
achieved is also through variations in promoter sequence, as is the case in mice 
when compared to humans. We hypothesized that genomic differences in the 
MyHC IIB promoter of pigs and humans dictate the differential expression of 
MyHC IIB in these large mammals and that these differences may explain the 
different muscle phenotypes displayed in these otherwise physiologically 
similar mammals. Using an in vitro fluorescence based promoter-reporter 
system; we utilized approximately 1kb of the MyHC IIB promoter from a 
domestic pig and a human to elucidate the role of the promoter sequence in 
regulating the high expression of MyHC IIB in porcine skeletal muscle. 
Further, we examined stimuli capable of inducing both the pig and human 
MyHC IIB promoters during myogenesis.  
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5.1.2 MATERIALS AND METHODS 
The materials and methods presented here are a brief description only. For a 
more detailed explanation of the methods used herein, refer to the ÒMolecular 
Biology MethodsÓ in the ÒMaterials and MethodsÓ chapter. 
 
5.1.2.1 Cloning 
Approximately 1kb of the pig and human myosin heavy chain IIB promoters (-
961bp to +32bp, relative to the TATA box) was generated by polymerase 
chain reaction (PCR) and cloned into the pZsGreenI-I fluorescence-reporter 
plasmid (Clontech) for transfection studies in the C2C12 mouse myoblast cell 
line. All base pair numbering is relative to the TATA-box, as a discrepancy 
existed as to the location of the transcription start site between the two 
promoters. Accession numbers for the pig and human MyHC IIB gene 
(NM_001123141.1 and ENSG00000264424.1, respectively) were used to 
locate the first exon and the 3Õ oligonucleotide primer was designed to span 
into the first exon to ensure inclusion of the transcription start site. All 
oligonucleotide sequences are displayed in the ÒMaterials and Methods 
ChapterÓ.  
Pig and human MyHC IIB promoters were subjected to 5Õ deletion analysis 
creating promoters of varying lengths (-961bp, -466bp, -231bp, -113bp, -67bp; 
promoter lengths are relative to the TATA-box). Site directed mutagenesis and 
site-specific deletions within the MyHC IIB promoters were introduced by 
PCR (specific base pair substitutions are described in the results section).   
Chimeric MyHC IIB promoters (containing combinations of both distal and 
proximal regions of the pig and human MyHC IIB promoters) were produced 
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according to a design previously demonstrated (Harrison et al. 2011). A 
HindIII restriction site (2bp mutation; at -218bp and -217bp) was introduced to 
both the pig and human 1kb promoter allowing the proximal promoter regions 
to be swapped by restriction digest, generating chimeric promoters. Proximal 
promoter regions were also swapped with a minimal CMV promoter (84bp) to 
test for potential regulatory regions in the 5Õ distal region (~750bp) of each 
promoter, independent of the proximal promoter.   
Full-length open reading frame MyoD cDNA (accession number: 
ENSMUST00000072514.1) was generated by RT-PCR, cloned into the 
pDsRed-Express-N1 plasmid (clontech) and over-expressed in C2C12 cells 
under the control of a CMV promoter. A pDsRed-Express-N1 plasmid lacking 
the CMV promoter was used as a vehicle transfection control.   
 
5.1.2.2 Electrophoretic mobility shift assay  
Protein-DNA interactions were assessed by incubating C2C12 myotube 
nuclear extracts with a 5Õ biotin labeled double-stranded probe for a 62bp 
region spanning (and inclusive of) the CArG-box and Ebox2 sequence (-93bp 
to -31bp relative to the TATA-box) from the pig MyHC IIB promoter (probe 
sequences are in the ÒMaterials and Methods ChapterÓ). Three shorter un-
labeled probes, from the same region (pig sequence), were used to compete for 
bound proteins and identify the specific regions within the 62bp probe 
interacting with nuclear protein(s). Three equivalent human un-labeled probes 
were used to assess whether the species-specific sequence variation in these 
regions impaired competition for the proteins bound to the pig 62bp labeled 
probe. Unlabeled competitor probes were designed to the following regions, 
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CArG-box: -91bp to -60bp, mid-probe: -74bp to -51bp and E-box2 probe: -
63bp to -31bp, all relative to the pig TATA-box.  
EMSAÕs were conducted using the LightShift Chemiluminescent EMSA kit 
(Thermo Scientific). Protein-DNA binding conditions and detection of the 
biotin-labeled probes using the LightShift Chemiluminescent EMSA detection 
module (Thermo Scientific) are outlined in the Materials and Methods 
Chapter.  
 
5.1.2.3 Cell culture and transfections 
C2C12 mouse myoblasts were cultured in proliferation medium (DMEM, 10% 
FBS, 1% PS) and induced to differentiate at confluence by switching to 
differentiation medium (DMEM, 2% HS, 1% P/S) for up to 6 days. Medium 
was refreshed every 48 hours. 
Myoblasts (at ~70% confluence) were transfected with the pig or human 1kb 
MyHC IIB pZsGreenI-I promoter-reporter plasmid using FugeneHD 
(Promega) transfection reagent at a ratio of 3:1 (FugeneHD:DNA). Each well 
was co-transfected with pDsRed-Express-N1 as a transfection efficiency 
control for normalizing ZsGreenI-I promoter-reporter fluorescence. MyHC IIB 
promoter activities (fluorescence output) were quantified following 5 or 6 days 
of differentiation using the Typhoon Trio+ (GE healthcare). MyoD over-
expression plasmids (or pDsRed-Express-N1 plasmids lacking the CMV 
promoter) were transfected into myoblasts at the same time as the MyHC IIB 
promoter-reporter plasmids at a ratio of 1:1.  
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5.1.2.4 dbcAMP treatments and myotube diameters 
Dibutyryl cyclic-AMP (dbcAMP; Sigma-Aldrich) or a vehicle control (water) 
was included in the differentiation medium of transfected cells and refreshed 
every 48 hours for up to 5 days. MyHC IIB promoter activities were quantified 
following 4 or 5 days of differentiation. Myotube diameters of MyHC IIB 
positive cells (as indicated by ZsGreen fluorescing myotubes) were measured 
on day 5 of differentiation. Myotube diameters were measured at 3 points (at 
25%, 50% and 75% of the full myotube length to give an average myotube 
diameter) on 50 myotubes from 5 fields of view per well (n = 4 wells; a total of 
200 myotubes per treatment). To remove bias, all images were blinded for 
analysis. 
 
5.1.2.5 Statistical analysis 
All fluorescence promoter-reporter assays were conducted on single 
experiments using 4 biological replicates (wells). The same promoter-reporter 
constructs were used in multiple experiments and confirmed reproducibility of 
results presented herein. Data is displayed as mean ± standard deviation (SD). 
Statistical analysis was conducted using GenStat (version 15) and significance 
was accepted at p < 0.05. 
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5.1.3 RESULTS 
5.1.3.1 The pig and human MyHC IIB promoter sequence 
Alignment of the pig and human MyHC IIB promoter revealed very high 
similarity (1kb: 80% identical; proximal 200bp: 95% identical; see Figure 5.1).  
Human -961 -----------CTTAGAGTAGGTATATTTCCTGCCATATTCAGTAACAGCTGTGTATGTA -913 
Pig   -961 TAGGTGACACACTTAGCGTGGACAGATTTGCTGTTACATTCAGCAGCAGCTGTGTCTGTG -902 
                      ***** ** *  * **** ***  * ****** * ********* ***  
 
Human -912 GCAAAACCATCAAAAGCCAATTTATGAGTATTATGGGCATATGTGATGGCCCATCCATCT -853 
Pig   -901 GCAAAACCACCAAAACCCAATTTACAAGCATCGTGGGCATATGTGATAGCCCCCTTATGT -842 
           ********* ***** ********  ** **  ************** ****    ** * 
 
Human -852 TTTCAATCCACAGGGAGAATATCGTGGATACCATGACTTTCCTCCCACCTTAAATAAAAA -793 
Pig   -841 TCTCAACCCACAA--AGAGTCCTGTGGGTATCACATCTCTCCTCCCACCTTAAATAAAAA -784 
           * **** *****   *** *   **** ** **   ** ********************* 
 
Human -792 TATGTGGTTCCCACCTCATTAGAGCTATAGCTAGTCATGAGAGTCTGCCCATGAACTAGG -733 
Pig   -783 TACGTATTACCCACCTCATTAGAGCTACTGCTAGTCATGAGGATTTGCCTGTGAACTAGG -724 
           ** **  * ******************  ************  * ****  ********* 
 
Human -732 AATGCATGTTTGTGTCTCCTTCCAT---TATGCAGAGGAAACATGCATGGAACATCACAC -676 
Pig   -723 AATGCATATTGATGCCTCCTTCCATCATTATGCGGTAGAAACACACATAGAACATCACAC -664 
           ******* **  ** **********   ***** *  ******  *** *********** 
 
Human -675 AGCATCCTGTTGTTCCTTCAGTGAAAACATACAAGCTGGAGATATCCATGGAAAGTCCTC -616 
Pig   -663 GGACTCCTGCAGTCCCCCCAGTGAAAACATGTGAGCTCAAGACAGCCACGGCAAGCTCTC -604 
            *  *****  ** **  ************   ****  *** * *** ** ***  *** 
 
Human -615 CAGAAAAAGAACAGAAGTGTTTATATCTATTCTAAATCCCTTATGCCTCCCCCAGTGGTC -556 
Pig   -603 CAGAAAAGGAAAAGAAGTGTTTCTATCTATTCTAAATCCCTTATGGCTCCCCCACTGGTC -544 
           ******* *** ********** ********************** ******** ***** 
 
Human -555 CATCACCACTGCCTAATCTGAGAATTC------ACTTTCACCTTCATATTTAGACTTTCA -502 
Pig   -543 TGTCACCATGGCTTAGCCCGAGAATCTGCCTAAACTTTCTCCTTCATGCTTAGTCTTTTA -484 
             ******  ** **  * ******        ****** *******  **** **** * 
 
Human -501 GACTTTAAAAGAATCTATCGCCAGTCTTTCTAAAATCCAGACTGTGGCTAGGAATGTTGT -442 
Pig   -483 GACTTTAAAAAAATCTATCATCAGTATTTCTAAAATCCAGACCCAGGCTAGGA--GTTTT -426 
           ********** ********  **** ****************   ********  *** * 
 
Human -441 CTTAAAATCCATCGCTCACTGCTTCCAATCATAGTGTCAGGTCTAAAATTCATTCCAGAC -382 
Pig   -425 CT-----------GCTT--TAATACCAATCATGTTGTCAGAGCTAAAACTCATCCCAG-C -380 
           **           ***   *  * ********  ******  ****** **** **** * 
 
Human -381 TCCTTAATGGCTCTAAGAACCAACAAATTAATTAATCCTAAATTCCTCACATCAGACTCA -322 
Pig   -379 TCCTCAATGGCCCTAAGCACTAACAAATCAATTAGTTCTCAACTCCTCGTGTCTGGCTCA -320 
           **** ****** ***** ** ******* ***** * ** ** *****   ** * **** 
 
Human -321 TTCTGTTGGACCAATTTTATAGGCAGAGGAGTAAGTGGGAATCTGGCTTTGAATTCTGTG -262 
Pig   -319 TTCTGTCGGACCAATTTTACAGGCAGGAGAGTAAGTGGGAACCTGGCTTTCAACTCAGTG -260 
           ****** ************ ******  ************* ******** ** ** *** 
 
Human -261 ATGAATGATGCAACAGCCAAACTGGAGAAACAGTGTTAGAAGCCCTGAATCCCCATCCCC -202 
Pig   -259 ATGAATGATGGAACAGCAAAGCTGGAGAAATAGCCTTAGAAGCCCTGAATCTCCATCCC- -201 
           ********** ****** ** ********* **  **************** *******  
      AT3   AT2 
Human -201 TATCAAATGCCTATAAAGAACCCTAGATCATCCTCTGTTAAATTATTTATGGGTGTCAAG -142 
Pig   -200 TATCAAATGCCTCAAAAGAACCCTAGATGATCCTCTGTCAAATTATTTATAGGTGTCAAG -141 
           ************  ************** ********* *********** ********* 
   AT1 
Human -141 AAATATTTCTAATTATATCCATTCACAGCCACAGTCAGTGAATATTGTGCAAAGAGATTG -82 
Pig   -140 AAATATTTCTAATTATATCCATTCACAGCCACAGTCAGTGAATATTGTGCAAAGAGATTG -81 
           ************************************************************ 
  CArG-box         E-box2   E-box1 
Human  -81 CCAAAAACGGTTTTGCCAAGTAGGTTCCCAGCTAGGACAGCTGAGGTGGCTGCTGTGTTT -22  
Pig    -80 CCAAAAAAGGTTT-GCCAAGTAGGTTCCCAGCTGGGACAGCTGAGGTGGCTGCTGTGTTT -22 
           ******* ***** ******************* ************************** 
   TATA-box (+1) 
Human  -21 GCAGAATGGTCTCTATAAAAGTGGAGCTGAGATGCCTCTTTCCCATCCTTCCT +32 
Pig    -21 GCAAAATGGTCTCTATAAAAGTGGAGCTGAGATGCCTCTGTCCTGTCCTTCCT +32 
           *** *********************************** ***  ******** 
Figure 5.1 Alignment of ~1kb of the pig and human MyHC IIB promoters. Base pair 
numbering is relative to the TATA-box (+1). Regions highlighted in grey represent areas of 
known regulatory importance. * Indicates matching bases between the pig and human 
sequences. 
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5.1.3.2 Pig and human MyHC IIB promoter activity 
Following transfection into mouse C2C12 muscle cells, activity of the 1kb pig 
and human MyHC IIB promoters was restricted to differentiated myotubes 
(indicated by ZsGreen fluorescence), unlike a CMV-driven ZsGreen control, 
which was expressed in myoblasts and myotubes; see Figure 5.2A). Despite 
both promoters being active in differentiated C2C12 myotubes, the 1kb pig 
MyHC IIB promoter had higher activity than the equivalent human promoter, 
which was only mildly active (Figure 5.2A and 5.2B; p = 0.006). Figure 5.2C 
shows a representative output of the ZsGreen-reporter and DsRed-co-reporter 
using the Typhoon Trio+ (used to quantify fluorescence output). 
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Figure 5.2 (A) Representative fluorescence images show 1kb MYHC IIB promoter-reporter 
constructs are differentiation specific. (B) 1kb pig and human MyHC IIB promoter activity in 
day 6 differentiated C2C12 myotubes (mean ± SD). * Indicates 1kb human MyHC IIB 
promoter activity was significantly different to the 1kb pig MyHC IIB promoter activity (p < 
0.05). Open bar = pig promoter; closed black bar = human promoter. (C) Representative 
fluorescence output of transfected myotubes using the Typhoon Trio+.  
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5.1.3.3 MyoD activates the pig and human MyHC IIB promoter 
Due to the disparity in MyHC IIB promoter induction during myogenesis, we 
asked whether MyoD, a myogenic regulatory factor known to induce MyHC 
IIB expression (Wheeler et al.1999; Allen et al. 2001; Ekmark et al. 2007; 
Harrison et al. 2011), was activating the pig, but not human MyHC IIB 
promoter during C2C12 myogenesis. Over-expression of mouse MyoD during 
C2C12 differentiation was capable of inducing both the pig and human MyHC 
IIB promoters by ~3 and ~4-fold respectively (Figure 5.3A; p < 0.01). 
Fluorescence microscopy revealed that MyHC IIB promoter activity was still 
restricted to differentiated myotubes in the presence of MyoD over-expression 
(Figure 5.3B). Although both the pig and human MyHC IIB promoters were 
induced by a myogenic signal (MyoD), the absolute capacity for induction of 
the human MyHC IIB promoter was restricted in comparison to the pig MyHC 
IIB promoter activity. It was therefore postulated that response elements within 
the human MyHC IIB promoter were limiting the capacity to fully activate the 
promoter and that the pig MyHC IIB promoter contained response elements 
that permitted a much greater potential for activation during myogenic 
differentiation. 
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Figure 5.3 (A) 1kb pig and human MyHC IIB promoter activity in response to (mouse) MyoD 
over expression in day 5 differentiated C2C12 myotubes (mean ± SD). * Indicates MyHC IIB 
promoter activity was significantly different to the control transfection (p < 0.05). (B) 
Representative fluorescence-reporter images showing MyHC IIB promoter induction by 
MyoD over-expression in day 6 differentiated C2C12 myotubes.  
 
 
5.1.3.4 Five prime deletion of the pig and human MyHC IIB 
promoter 
In order to locate regulatory regions controlling the differential activity of the 
pig and human 1kb MyHC IIB promoters, we conducted equivalent 5Õ deletion 
analysis of both promoters. Disparity in pig and human MyHC IIB promoter 
activity persisted with decreasing promoter length (from -961bp to -113bp) and 
declined similarly for promoters from both species (Figure 5.4). Removal (by 
5Õ deletion) of ~120bp, between -231bp to -113bp, essentially removing the 
AT-rich regions (AT 1, 2 and 3), caused the largest reduction in promoter 
activity for both the pig and human MyHC IIB promoters (84% and 82% 
respectively). Deletions at the 5Õ end of the pig and human MyHC IIB 
promoters from -961bp to -466bp caused a 26% and 37% reduction, 
respectively, and deletion from -466bp to -231bp caused a 50% and 58% 
reduction, respectively. The largest disparity in promoter activity between the 
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pig and human MyHC IIB promoters existed in the -231bp promoters (~5-fold 
difference; p<0.001), indicating that response elements controlling high and 
low MyHC IIB promoter activity likely resided downstream of -231bp. 
 
 
 
Figure 5.4 Equivalent 5Õ deletion analysis of the pig and human MyHC IIB promoters. 
Promoter activities in Day 6 differentiated C2C12 myotubes (mean ± SD). * Indicates Human 
MyHC IIB promoter activity was significantly different to the equivalent length pig promoter 
(p < 0.05).  
 
 
5.1.3.5 Chimeric MyHC IIB promoters 
To confirm the role of the proximal promoter sequence in dictating high and 
low MyHC IIB promoter activity, we produced chimeric MyHC IIB promoters 
(generated by swapping the proximal region (-218bp to +32bp) of the pig and 
human promoters). When the proximal region of the pig 1kb MyHC IIB 
promoter was replaced with the equivalent human proximal promoter, activity 
was reduced (p < 0.001) to the same level as the human 1kb MyHC IIB 
promoter (Figure 5.5A; p = 0.627). When the proximal region of the human 
1kb MyHC IIB promoter was replaced by the equivalent pig proximal 
promoter, activity was increased (p < 0.001) and interestingly exhibited an 
almost 2-fold greater activity than the 1kb pig MyHC IIB promoter (p = 
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0.005). The chimeric promoters confirmed that sequence differences in the 
proximal promoter regions (totaling 14bp differences) dictate the high and low 
MyHC IIB promoter activities. For completeness, the pig and human proximal 
MyHC IIB promoters (-218bp to +32bp) were replaced by an 84bp minimal 
CMV promoter which revealed that the 5Õ distal human (p < 0.001), but not 
pig (p = 0.135), MyHC IIB promoter region was capable of increasing the 
basal promoter activity of the minimal CMV promoter (Figure 5.5B). This 
highlighted that the proximal MyHC IIB promoter region contains the key 
response elements required to elicit differential promoter activity between pigs 
and humans. 
 
 
Figure 5.5 (A) Pig-human and human-pig (5Õ to 3Õ) chimeric MyHC IIB promoters were 
constructed to assess the role of the proximal 250bp of each promoter within the context of a 
1kb promoter. (B) The distal (~750bp) of the pig and human MyHC IIB promoters were 
cloned upstream of a minimal CMV promoter (84bp) to assess whether this region elicits 
enhancer activity independent of the proximal (~250bp) MyHC IIB promoter (mean ± SD). 
Differing letters (a,b,c) constitute a significant difference between promoter activities (p < 
0.05). 
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5.1.3.6 Site directed mutagenesis of the human MyHC IIB 
promoter 
To identify the specific sequence differences responsible for the differential 
pig and human MyHC IIB promoter activities, we analyzed the effects of site 
directed mutagenesis on promoter activities in C2C12 myotubes. Site directed 
mutagenesis within the AT rich regions (mAT2 and mAT3) of the human 1kb 
MyHC IIB promoter (making base pair alterations to match the equivalent pig 
promoter), had no impact on MyHC IIB promoter activity (Figure 5.6). 
However, a single base pair alteration within the human CArG-box (at -74bp), 
was sufficient to increase promoter activity by ~2.5-fold (p = 0.001), but 
promoter activity remained lower than the 1kb pig MyHC IIB promoter (p = 
0.007; Figure 5.6).  
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Figure 5.6 Site directed mutagenesis within the AT-rich region and the CArG-box of the 1kb human MyHC IIB promoter (substitutions 
indicated by a ÒboltÓ symbol). Promoter activities were measured in day 6 differentiated C2C12 myotubes (mean ± SD). Differing letters 
(a,b,c) constitute a significant difference between promoter activities (p < 0.05). Open bar = pig promoter; black bar = human promoter; 
grey = mutant human promoter.  
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5.1.3.7 Site directed mutagenesis (round 2) of the human MyHC 
IIB promoter 
Further site directed mutagenesis downstream of the CArG-box in the human 
MyHC IIB promoter highlighted a group of 3bp mutations required to increase 
promoter activity to the same level as the pig MyHC IIB promoter (Figure 
5.7). A single base pair mutation within the human CArG-box sequence (at -
74bp) increased promoter activity (p < 0.001) but remained lower than the 
activity of the 1kb pig MyHC IIB promoter (p < 0.001). Removal of a single 
nucleotide (at -68bp) from the human MyHC IIB CArG-box mutant promoter 
resulted in a further increase in promoter activity, compared to the CArG-box 
mutant promoter (p < 0.001), but this level of activity still remained lower than 
the 1kb pig MyHC IIB promoter (p = 0.023). Finally, a combination of the 
CArG-box mutation (at -74bp), with the removal of a single nucleotide (at -
68bp), and a single base pair change in the E-box2 (at -48bp) caused an 
increase in human MyHC IIB promoter activity (p < 0.001) to a level equal to 
the 1kb pig MyHC IIB promoter (p = 0.895). 
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Figure 5.7 Site directed mutagenesis within the CArG-box and E-box of the 1kb human MyHC IIB promoter. A ÒboltÓ indicates a single 
base pair mutation and a ÒcrossÓ indicates a single base pair removal. Promoter activities were measured in day 6 differentiated C2C12 
myotubes (mean ± SD). abcde = differing letters constitute a significant difference between promoter activities (p < 0.05). Open bar = pig 
promoter; black bar = human promoter; grey = mutant human promoter.  
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5.1.3.8 Electrophoretic mobility shift assay of the CArG/Ebox 
region 
Electrophoretic mobility shift assays were conducted to determine whether the 
3bp mismatch, responsible for the disparity in promoter activity between the 
pig and human MyHC IIB promoters, caused differential nuclear protein 
binding to this region (Figure 5.8). Two protein-DNA complexes (labeled A 
and B) formed with the pig 62bp probe (spanning and inclusive of the CArG-
box and Ebox2 (-93bp to -31bp)). To identify specific regions of the 62bp 
probe bound by protein(s), 200-fold molar excess of shorter, un-labeled 
competitor probes were included in the binding reactions. The un-labeled pig 
CArG-box probe (29bp in length) bound the proteins forming both complexes 
A and B with the 62bp pig probe, as both bands were lost/reduced (Figure 5.8). 
The un-labeled pig mid-probe and Ebox2 probes, however, were unable to 
compete for proteins bound to the 62bp probe, as there were no effects on 
either band. Interestingly, proteins bound to the pig CArG-box sequence were 
sensitive to the species-specific differences in the pig and human CArG-box 
sequences (2bp mismatch). The un-labeled human CArG-box competitor probe 
was capable of competing with the pig 62bp probe for proteins forming 
complex A, but not B. Like the equivalent pig competitor probes, the human 
mid-probe and Ebox2 probes were also unable to compete for proteins bound 
to the 62bp pig probe. Therefore, the 2bp mismatch in the pig and human 
CArG-box probes resulted in differential protein-DNA interactions.  
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Figure 5.8 Electrophoretic mobility shift assay using a 62bp biotin labeled probe 
(spanning the pig CArG and Ebox2 region; -91bp to -31bp relative to the TATA-box). 
Probes were incubated with C2C12 myotube nuclear extracts. Cross-species 
competition for bound proteins was conducted using shorter un-labeled pig and 
human probes. The human CArG-box is unable to bind proteins forming complex B 
with the pig CArG-box. EMSA assays were repeated 3 times to confirm the 
result. 
 
5.1.3.9 Deletion of the CArG-box promoter response element 
Finally, to confirm that sequence variation in the CArG-box region did not 
convert this region from an activating to a repressive response element in the 
human compared to pig 1kb MyHC IIB promoter, the CArG-box region (-63bp 
to -84bp; inclusive of the two mismatches at -74bp and -68bp) was deleted 
from both promoters. Deletion of the pig CArG-box region reduced MyHC IIB 
promoter activity (p < 0.001; Figure 5.9) to the same level as the 1kb human 
MyHC IIB promoter (p = 0.134). Despite sequence differences in this region, 
removal of the CArG-box from the 1kb human MyHC IIB promoter also 
moderately reduced promoter activity (p < 0.001; Figure 5.9). These data 
confirm that the CArG-box region presents an activiating, not repressive, 
response element in the both MyHC promoters.  
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Figure 8 Removal of the CArG-box (total of 22bp removed) from the 1kb pig and human MyHC IIB promoters. Promoter activities were 
measured in Day 6 differentiated C2C12 myotubes (mean ± SD). abc = differing letters constitute a significant difference between promoter 
activities (p < 0.05).!
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5.1.3.10 Summary of genomic differences 
An alignment of the proximal pig and human MyHC IIB promoter (Figure 
5.10A) highlighted the close proximity of the 3bp mismatches in the CArG-
box region that are responsible for the high level activity of the porcine MyHC 
IIB promoter. An additional alignment of this CArG-box region from multiple 
MyHC IIB expressing and non-expressing species (Figure 5.10B) identified 
that there is no common variation in sequence that is responsible for the 
differential expression of MyHC IIB, but sequence variation within this region 
does exist between species. 
 
Figure 5.10 (A) Alignment of the proximal pig and human MyHC IIB promoter. All base pair 
numbering is relative to the respective TATA-box (+1). Base pair mismatches, highlighted in 
black (with base pair numbering relative to the human TATA-box), were responsible for the 
differential activity of the 1kb pig and human MyHC IIB promoter in C2C12 myotubes. Bold-
underline indicates the 62bp pig probe used in EMSA experiments (spanning the CArG-box 
and E-box region (-93bp to -31bp)). The two bold base pairs (CC) indicate the mutated 
HindIII site for generating chimeric-promoters. (B) Cross-species alignment of the CArG-box 
and E-box region from MyHC IIB expressing and non-expressing animals. Bases highlighted 
in the black columns indicate the location of crucial base pair differences required for high 
MyHC IIB expression in pigs relative to humans. There is no common mutation amongst 
MyHC IIB expressing and non-expressing species but differences within this highly conserved 
region (highlighted in grey) are likely critical to the strength of promoter activation. 
! ! ! ! ! ! ! !!!!!!HindIII 
       chimeric-junction 
Human   -261   ATGAATGATGCAACAGCCAAACTGGAGAAACAGTGTTAGAAGCCCTGAATCCCCATCCCC   -202 
Pig     -259   ATGAATGATGGAACAGCAAAGCTGGAGAAATAGCCTTAGAAGCCCTGAATCTCCATCCC-   -201 
               ********** ****** ** ********* **  **************** *******  
 
      AT3      AT2 
Human   -201   TATCAAATGCCTATAAAGAACCCTAGATCATCCTCTGTTAAATTATTTATGGGTGTCAAG   -142 
Pig     -200   TATCAAATGCCTCAAAAGAACCCTAGATGATCCTCTGTCAAATTATTTATAGGTGTCAAG   -141 
               ************  ************** ********* *********** ********* 
 
   AT1 
Human   -141   AAATATTTCTAATTATATCCATTCACAGCCACAGTCAGTGAATATTGTGCAAAGAGATTG   -82 
Pig     -140   AAATATTTCTAATTATATCCATTCACAGCCACAGTCAGTGAATATTGTGCAAAGAGATTG   -81 
               ************************************************************ 
 
         CArG-box            E-box2       E-Box1 
Human   -81    CCAAAAACGGTTTTGCCAAGTAGGTTCCCAGCTAGGACAGCTGAGGTGGCTGCTGTGTTT   -22 
Pig     -80    CCAAAAAAGGTTT-GCCAAGTAGGTTCCCAGCTGGGACAGCTGAGGTGGCTGCTGTGTTT   -22 
               ******* ***** ******************* ************************** 
       
              TATA-box (+1) 
Human   -21    GCAGAATGGTCTCTATAAAAGTGGAGCTGAGATGCCTCTTTCCCATCCTTCCT   +32 
Pig     -21    GCAAAATGGTCTCTATAAAAGTGGAGCTGAGATGCCTCTGTCCTGTCCTTCCT   +32 
               *** *********************************** ***  ******** 
-48bp -68bp -74bp 
A 
      CArG-box                E-box2      E-box1 
Shrew    TGCAAAGAGATTGCCAAAAAAGGTTTTGCCAAGTAGGTTCCCAACTAGGACAGCTGAGGTGGC 
Mouse    TGTAAAGAGATTGCCAAAAATGGTTTTGCCAAGTAGGTCCGCAGCTAGGACAGCTGAGGTGGC 
Rat      TGCAAAGAGATTGCCAAAAATGGTTTTGCCAAGTAGGTCCCCAGCTAGGACAGCTGAGGTGGC 
Rabbit   TGCAAAGAGATTGCCAAAAAAGGTTTTGCCAAGTAGGTTCCCAGCTAGGACAGCTGAGGTGGC 
Pig      TGCAAAGAGATTGCCAAAAAAGGTTT-GCCAAGTAGGTTCCCAGCTGGGACAGCTGAGGTGGC 
 
Human    TGCAAAGAGATTGCCAAAAACGGTTTTGCCAAGTAGGTTCCCAGCTAGGACAGCTGAGGTGGC 
Macaque  TGCAAAGAGATTGCCAAAAATGGTTTTGCCAAGTAGGTTCCCAGCTAGGACAGCTGAGGTGGC 
Cow      TGCAAAGAGATTGCCAAAAAAGGTTTTGCCAAGTAGGTTCCCAGATGGGACAGCTGAGGTGGC 
Sheep    TGCAAAGAGACTGCCAAAAAAGGTTTTGCCAAGTAGGTTCCCAGATGGGACAGCTGAGGTGGC 
Dog      TGCAAAGAGTTTGCCAAAAAAGGTTTTGCCAAGTAGGTTCC-AGCTAGGACAGCTGAGGTGGC 
         ** ******  ********* ***** *********** *  *  * **************** 
B 
IIB 
expressing 
animals 
 
!
 
Non-IIB 
expressing 
animals!
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5.1.3.11 Induction of MyHC IIB promoter-reporters with cAMP 
We next treated C2C12 cells with an analog of cAMP (dbcAMP) as a 
downstream mediator of a beta-adrenergic response (a stimulus know to drive 
a fast muscle phenotype in MyHC IIB expressing species in vivo; Baker et al. 
2006; Bricout et al. 2004; Depreux et al. 2002; Oishi et al. 2002; Gunawan et 
al. 2007). dbcAMP treatment during the first 5 days of C2C12 differentiation 
induced a modest increase (p < 0.05) in 1kb pig and human MyHC IIB 
promoter activities (Figure 5.11A, 5.11D), whilst also inducing an ~2-fold 
increase in myotube diameters (p < 0.001; Figure 5.11B, 5.11C, 5.11E, 5.11F). 
We were concerned that the ZsGreen protein was being diluted as myotubes 
grew larger with dbcAMP treatments, thus masking or reducing the magnitude 
of change in fluorescence-reporter intensity in response to dbcAMP treatments. 
Using a CMV-driven ZsGreen plasmid (pZsGreenI-NI), which would not be 
expected to respond to dbcAMP treatment, we observed a decline in 
fluorescence output (p = 0.001; Figure 5.11G) when myotube diameters were 
increased (p < 0.001; Figure 5.11I) in response to dbcAMP, confirming that 
increased myotube diameters can reduce ZsGreen fluorescence intensity of 
transfected myotubes. This shows that the human MyHC IIB promoter can be 
induced by dbcAMP treatment but the absolute capacity for promoter 
induction remained blunted in comparison to the equivalent pig promoter. This 
also highlights a limitation of the use of fluorescence promoter-reporters when 
cell size/volume is likely to change with the intervention of interest.  
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Figure 5.11 (A) Pig and (D) human MyHC IIB promoter activity and (G) 
CMV-driven ZsGreen fluorescence output in C2C12 myotubes in response to 
4 and 5 days exposure to 1mM dbcAMP treatment (mean ± SD). Average day 
5 myotube diameters of myotubes with (C) pig or (F) human MyHC IIB or (I) 
CMV promoter activity (ZsGreen fluorescent). Representative images of day 5 
differentiated C2C12 myotubes treated with dbcAMP (or vehicle control) 
expressing ZsGreen controlled by the 1kb (B) pig or (E) human MyHC IIB 
promoter or (H) CMV promoter. * or differing letters (a,b,c,d) indicate a 
significant difference between promoter activities, myotube diameters or 
mRNA expression (p < 0.05).   
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5.1.4 DISCUSSION 
Myosin heavy chain (MyHC) isoform expression is a key determinant of the 
contractile performance of the muscle fibre, with maximal shortening velocity 
increasing in the order of MyHC I<IIA<IIX<IIB (Pellegrino et al. 2003). 
Mechanisms regulating the expression of the different MyHC isoforms in 
skeletal muscle have therefore been of significant interest within the scientific 
community (Spangenburg and Booth 2003; Schiaffino 2010). Interestingly, 
extensive characterization has revealed species-specific expression of the 
fastest contracting isoform, MyHC IIB, lending to vastly different muscle 
phenotypes between species. Of particular interest, domestic pigs express very 
high levels of MyHC IIB (Ruusunen and Puolanne 2004; Lefaucheur et a. 
1998; 2004), unlike most large mammals (which do not normally express 
MyHC IIB), and exhibit a faster and more glycolytic muscle phenotype in 
comparison. We examined the role of the MyHC IIB promoter sequence in 
dictating the expression of MyHC IIB in pigs, compared to humans, which do 
not express MyHC IIB (Smerdu et al., 1994, Pellegrino et al. 2003). Due to its 
similarity to humans, the pig is increasingly being considered as an animal 
model for a range of human diseases (Luo et al. 2012) and it is therefore useful 
to understand the mechanisms responsible for the physiological differences 
between these species. We identify the genomic differences within the MyHC 
IIB promoter of pigs and humans that dictate differential promoter activity 
during myogenesis and postulate that these genomic differences partly explain 
the vastly different muscle phenotypes displayed in these otherwise 
physiologically similar mammals.  
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We previously reported that the C2C12 cell line is a dynamic MyHC IIB 
expressing environment, with mRNA expression increasing throughout the 
later stages of myogenic differentiation (Brown et al. 2012; Chapter 3.1). This 
cell line was selected for transfection studies of the pig and human MyHC IIB 
promoter-reporter constructs, providing a common and non-biased MyHC IIB 
inducing environment for testing both promoters. In this environment, 1kb of 
the pig MyHC IIB promoter elicited very strong activity that is consistent with 
the very high level of endogenous MyHC IIB expression observed in pigs 
(Lefaucheur et a. 1998; Gunawan et al. 2007). In contrast, the human 1kb 
MyHC IIB promoter was only mildly active during C2C12 myogenic 
differentiation. We were slightly surprised by the extent of the human MyHC 
IIB promoter activity in C2C12 cells given that humans do not normally 
express MyHC IIB transcripts in vivo (Smerdu et al. 1994; Pellegrino et al. 
2003), suggesting that this promoter can display mild activity given the 
appropriate environment. In support of this, Harrison et al. (2011) previously 
reported expression of the MyHC IIB transcript in cultured human fetal 
primary myotubes, but not in adult human muscle biopsy samples, suggesting 
that the human MyHC IIB promoter may only be active during myogenesis. 
Despite being active during C2C12 myogenesis, the human MyHC IIB 
promoter activity remains blunted in comparison to equivalent promoters from 
MyHC IIB expressing species, such as pigs (data presented herein) or mice 
(Harrison et al. 2011). Taken together, this suggests that the MyHC IIB 
promoter sequence plays a critical role in dictating the strength of MyHC IIB 
promoter induction during myogenesis and that this disparity in promoter 
activity can occur independent of nerve innervation in muscle cells. 
219 
Furthermore, we also show that although both the pig and human MyHC IIB 
promoters are responsive to known MyHC IIB inducing stimuli, such as MyoD 
over-expression (Ekmark et al. 2007; Allen et al. 2001; Harrison et al. 2011) 
and beta-adrenergic signaling (Baker et al. 2006; Bricout et al. 2004; Depreux 
et al. 2002; Oishi et al. 2002; Gunawan et al. 2007), the absolute capacity to 
activate the human MyHC IIB promoter was limited in comparison to the 
equivalent pig promoter, suggesting that sequence differences between the two 
promoters dictate the capacity for induction during myogenesis.  
We proceeded to elucidate the specific genomic sequence variation responsible 
for the differential MyHC IIB promoter activities during myogenesis. 
Surprisingly, a cluster of just 3bp mismatches in the proximal CArG and Ebox 
region (at -74bp, -68bp and -48bp) was responsible for the disparity in pig and 
human MyHC IIB promoter activities during myogenesis. The nucleotide 
mismatch at -74bp was located in the AT-rich region of a proximal CArG-box 
(consensus sequence: CC(A/T)6GG), resulting in the human CArG-box being a 
non-consensus CArG-box (CCAAAAAcGG), unlike the equivalent consensus 
CArG-box in the pig MyHC IIB promoter (CCAAAAAaGG). This single bp 
difference was partly responsible for the differential pig and human MyHC IIB 
promoter activities during myogenesis. The CArG-box is a response element 
that is typically (but probably not exclusively) bound by serum response factor 
(SRF) and is instrumental for activating many muscle specific genes, 
particularly genes encoding contractile and structural components of muscle 
(Groisman et al. 1996; Miano 2003). By deleting the CArG-box region 
(inclusive of mismatch sites -74bp and -68bp) from the MyHC IIB promoters, 
we report a critical role of the CArG-box in regulating transcriptional 
220 
activation of MyHC IIB during myogenesis. Furthermore, by mutating the 
species-specific mismatches (-74bp and -68bp) in the CArG-box region, we 
confirm that these subtle sequence variations within the CArG-box region are 
crucial to the species-specific strength of MyHC IIB promoter induction during 
myogenesis. This is in agreement with the findings of Harrison et al. (2011) 
who also report that a single bp mutation in the same location (-74bp) of the 
AT rich region of the proximal CArG-box is instrumental in dictating the 
strong induction of the mouse MyHC IIB promoter. Interestingly, we show 
that the human non-consensus CArG-box was still partially functional, as 
removal of this element was sufficient to moderately reduce promoter activity. 
Therefore, we speculated that binding of nuclear protein(s) to the human 
CArG-box is likely impaired but perhaps not completely eliminated. 
Alternatively, as shown by Catala et al. (1995), an intact CArG-box may have 
been required for the binding of nearby myogenic regulatory factors, thus 
impairing promoter activation in the absence of the CArG-box. We report 
differential protein-DNA interactions at the pig and human CArG-box site 
(with a 2bp difference) and show that only 1 of the 2 complexes that form with 
the pig CArG-box are capable of forming with the human CArG-box. We 
therefore suggest that the genomic sequence variation between pigs and 
humans at this location (-74bp and -68bp) improves the stability of factors 
binding the CArG-box region of the porcine MyHC IIB promoter and that this 
causes stronger induction of the porcine MyHC IIB promoter during 
myogenesis.  
It is also interesting to speculate whether the close proximity of the 3bp 
mismatches identified herein may permit, or restrict, co-operative interactions 
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between factors binding CArG-boxes and E-boxes, since such factors have 
been shown to physically interact and form trimeric heterodimers (Groisman et 
al. 1996). Furthermore, sequence variation within CArG-boxes has been 
reported to influence promoter trans-activation by myogenic regulatory factors 
that bind nearby E-boxes (Catala et al. 1995), suggesting co-operation between 
SRF and the myogenic regulatory factors is likely. We show that the removal 
of a single nucleotide at -68bp (from the human CArG-mutant MyHC IIB 
promoter), which effectively reduces the gap between the CArG-box and the 
E-box2, resulted in an increase in promoter activity that, although speculative, 
may be facilitated by co-operative binding at these two response elements. 
Indeed, others have shown that spacing between E-boxes can be critical to the 
transcriptional regulation of the Myosin Light Chain 1A gene (Catala et al. 
1995) and made similar speculations of interactions between CArG and E-
boxes. Therefore, we speculate that species-specific differences in the 
CArG/E-box2 region, rather than within a specific response element, likely 
influence co-operative protein-DNA interactions to facilitate a strong induction 
of the MyHC IIB promoter. It is important to note that the specific promoter 
sequence mismatches identified herein between pigs and human are unlikely to 
account for the lack of MyHC IIB expression in other non-expressing species 
(see Figure 8B). For example, the MyHC IIB promoters of cows and sheep 
contain a consensus CArG-box sequence (in the equivalent location) yet still 
display a lack of MyHC IIB expression. These species do however show 
mismatches (relative to MyHC IIB expressing species) within the highly 
conserved CArG/E-box2 region, supporting our speculation that sequence 
variation within this region is likely a critical mechanism underlying 
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differential MyHC IIB promoter activation. Further work investigating the 
complexities of protein-DNA interactions occurring in the CArG/E-box region, 
between MyHC IIB-expressing and non-expressing species, would be 
informative for muscle biology research. 
In summary, for the first time, we identify a genomic mechanism responsible 
for the very high expression of MyHC IIB in domesticated pigs, explaining the 
vastly different muscle phenotypes between pigs and humans. We therefore 
extend the work of Harrison et al. (2011) and conclude that the sequence of the 
CArG-box and its immediate flanking regions, are not only critical for MyHC 
IIB expression in small mammals, but is also a region whereby critical 
sequence variation can permit or restrict MyHC IIB expression in large 
mammals as well. We also demonstrate that the human MyHC IIB promoter is 
responsive to stimuli (i.e. MyoD and cAMP) known to increase MyHC IIB 
expression, but the capacity for induction is severely limited by the 3bp 
genomic mutation identified herein. This work furthers our understanding of 
genomic mechanisms dictating expression of the fast contracting MyHC IIB 
isoform in mammalian skeletal muscle cells. Further work should be 
conducted to investigate the complexities of protein-DNA interactions between 
the CArG- and E-box response elements to investigate their role in controlling 
muscle specific gene expression. 
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6.1 FINAL CONCLUSIONS AND DIRECTIONS FOR FUTURE 
WORK 
Traditionally, research investigating muscle fibre type regulation has been 
conducted in vivo, analyzing global changes at a whole muscle level. The body 
of work presented herein aimed to utilize molecular and cell biology-based 
approaches to improve our understanding of the regulation of myosin heavy 
chain (MyHC) isoform expression, as an indicator of muscle fibre 
composition. Firstly, the C2C12 cell line was fully characterized to establish 
its suitability for conducting in vitro examination of MyHC regulation. 
Specifically, the dynamics of endogenous and induced MyHC isoform 
expression were explored and compared to in vivo situations. Secondly, the 
C2C12 cell line was utilized as a host environment for the molecular analysis 
of the mechanisms regulating the very high level expression of the MyHC IIB 
isoform in porcine skeletal muscle. Particular emphasis was placed on 
investigating the regulation of the type IIB MyHC isoform since the regulatory 
mechanisms dictating expression of this isoform remain poorly understood. 
Improving our understanding of the fundamental biology controlling MyHC 
isoform expression is important since these proteins are key determinants of 
the contractile and metabolic characteristics of the muscle fibre; influencing 
locomotion, metabolism and age related musculoskeletal diseases (Schiaffino 
and Reggiani 2011). Furthermore, establishing whether muscle fibre type 
research can be conducted using molecular and cell biology-based approaches, 
as explored herein, may encourage more extensive work to be conducted by 
such methods and advance our molecular understanding of muscle fibre type 
regulation.  
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6.1.1 Characterization and exploration of MyHC isoform gene 
expression 
Despite the common use of the C2C12 mouse muscle cell line in muscle 
biology laboratories across the world, when this work was conducted very little 
information was available regarding the induction of the MyHC isoforms 
during myogenesis. Therefore, a comprehensive characterization of gene 
expression during C2C12 myogenesis was conducted, describing the mRNA 
profiles of MyHC isoforms, myogenic regulatory factors and metabolic 
enzymes throughout myogenesis. An objective of this characterization was to 
establish whether muscle fibre ÒtypeÓ research could be conducted in vitro 
using the C2C12 cell and to establish a series of biomarkers to reflect the 
differentiation status of the C2C12 cells, providing useful information for 
future experiments conducted using this commonly used cell line.  
It is well documented that during muscle cell differentiation, genes encoding 
contractile proteins, such as the MyHCÕs, are activated and expressed 
(Silberstein et al. 1986; Weydert et al. 1987; Miller 1990). Data presented in 
this thesis advanced the understanding of MyHC isoform gene expression and 
showed, for the first time, that the activation of MyHC genes during C2C12 
myogenesis are not all activated at the same time, nor in the same pattern. 
Specifically, MyHC mRNA isoforms are expressed in two distinct cohorts, 
denoted as ÒearlyÓ and ÒlateÓ expressed isoforms, transitioning from the 
embyonic, neonatal and type I to the fast, type II MyHC isoforms. This 
detailed analysis provides important information regarding the expression 
profiles of MyHC isoform genes in what is likely the most commonly used 
muscle cell line for muscle biology research. In particular, this thesis reports 
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that the C2C12 cell line mimics developing fast-twitch muscle fibres, 
information that should be taken into consideration by scientists utilizing this 
cell line. Furthermore, the detection of MyHC expression is often used as a 
biomarker of differentiation status of cultured muscle cells. Thus, the 
identification herein of two distinct cohorts of ÒearlyÓ and ÒlateÓ expressed 
MyHC isoforms, provides a comprehensive set of MyHC biomarkers for a 
more precise indication of differentiation status of C2C12 muscle cells using 
MyHC mRNA expression. This characterization of muscle specific gene 
expression during C2C12 myogenesis therefore provides useful information 
for scientists utilizing the C2C12 cell line, as evidenced by a number of 
authors having already cited this research for its intended purpose (An et al. 
2013; Elkalaf et al. 2013; Yang et al. 2013; Ryan at al. 2014; Wright et al. 
2014). 
In addition to identifying the endogenous transitions in mRNA expression of 
the MyHC isoforms during C2C12 myogenesis, the research presented in this 
thesis demonstrates the dynamic plasticity of these genes. In particular, beta-
adrenergic agonist administration, both in fully differentiated adult pig muscle 
and during C2C12 myogenesis in vitro, induced alterations in MyHC isoform 
gene expression. Specifically however, MyHC IIB was the only isoform to 
elicit a similar response to treatment in the two developmentally distinct 
muscle cell types (i.e. adult muscle and differentiating muscle cells). Due to 
the consistency in responsiveness of MyHC IIB gene expression to beta-
adrenergic receptor stimulation, both in vivo and in vitro, expression of the 
MyHC IIB gene may be a useful end-point biomarker to screen for novel beta-
adrenergic agonists using cultured muscle cells (as demonstrated herein using a 
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1kb MyHC IIB promoter-reporter plasmid in C2C12 cells). Furthermore, the 
plasticity of the MyHC IIB gene, as demonstrated by the endogenous induction 
during late myogenesis and by beta-adrenergic receptor stimulation in vitro, 
demonstrate that expression of the MyHC IIB gene is highly responsive to 
factors not regulated by neural innervation.  
Future work should focus on investigating the proteins interacting with the 
MyHC IIB promoter in response to beta-adrenergic receptor stimulation. 
Investigating protein-DNA interactions on the MyHC IIB promoter in response 
to beta-adrenergic receptor stimulation, perhaps utilizing ChIP-seq and EMSA 
approaches, could elucidate the specific transcriptional regulators involved in 
this now well-characterized response to beta-adrenergic signaling. 
Furthermore, it should be determined whether beta-adrenergic signaling 
influences DNA methylation within the type II MyHC gene cluster to 
subsequently influence transitions in the expression of the type II MyHC 
genes. Similar experiments could be conducted on the MyHC IIB promoter 
during the early and late phases of myogenic differentiation to elucidate the 
transcriptional regulators inducing this gene during myogenesis.  
 
 
6.1.2 Metabolic gene expression of proliferating and 
differentiated C2C12 cells 
Following the identification of a dramatic transition in MyHC isoform mRNA 
expression during C2C12 myogenesis, to a predominantly type II MyHC 
expressing profile, it was speculated that cellular metabolism would likely be 
very glycolytic to support the contractile machinery being expressed. By 
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comparing the metabolic gene expression profile of fully differentiated C2C12 
myotubes, expressing type II MyHC mRNA isoforms, against proliferating 
myoblasts, an interesting and novel observation was made. It was shown, for 
the first time, that a dramatic restructuring of metabolic gene expression 
occurred during the switch from proliferating to differentiated C2C12 muscle 
cells. Specifically, the changes in metabolic gene expression suggest that post-
mitotic muscle cells might redirect glucose carbons into ATP generating 
pathways and away from macromolecule biosynthesis. The work generated in 
this thesis highlights that continued research is needed to elucidate whether 
myogenic differentiation can be regulated by specific metabolic profiles, an 
idea recently reviewed by Ryall (2013). Indeed, it has been shown that 
proliferating cancer cells display a dramatic metabolic remodeling to support 
mitotic cell growth (Possemato et al. 2011; Tong et al. 2009). Furthermore, it 
was recently shown that specific metabolic pathways could act as novel 
regulators of myogenic differentiation with some interesting results (Bracha et 
al. 2010), emphasizing that this area of muscle biology is an exciting and 
relatively unexplored scientific niche. Therefore, further work should be 
conducted, perhaps by over-expression and/or knockdown of specific 
metabolic genes, or by pharmacological inhibition of metabolic intermediates, 
to elucidate the role of cellular metabolism in myogenesis. Metabolic targets 
need to be carefully selected, with a strong hypothesis, and the use of high 
throughput methods for screening metabolic targets could accelerate the 
identification of key metabolic regulators of myogenesis.  
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6.1.3 Regulation of the MyHC IIB gene in porcine skeletal 
muscle 
Utilizing the C2C12 cell line as a host environment, a molecular mechanism 
was identified that is responsible for the unusually high expression of the 
MyHC IIB isoform in porcine skeletal muscle. Pigs are physiologically similar 
to humans and are therefore increasingly being considered as a good animal 
model for studying a range of human diseases (Luo et al. 2012). However, the 
high level expression of MyHC IIB in porcine skeletal muscle, which is 
associated with a dramatically faster and more glycolytic muscle phenotype 
compared to that of human skeletal muscle, presents a major limitation of the 
pig for use as a model of human skeletal muscle biology. Therefore it is 
important to determine what differences exist between these species in order to 
have confidence in the use of the pig as a model. Furthermore, the fundamental 
biology responsible for the expression of the MyHC IIB gene in porcine 
skeletal muscle is not only physiologically interesting but also has potential 
implications for livestock production, growth performance and meat quality. 
At the initiation of the work presented herein, no mechanisms had been 
highlighted with regard to the species-specific expression of MyHC isoforms. 
However, after commencing this work, Harrison et al. (2011) reported that a 
single base pair difference in the mouse MyHC IIB promoter was responsible 
for differences in expression of MyHC IIB between mice and humans. Work 
presented in this thesis, comparing the pig and human MyHC IIB promoters, 
was continued to elucidate if a similar mechanism was responsible for the high 
level expression of MyHC IIB in pigs. Data presented in this thesis shows, for 
the first time, that a genetic difference of 3bp in the proximal MyHC IIB 
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promoters of pigs and humans is critical in determining the differential 
expression of this gene between these otherwise physiologically similar 
mammals. Specifically, the porcine MyHC IIB promoter is likely Òhyper-
responsiveÓ (relative to humans) to factors interacting with the CArG-Ebox 
promoter response element region, as demonstrated by differential protein-
DNA interactions in this region between the pig and human MyHC IIB 
promoters. The genomic mechanisms reported herein advance our biological 
understanding of the mechanisms dictating a physiological difference in 
muscle phenotype between pigs and humans. In particular, a genomic 
mechanism was identified controlling the expression of the MyHC IIB gene in 
porcine skeletal muscle, a gene that is not normally expressed in the muscles of 
large mammals. Data presented in this thesis therefore advances the work of 
Harrison et al. (2011) by elucidating a genomic mechanism regulating the 
MyHC IIB gene in a species that was previously unexplored. Taken together, 
with the work of Harrison et al. (2011), the CArG-Ebox promoter-response 
element region of the MyHC IIB promoter is critical in determining the 
strength of MyHC IIB promoter activity across multiple species, including 
both small rodents and large mammals. Finally, this work has provided an 
understanding of a mechanism responsible for a major limitation of the pig as a 
model of human skeletal muscle biology.  
It is also noteworthy that the subtle differences in promoter sequence 
responsible for the large disparity in MyHC IIB promoter activity between pigs 
and humans highlight the potential impact of single nucleotide polymorphisms 
(SNPÕs) in non-coding, promoter regions of DNA on subsequent gene 
expression. Thus it is evident that SNPÕs in important promoter response 
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elements may be critical in determining the Òend-pointÓ physiology within an 
animal and that sequence variation in promoter regions could be causative to 
certain pathologies.  
Future work should be focused on identifying the transcriptional regulators 
differentially binding at the CArG-Ebox region, which are considered 
fundamental to the strength of the pig and human MyHC IIB promoter activity. 
Unfortunately, due to technical difficulties and limited time, it was not possible 
to identify the specific proteins interacting with this region of DNA in this 
thesis. As discussed in Chapter 5, it is postulated that multiple proteins, likely 
involving serum response factor (SRF) and myogenic regulatory factors 
(MRFÕs), are differentially interacting in the region identified and warrants 
further exploration. Such a body of work (which would be technically 
demanding and time consuming) could elucidate binding activities of 
transcriptional regulators co-operatively interacting at CArG and E-boxes to 
further establish their complex role in regulating muscle specific gene 
expression and in particular, the regulation of the MyHC IIB gene.  
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6.1.4 Final summary of novel findings from this thesis 
 
In conclusion, this body of work has shown, for the first time, the following: 
1. The distinct mRNA expression profiles of six MyHC isoform genes 
during C2C12 myogenesis and importantly, that the C2C12 cell line 
mimics developing fast-twitch muscle fibres. These results provide 
useful information for future research conducted using this cell line. 
2. The dynamic plasticity of the MyHC IIB gene in response to beta-
adrenergic receptor stimulation in both fully differentiated adult muscle 
and differentiating muscle cells, highlighting a role for beta-adrenergic 
signaling in MyHC IIB transcriptional regulation during two 
developmental distinct stages of muscle growth.  
3. A dramatic restructuring of metabolic gene expression during the 
switch from proliferating to fully differentiated C2C12 muscle cells, 
highlighting the requirement for future work to investigate the role of 
metabolism in regulating myogenic differentiation.   
4. A genomic mechanism dictating the high level expression of the 
MyHC IIB gene in porcine skeletal muscle, identifying a molecular 
mechanism regulating a major physiological difference in the muscle 
phenotype between pigs and humans (which is important for 
understanding the pig as a model of human muscle biology research).  
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